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Conclusions
In this study I have investigated alterations in the regulation and 
hormonal responsiveness of adipocyte adenylate cyclase occurring in animal 
models showing insulin-resistance. Three models have been investigated, the 
streptozotocin diabetic rat, which approximates as a model of juvenile onset 
diabetes in humans, genetically obese Zucker fatty rat, approximating a 
model of human obesity and the genetically obese diabetic mouse, which also 
approximates to a model of human obesity. My reason for undertaking such a 
study was because therapeutic benefits may come from a greater 
understanding of alterations in signal transduction systems of hormones 
controlling metabolism in insulin-resistant pathological states. These are 
seen in diabetes and in obesity where profound alterations in metabolism have 
been noted. An important underlying facet in determining these alterations in 
metabolism may be that defects have occurred in signal transduction systems 
of various hormones which regulate metabolic events. Any such changes 
occuring in signal transduction systems associated with the liver, skeletal 
muscle and adipose tissue are likely to give rise to serious metabolic 
disturbances.
Previous studies on the streptozotocin diabetic rat have shown that 
alterations do occur in the signal transduction of the adenylate cyclase system 
in both hepatocytes and adipocytes. Alterations in other signal transduction 
systems have also been noted, most notably in the insulin transmembrane 
signal transduction system itself. Previous studies from Professor Houslays 
group in which this work was undertaken had shown that changes in G- 
protein regulation of adenylate cyclase had occurred in hepatocytes from 
streptozotocin diabetic rats. The changes appeared to be directed at a 
particular subclass of the G-protein family, that is the *Gj' subgroup which 
are involved in the inhibition of adenylate cyclase activity. Alteration in the
XVI
regulation of adipose tissue hormone-stimulated lipolysis had already been 
documented in the same pathological state and these changes seemed to be due 
to alterations in the regulation of adipocyte adenylate cyclase activity. 
However very little was understood about the molecular mechanisms 
involved. I thus conducted an investigation into the regulation of adenylate 
cyclase with particular respect to the kind of molecular changes that may 
occur as a result of alterations in the G-protein system. My results indicated 
that reduced activity of Gj had a potentiating effect on the stimulation of 
adenylate cyclase by B-adrenergic agonists. This appeared to relate to an 
abolition of the ability of Gj to exert a 'tonic' inhibitory effect upon adenylate 
cyclase. I concluded that the nature of the altered regulation of adenylate 
cyclase in adipocyte membranes from streptozotocin diabetic rats was 
essentially very similar to the changes seen in hepatocyte membranes from 
streptozotocin diabetic animals.
My investigation into the regulation of adenylate cyclase in adipocyte 
membranes from lean and obese Zucker rats was conducted, in particular, to 
see if there was a reduction in the ability of lipolytic hormones to stimulate 
adenylate cyclase. The reason for suspecting the latter scenario relates to the 
observations that such defects have been noted in the adipose tissue of the 
genetically obese, obese mouse and diabetic mouse. The defect in adenylate 
cyclase, and hence lipolysis, found in the latter two model systems was 
viewed to be capable, potentially, of explaining the hyperadiposity which is 
characteristic of obesity. A further reason for predicting that changes in the 
signal transduction system of such animals may occur relates to the fact that 
obese Zucker rats are hypothyroid. In this regard adipocytes from 
hypothyroid rat have been shown to be much less responsive to the 
stimulation of lipolysis by lipolytic hormones. This latter defect appears to 
be due to a parallel reduction in the ability of lipolytic hormones to stimulate
XVII
lipolysis.
My results have shown that there is, as I surmised, a large reduction 
in the ability of a variety of lipolytic hormones to stimulate adenylate cyclase 
in adipocyte membranes from obese Zucker rats. The molecular basis of the 
effect is still uncertain, however a number of strong possibilities have been 
proposed. These include: (i) reduced numbers of receptors, R type: (ii)O
reduced amounts of Gs: and (iii) reduced activity of Gs.
The genetically diabetic db/db mouse has been shown by others to 
exhibit a reduced responsiveness to adrenaline as regards stimulation of 
lipolysis and of adenylate cyclase activity in adipose tissue. Thus my studies 
were conducted in order to investigate the molecular basis observations. I 
found that the responsiveness of adenylate cyclase to most but not all lipolytic 
hormones was severely reduced in adipocyte membranes from these animals. 
In contrast to the changes found in obese Zucker rat adipocyte membranes, no 
alterations in G-protein subunit levels were found other than an increase in 
the amount of the a-subunit for G,-1. It was concluded that a diminuition in 
receptor number or activity was one of the most likely molecular 
explanations for reduced responsiveness of adenylate cyclase to stimulation 
by catecholamines and other hormones.
In my studies on the obese Zucker rat and diabetic mouse, although the
alterations in the regulation of adenylate cyclase were well studied it was not
possible to define the molecular cause of the alterations with a high degree of
certainty. It was however, in each model system, possible to list a number of 
possibilities.
strong. For instance (i) regulation of B-adrenergic receptor to Gs coupling 
could be investigated by classical ligand binding studies: (ii) the possibility 
of* alteration in the ratio of B^/B2 -adrenergic receptors: (iii) further 
investigations into the nature of the Gs directed defect in obese Zucker rat 
adipose tissue could be made. In addition, studies on hormone stimulated 
lipolysis could be conducted in order to ascertain how the alterations in the
XVIII
regulation of adenylate cyclase express themselves further downstream, at 
the level of lipolysis. Similarly one, could determine whether there 
might be a reduction in the activity of lipolytic enzymes within the adipocyte. 
This could be simply addressed by measuring lipolysis stimulated by non- 
metabolizable analogues of cAMP, such as dibutynjlcAMP. The possible 
occurrence of reduced hormone stimulated adenylate cyclase and/or lipolysis 
in adipocytes from other obesity model systems, including humans, could be 
investigated. Such genetically obese insulin resistant animal syndromes 
include: the obese yellow mouse; the yellow-KK mouse: KK-mouse: New 
Zealand obese mouse and the DBM mouse.
Another possible locus of a metabolic defect in adipocytes, which may 
contribute to the hyperadiposity characteristic of obesity, may be that of 
lipogenesis. Increased hormone stimulated lipogenesis might well act in 
parallel with decreased hormone stimulated lipolysis to increase the size of 
the fat globule in the greatly enlarged adipocytes characteristic of obesity. 
Inositol polyphosphate mobilizing hormones regulate lipogensis in adipose 
tissue. Consequently one might consider looking at the ability of such 
hormones to stimulate phospholipase C in adipocytes from genetically obese 
animals, such as those listed above.
The heart tissue of obese Zucker rats shows impaired contractility 
and adenylate cyclase stimulation in response to inotropic cAMP mobilizing 
hormones such as secretin and adrenaline (Robberecht et al, 1983). Since 
the cAMP mobilizing hormones are inotropic agents, the pathological 
significance of the above defect(s) may relate to the tendency for impaired 
cardiac function to be associated with obesity (Crandall & DiGirolamo, 
1990). Further investigations into the hormonal regulation of adenylate 
cyclase in heart tissue from obese Zucker rats could be conducted with a view 
to uncovering the molecular basis of the defect. In addition studies along the
XIX
same lines could be performed in heart tissue from other obesity model 
systems in order to establish the prevelevance of the effect.
xx
CHAPTER 1 
INTRODUCTION
1.1 THE cAMP SIGNALLING SYSTEM
The cAMP signalling system is probably present in all mammalian 
cells and is absolutely crucial for the correct regulation of a wide variety of 
intracellular processes by extracellular signals. In addition to generation of 
cAMP by adenylate cyclase, j the production of cAMP is also
regulated by cAMP-phosphodiesterases, cAMP-PDEs, which degrade cAMP to 
AMP.
It is now apparent that a number of other signal transduction systems 
are regulated in apparently similar fashions to that of adenylate cyclase. 
Consequently much can be learned about the regulation of adenylate cyclase by 
comparison with the regulation of other G-protein-regulated effector 
enzymes and vice-versa. Also the study of the regulation of adenylate cyclase 
in disease states, important in its own right for obvious reasons, 
significantly improves our understanding of the regulation of adenylate 
cyclase in the normal state.
1.2 FLOW OF IM FORM ATION THROUGH G -PRO TEIN COUPLED  
SIGNAL TRANSDUCTION SYSTEMS IN VERTEBRATES.
It has been estimated that 80% of all known hormones/autocrine 
factors and neurotransmitters (primary messengers) are known to elicit 
cellular responses by combining with receptors coupled to G-proteins which 
then activate effectors. To date approximately 80 receptors have been 
identified, while the total number of agonists known is approximately 40. 
Some investigations (Birnbaumer et al, 1990) have predicted that the total 
number of distinct receptors coupled to G-proteins will be in the region of 
100 to 150. Thus the number of receptors (R) is greater than the number of 
primary messengers. In contrast the number of G-proteins is probably only 
in the region of 15 of which 12 have been identified to date, representing five 
different classes of G-protein. Similarly the number of effectors is small, 6
being known, with the possible total of around 12 suggested. Of the receptors, 
18 have been purified and cloned. Of the other effectors, only two have been 
purified close to homogeneity in a G-protein-responsive state.
In contrast to the many conserved features amongst different G- 
protein signalling systems, the effector step is the least conserved as one 
might logically predict. The range of effectors regulated includes the 
following; adenylate cyclase (Levitski 1990); PIP2-specific PLC which 
hydrolyses PIP2 to diacylglycerol and inositol 1,4,5 triphosphate (Fain 
1990); cGMP-phosphodiesterase of retina (Stryer 1988); PLA2 which  
hydrolyses phophatidyl choline to arachidonic acid and lysophosphatidyl 
choline (Burch et al, 1986); K+ channel (Yanati et al, 1987); Ca+ + 
channel (Yanati et al, 1987) and the Na+ channel (Cantiello et al, 1989; 
Krapisinky et at, 1989). Other potential candidates include a Mg+ + 
transporter (Erdos et al, 1981) and the glucose transporter(s) (Kuroda et 
al, 1987).
Strictly speaking only adenylate cyclase, PLC and calcium channels 
are effector enzymes since they are hormonally regulated enzymes which 
catalyse the production of second messengers leading to changes in the 
activity of protein phosphorylation within the cell.
1.3.1 HORMONAL REGULATION OF ADENYLATE CYCLASE
Adenylate cyclase is a multicomponent system composed of five 
functional units.
(1) The stimulatory receptor Rs. This class of receptor appear to be 
transmembrane glycoproteins with seven transmembrane-spanning  
sequences. The 6-AR is the only member of this large family of receptors 
which has been purified and reconstituted with other pure components of the 
adenylate cyclase system (Feder et al, 1986).
(2) The Gs protein, which binds GTP and may be tightly associated
with the catalytic unit C. Gs (Arad et al, 1984) is composed of 3 subunits; 
a s which possesses the GTP binding site and is the target for ADP- 
ribosylation by NAD+ catalysed by cholera toxin, and the (5-subunit and the 
y-subunit which are believed to be tightly associated with each other (Cassey 
& Gilman, 1988). The heterotrimeric Gs is localized on the inner leaflet of 
the plasma membranes and is much less hydrophobic than either the p-AR or 
the catalytic unit of adenylate cyclase.
(3) The catalytic unit (C) is a hydrophobic protein with 12 
transmembrane-spanning domains carrying its catalytic site at the 
cytoplasmic side of the membrane (Krupinski et al, 1989).
(4) The inhibitory receptor, Rj, appears to be homologous in 
structure to Rs (Kubo et al, 1986), (Bonner et al, 1987), (Kobilka et al, 
1 9 8 7 ) .
(5) The inhibitory GTP binding protein, Gj, is structurally 
homologous to Gs where py subunits are either very similar or identical to 
those of Gs. The aj subunit is a substrate for ADP-ribosylation catalysed by 
pertussis but not cholera toxin, except under special conditions in vitro.
The homology between otj and a s is high in the GTP-binding domain, 
but lower at the C-terminal sequence which is involved in receptor 
recognition (Masters et al, 1989). It is expected that the effector 
interaction domain will be different for each G-protein. Different py are 
known to exist and therefore Rj-and Rs-type receptors may recognize 
particular apy complexes and not just simply the a subunit. Never the less it 
has been assumed that the py of Gs and Gj are identical and functionally 
interchangable (Levitzki, 1990).
1.3.2 Ubiquity of the adenylate cyclase system
The adenylate cyclase system is very similar across the evolutionary 
sphere. The p-adrenergic receptor from turkey erythrocytes and the glucagon
receptor from rat liver can be transferred into Friend erythroleukaemia 
cells and activate their adenylate cyclase (Schramm et al, 1977; Schramm 
et al, 1979). In rat brain it is known that p-AR (Rs) and A2-adenosine  
receptor (Rs) couple to the same pool of adenylate cyclase catalytic units 
(Braun & Levitzki, 1979).
1.3.3 The adenylate cyclase catalytic unit (C subunit).
Both genetic and biochemical evidence indicate multiple forms of 
adenylate cyclase, with an estimated molecular weight range from 120- 
150kD (Smigel, 1986; Mollner & Pfeuffer, 1988).
Evidence suggests that neural tissue contains calmodulin-sensitive 
and insensitive adenylate cyclases (Westcott et al, 1979). The calmodulin- 
sensitive form is believed to bind calmodulin directly (Salter et al, 1981). 
Calmodulin-mediated stimulation of activity ranges from 1.4 to 5-fold 
depending on the region of the brain (Cooper et al, 1988). Stimulation is 
observed at Ca++ concentrations in the range 0.1-1.0pM, that can be 
achieved either upon neural depolarisation or activation of receptors linked 
to PLC (Cooper et al, 1988). Since calmodulin is present in high 
concentrations in the brain the stimulation of adenylate cyclase becomes 
linked with the stimulation of PLC.
The C unit must have the following domains.
(i) an active site which binds Mg2+ATP.
(ii) a site for interaction with Gs .
(iii) a domain for P-site inhibition by adenosine.
(iv) a possible domain for the interaction with any of c /^By.
The P-site binds adenosine and thereby inhibits the activity of C 
(Johnson et al, 1989). Inhibition is characteristically non-competitive 
with respect to MgATP and is very potent; greater than 80% inhibition of 
hormone stimulated activity can be achieved. Stimulated adenylate cyclase is 
substantially more sensitive to P-site agonists than the unstimulated
adenylate cyclase (MacKenzie & Bar, 1973). The physiological significance 
of P-site is unknown.
There are four possible sites in the model of (Krupinski et al, 
1989) for glycosylation (N-linked) but only one of these sites, Asn706, 
would be exposed extracellularly. A 120kD form of C is phosphorylated by 
PKC in frog erythrocytes (Yoshimasa et al, 1987), a possible site for this 
being Ser481. Similarly, a consensus site for phosphorylation by PKA is 
present at Ser1035.
The most strikingfeature of C is the tertiary structure of the enzyme. 
The enzyme contains 12 transmembrane helices, this seems rather excessive 
in light of the fact that all of the regulatory domains are located in the 
cytoplasmic parts (Krupinski et al, 1989). The 12 transmembrane helices 
resemble the tertiary structure of certain G-protein linked ion channels, 
such as the dihydropyridine-sensitive Ca++channel (Yanati et al, 1987).
1.3.4 S tructural features of Gs and Gj of adenylate  cyclase  
system
Gs
Multiple forms of Gs have been identified. These arise as four 
alternative splice variants of a single mRNA (Northup et al, 1980) yeilding 
of 394, 381, 380 and 395amino acid variants of a s1, 2, 3 & 4. The actual 
M r of the lower (381 & 380 amino acid) and higher (394 & 395 amino 
acid) Mr forms are 44kD and 46kD respectively (Kozasa et al, 1988).
The turnover number of the GTPase activity is quite low, as one might 
predict for a regulatory enzyme, at 13-15 min’1 (Arad & Levizki, 1979).
Unlike aj, a s does not undergo acylation so that the method of
attachment to the membrane may be by association with adenylate cyclase
(Levitski, 1987). The nature of the attachment is important because G-
protein activation seems to involve dissociation of the a  from the py subunits
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and if the latter provide the only site of membrane attachment the activated 
as would leave the membrane.
A fifth a s like species is known but this is only expressed in olfactory 
neuroepithelial cells, as far as is known to date (Jones et al, 1988) and has 
been termed a o)f. This is a 381 amino acid protein, sharing 90% homology 
with other a s species and apparently stimulates adenylate cyclase in 
neuroepithelial cells. The expression of a o(f in S49 eye' kin" lymphoma 
cells, which lack Gs, has been used to demonstrate its capacity to stimulate C 
in a non-olfactory system (Jones & Reed 1989).
Gi
Three distinct genes are known each coding for different forms of Gj. 
aj1 consists of 355amino acid, aj2 of 354, and aj3 of 354amino acid and 
they exhibit between 87 and 93% sequence identity (Suki 1987). The 
molecular weights of aj1, aj2 and aj3, found by SDS-PAGE, are 41kD,40kD 
and 41 kD (actual Mr for cxjl is 40.4kD), respectively.
As regards covalent modification, Gj undergoes N-myristylation (Buss 
et al, 1987) at the N-terminal residue (glycine), the function of which is 
uncertain, although it could simply to be to anchor the protein in the 
membrane. Metabolic labelling studies with [3H]myristate of monkey kidney 
COS cells transfected with cytomegalovirus-based expression vectors have 
shown that otjl, ocj2, ccj3, a 0 , ocz , a t but not a s undergo myristolyation 
(Mumby et al, 1990). Myristoylation which appears to be important for the 
attachment of the protein to the membrane. Experiments on the distribution 
of [3 5 S]m ethionine labelled a j  and a s show that the former 
immunoprecipitates from particulate fractions when myristoylated. However 
otjl precipitates from soluble fractions when myristoylation is blocked by 
utilizing cDNAs in which the second residue, glycine, was converted to alanine 
(Jones et al, 1990). The lack of the myristoylation modification does not
prevent association with py subunits since py are required for Pertussis 
toxin catalysed ADP-ribosylation of aj and this reaction is not impaired with 
non-myristoylated substrate (Jones et al,1990). However the dose 
response curve for the stimulatory effect of exogenous py added to soluble 
aj1, is shifted to the right for the mutant aj1.
Gj apparently also undergoes phosphorylation on the aj subunit which 
appears to inhibit its activity (Jakobs et al, 1985). Treatment of intact 
hepatocytes with the PKC activating phorbol ester TPA, elicits the 
phosphorylation and inactivation of Gj (Pyne et a/,1989). This may account 
for the fact that phorbol esters can by a presumed loss of tonic Gj function 
augment the stimulation of adenylate cyclase by isoproterenol in S49 
lymphoma cells (Bell et al, 1985).
Other Gj like proteins
Go
G0 was first identified as a predominant Pertussis toxin substrate in 
bovine brain (Sternweiss & Robishaw, 1984). Several lines of evidence 
indicate the presence of multiple forms of G0 . Two different cDNAs for a 0 
have been cloned from several mammalian tissues including rat brain (Itoh 
et al, 1988; Van Meurs et al, 1987). Bovine a Q1 contains 354 amino acid, 
the same number as a Q2, their sequences being identical up to position 246, 
thereafter 26 amino acid are different. It has been proposed that aQ1 and a02 
arise due to alternative splicing of a single transcript (Hsu et al, 1990). 
The function of a 0 is uncertain although a number of target effector units 
have been implicated.
Gz
The cDNA for a 2 was isolated from a bovine retinal library with a t 
cDNA at low stringency (Fong et al, 1988). The deduced amino acid sequence 
consists of 355 amino acid (Mr =40,879) exhibiting a particularly strong 
homology with the aj proteins (66-67% identity in sequence with aj1, aj2
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and aj3) although not strong enough to be part of a separate subfamily (cxj 
subunits exhibit 85-94% identity between each other). Northern and 
western blotting analyses have shown that a z occurs in the retina, brain, 
adrenal gland, kidney and liver but not testis, lung or spleen (Fong et 
a/,1988). One interesting deviation from classical aj structure is the lack 
the cysteine residue, 4 amino acid from the C-terminus, which serves as the 
site for Pertussis toxin ADP-ribosylation of the aj subunits. The intrinsic 
GTPase activity of Gz is very low, 0.05min'1 at 30 Celsius,ie 200 times 
slower than for other G-proteins (Cassey et al, 1990). Thus Gz is very 
likely to have quite a different mode of regulation from the more classical G- 
proteins.
B subunits
Three B subunit cDNAs are known, and these are derived from three 
non-allelic genes located on chromosomes 1 (B1 encoding a 37.329kD), 7 
(B2 encodes a protein 90% identical to B2), and 12 (B3 encoding a 340 
amino acid 37.221 kD protein) (Blatt et al, 1988; Levine et al, 1990). B3 
mRNA may undergoe two alternative splices but its tissue distribution is not 
yet known (Levine 1990). Most tissues appear to contain two B subunits of 
35 and 36 kD on SDS-PAGE both 340 amino acid and differ by only 42 amino 
acid.
y subunits
The y subunit, is a hydrophobic protein, of 74 amino acid, and binds 
tightly to the B subunit and consequently remains bound to B subunit during 
purification (Marbach et al, 1990).
A y specific to ROS membranes, Yt> associated with the transducin 
system is also of 74 amino acids, and contains a large proportion of acidic 
residues while remaining a highly hydrophobic protein (Yatsunami et al, 
1985; Ovchinnikov et al, 1985).
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Functional differences may exist between these two y subunits since 
By purified from bovine brain is much more effective at inhibiting adenylate 
cyclase than Byt purified from ROS membranes (Cerione et al, 1987).
1.3.5 Mechanisms of hormonal regulation of Adenylate cyclase
The kinetics of adenylate cyclase regulation have been studied in great 
detail. The kinetics are very complicated but relatively easy to study 
experimentally since the adenylate cyclase system can be studied in isolated 
membranes where it retains generally excellent hormone responsiveness. 
Thus the vast differences in the understanding of the regulation of adenylate 
cyclase as compared with PLC, PLA2 and ion channels, for example is mostly 
due to the ability to study the system as isolated membranes by classical 
biochemical means in vitro.
The kinetics of regulation of adenylate cyclase show thatsfeimulators, 
Rs Gs, activate by increasing Vmax without altering Km for ATP (Birnbaumer 
et al, 1980). Since Gs is essentially regulating adenylate cyclase in an 
allosteric manner then the regulation of adenylate cyclase can be seen to of 
the V-system type as described by Monod et al, (1965), (Monod et al, 
1963) as opposed to the much more common K-system in which allosteric 
efectors only alter affinity of substrate for the enzyme.
Amplification of the initial signal is a prominent feature of the 
adenylate cyclase system. This occurs firstly at the step of Gs activation since 
a single B-AR molecule can activate several molecules of Gs in native 
membranes (Tolkovsky & Levitski 1978) and in reconstituted systems 
(Hekman et al, 1984). It has been estimated that amplification is of the 
order of 1000, that is one activated receptor results in the production of 
1000 molecules of cAMP (Levitzki et al, 1988). The first step in the 
amplification process is the ability of 1 A-Rs to activate a number of Gs. The 
second stage relates to the relative turnover numbers of Gs and C. The overall
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rate of Gs activation (Kon), i.e exchange of GDP for GTP, is 0.5-1.5 min'1 
which is much slower than the rate of turn off, ie the GTPase reaction, at 
13-15 min'1 (Arad & Levitzki 1979). Thus GTP hydrolysis occurs quickly 
in comparison to the rate of nucleotide exchange. The turnover number Kcat 
of C is 1100min'1. Thus since Gs has a Koff of 13 min'1 it is in its active 
form for .J 0 0  times as long as the active form of C, thus allowing active Gs 
to activate further molecules of C and hence increase the amplification of the 
initial signal.
The activation of adenylate cyclase by B-AR is first order where the 
rate constant of activation Kon is linear with the concentration of A-Rs 
(Hekman et al, 1984). This can be expressed as 
Kon = k[Rt].[A)/(Kd + [A])
= k[Rt] x fraction of active receptor population 
where [Rt] is the total receptor concentration and Kd is the equilibrium 
dissociation constant for the A-R complex.
In reconstituted systems (Asano et al, 1984) it has been shown that 
the K0 5 for isoproterenol stimulation of [35S]GTPyS to Gs is only 2% of the 
Kd for the B-AR antagonist [125I]-CYP binding to B-AR of the vesicles. The 
Kd of the 8-antagonist propanolol, at 2.3nM to compete off [125I]-CYP is the 
same as the Kj for propanolol to inhibit isoproterenol stimulation of GTPyS 
binding to Gs. The amount of Gs greatly exceeds that of B-AR so that the 
explanation cannot be that their is a molar excess of B-AR. These results 
could be explained by the catalytic efficiency of B-AR, such that only a 
fraction of the total population of B-AR is required to be activated in order to 
achieve full activation of the entire population of Gs.
Reconstitution of purified B-AR, Gs , Gj, and C (Citri & Schramm, 
1980) has greatly aided the kinetic analysis of the adenylate cyclase system. 
This overcomes determinations done in native membranes which are subject 
to the major drawback that the amounts of each component, B-AR,Gs,Gj and C,
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cannot be altered in order to analyses the effects on rate constants.
1.3.6 Activation of Gs by Rs.
When an agonist has diffused within a few molecular diameters of the 
receptor the two begin to interact and part of the free energy of binding is 
used to deform the protein (Jencks, 1975; Burgen, 1981) and thereby 
switch the receptor to an active conformation.
R and G can easily be seen as E and S respectively. Both enzymes and 
A-R complexes (agonist bound receptor) bind tightly to reactive intermediate 
or transition state (apy with no nucleotide bound) but only weakly to the 
substrate or product (aPy-GTP).
The activation of Gs , has been relatively well worked out in 
comparison with the activation of other G-proteins. Basically, activated 
agonist-receptor complex appears to activate Gs by increasing its affinity for 
M g++ and thereby activating Gs (Iyengar & Birnbaumer 1982). Activation 
of Gs by Rs is recognized to involve the formation of a ternary complex of 
agonist,receptor and G-protein (A-RS*G S) but theoretically this does not 
have to exist since alternatively agonist-receptor complex, A-R, could 
dissociate to A+R and R could then interact with G to form a binary complex 
R S* G S. The existence of the ternary complex can be inferred by the 
observation that addition of purified Gj to purified and reconstituted mAch- 
receptor increases the affinity of mAch-receptor for agonists, thus implying 
that Gj stabilizes the receptor (Florio & Sternweiss, 1985). The addition of 
GTP to the reconstituted components results in the loss of high affinity 
binding
The ternary complex of A-R*G (Delean et al, 1980) is normally 
transitory because guanine nucleotide binds to the a  subunit within 
milliseconds (May & Ross 1988). The affinity of R for G is then decreased 
and the R*G complex dissociates. However under experimental conditions
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where guanine nucleotides can be omitted, the association between the protein 
is long lived and can be measured (Delean et al, 1980).
Radiolabelled agonist and antagonist binding to B-AR present in 
digitonin solubilised membranes, prepared in absence of GTP, binding 
separated into two clearly distinct peaks on an AcA-34 Ultrogel column 
(Limbird et al, 1980). Thus agonist and antagonist bound receptors form 
different sized complexes, that is antagonist bound receptor does not form a 
ternary complex unlike the agonist bound receptor. The antagonist and 
agonists peaks were eluted in same fractions when GTP was included in the 
solubilization buffer, thus showing that the A-R-G ternary complex is GTP 
labile. The same effects were exhibited by the bovine anterior pituitary 
dopamine receptor (Kilpatrick & Caron 1983).
If frog or turkey erythrocyte membranes are preincubated in the 
absence of GTP with isoproterenol or water, then subjected to washes by 
centrifugation in the presence of B-AR antagonists and then assayed for their 
abilities to support stimulation of adenylate cyclase activity by GppNHp, then 
the membranes pretreated with isoproterenol show significantly greater 
stimulation of adenylate cyclase (Stadel et al, 1980). This effect comes 
about because the ability of activated receptors to form a ternary complexes 
with G-proteins. If GTP is included in the preincubation there is no 
difference between stimulations achieved by isoproterenol or water 
preincubated membranes. Since there is no isoproterenol present there must 
be a memory process. The molecular explanation offered (Stadel et al,
1980) is that activated B-AR forms a stable complex with Gs (B-AR*GS) but 
only in the absence of GTP. If GTP is included in the pre-incubation then the 
B-AR*GS complex breaks down rapidly.
Whereas GTP promotes activation of a G-protein and therefore 
dissociation, GDP stabilizes the oligomeric form and thereby prevents
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activation. When GDP binds, the G-protein leaves the receptor in the 
holomeric form, but when GTP binds G dissociates into a  + Py and can only 
reassociate after GTP has been hydrolyzed. Thus the dissociation of G that 
follows GTP binding effectively makes the process irreversible (Fung, 
1 9 8 3 ) .
The activated receptor binary complex has a high affinity for a 
conformation of the G-protein in which a and py are associated and the single 
guanine nucleotide binding site is empty (Wessling-Resnick et al, 1987; 
Chabre et al, 1988). If py are not present there is no activation of the G- 
protein. There is evidence to favor py having a role in receptor 
recognition/contact for the transducin cGMP-PDE system (Fung, 1987).
With a physiological Mg++ concentration of around 0.5mM, Gs cannot 
bind Mg++ until its affinity for this cation is increased. The Km of Gs for GTP 
is not greater than 1pM and with intracellular GTP around 320jiM and GDP 
around 90pM in hepatocytes (Kleineke, 1979), Gs is always saturated with 
GTP. Thus the binding of GTP to Gs cannot be the rate-determining step in the 
G-protein activation cycle.
The binding of Mg++ to Gs is thought to promote dissociation to a s and 
Py subunits, thus releasing the active form of a s . The affinity for Mg++ has 
been estimated at 25mM in basal state and is reduced upon activation to 
10pM. Thus with a physiological Mg++ concentration of around 0.5mM, Gs 
cannot bind Mg++ until its affinity is increased (Iyengar, 1981).
The activation of Gs by A-R is at least partially achieved by, 
stimulating the release of GDP from Gs since Murayama & Ui (1983) showed 
that adipocyte membranes labelled with [3 H]GTP when stimulated with 
isoproterenol release [3H]GDP. The activated R not only increases the rate of 
GDP release but (i) hold open the GTP binding site and (ii) they may even 
increase its affinity for GTP relative to GDP (Birnbaumer et al, 1980; May 
& Ross, 1988; Florio & Sternweiss, 1989).
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In the mutant cell line H21a,. a s has a single amino acid alteration 
which radically alters its activity (Miller et al, 1988). This mutant Gs 
interacts normally with B-AR but fails to dissociate to a+ {5y upon binding 
GTP and therefore fails to activate adenylate cyclase (Miller et al, 1988). 
The mutant as evidently binds GTP and undergoes the comformational change 
which causes B-AR*GS to dissociate but cannot undergo the next step which 
leads to dissociation of Gs. A similar situation can be achieved by removal of 
Mg++. Addition of isoproterenol+ GTP, GTP binds B-AR*GS dissociates to B- 
AR + Gs , a spy does not dissociate until Mg++ is added (Higashima et al,
1987) thus showing the role of A-Rs is to promote the binding of Mg++ and 
thereby the activation of adenylate cyclase.
The kinetics of activation of Gs by isoproterenol in phospholipid 
vesicles have been studied by measuring the slowly-reversible (quasi- 
irreversible) binding of [35S]-GTPyS to Gs (Asano & Ross, 1984; Asano et 
al, 1984). Analysis shows that the apparent first order rate constant for 
binding of [35S]-GTPyS, Kapp, does not vary with increasing concentration of 
GTPyS but when 100p.M isoproterenol is included Kapp the relationship is 
nonlinear and as such indicates that binding of GTPyS is not a simple second 
order bimolecular reaction. For a bimolecular reaction in which one 
component, GTPyS is in excess, the rate should be psuedo-first order in the 
other reactant (Gs), but should be linearly proportional to the concentration 
of the reactant in excess and this is clearly not the case. Thus the activation of 
Gs and subsequent dissociation upon activation is not just a simple association 
of B-AR and Gs.
An apparently ubiquitous idiosyncrasy of R*G interactions is the 
nucleotide sensitivity of agonist binding. Why should the ability of G to 
physically increase the affinity of R for A be ubiquitous amongst all known 
R*G species. Obviously the R*G binary complex should have a lower free
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energy than R+G,/.e should have a greater stability so that the process of 
association is thermodynamically favourable. But on these grounds there 
seems to be no reason why this should always manifest itself as an increase in 
affinity between R and A. The real reason for this latter effect must be to meet 
the catalytic requirements of a later step in G-protein activation by R. The 
activation of G is driven by the transfer of the binding energy of A to R. Since 
this binding energy is of only a finite amount there must therefore be a limit 
to the number of G-proteins which can be activated.
For many receptors this increased rate of dissociation is substantial 
for full agonists. For example 50-100 fold B-AR, a ^ A R  or mAch-receptor 
(Kent et al, 1980; Goodhardt et al, 1986; Evans et al, 1985). Thus 
activation of G is effectively coupled to recycling of R.
1.3.7 Activation of Gj by Rj
The hormonal inhibition of adenylate cyclase by platelet a 2-AR has 
been shown to involve the release of guanine nucleotides from Gj (Michel & 
Lefkowitz, 1981). It was shown that stimulation of a 2-AR will stimulate the 
release of [3 -H]GppNHp from membranes pre-incubated with this 
nucleotide.
Direct evidence for the ternary complex in the activation of Gj has 
come from the demonstration of different sedimentation properties of agonist 
and antagonist labelled a 2-AR (Rj) in the absence of GTP as separated on 
sucrose density gradient profiles (Michel et al, 1981).
Overall the activation of Gj by Rj is very similar to that for Gs by Rs, 
except for the notable difference that Rj does not stimulate Gj by increasing 
its affinity for Mg++. The affinity of Gj for Mg++ is ,J 0 p M  ensures that at 
physiological Mg++ concentrations Gj is always saturated with this divalent 
cation (Hildebrandt & Birnbaumer, 1983).
1.3.8 Activation of C by Gs
l 5
The regulation of adipocyte adenylate cyclase by GTP was shown to be 
bimodal by Cooper et al, (1978). Thus low concentrations of GTP were 
stimulatory and high concentrations were inhibitory. These actions were then 
attributed to the function of Gs and Gj by virtue of their distinctive 
susceptibility to inactivation by various agents (Cooper et al, 1979). Low 
concentrations of GTP thus activate Gs while at higher concentrations Gj 
becomes activated and this leads to a net inhibition of activity (Cooper et al, 
1979). For the stimulatory effect of GTP to be seen in adipocyte membranes, 
isoproterenol has to be included otherwise the response to GTP is very poor 
(Cooper et al, 1979). Similarly, inhibition of adenylate cyclase at high 
concentrations of GTP requires adenylate cyclase to be stimulated with 
isoproterenol in order to detect inhibition (Cooper et al, 1979). However it 
is significant that the presence of an Rj agonist is not required, thus implying 
the presence of tonic (receptor-independent) inhibition. The bimodal 
regulation undoubtly endows the system with a very high degree of hormonal 
regulation befitting its crucial role in cellular regulation.
The activation of adenylate cyclase by the non-hydrolysable GTP 
analog GppNHp was found to be hysteretic in contrast to that achieved using 
GTP itself (Iyengar & Birnbaumer, 1981). This could be interpreted as 
meaning that the pre-steady state lag phase, lasting minutes, found with 
GppNHp is due to its nonhydrolysabie nature. However by reducing the 
[Mg++] to <1.0mM it was found that GTP and NaF both show lag phases in 
their stimulation of adenylate cyclase (Iyengar & Birnbaumer, 1981). Most 
enzymes that display long lag phases (ie minutes), in terms of ligand, binding 
show this effect because of the time required for the association of discrete 
subunits. Hence the lag phase in the case of adenylate cyclase is then probably 
related to the separate subunit composition of adenylate cyclase (Iyengar & 
Birnbaumer, 1981). The greater lag phase with GppNHp at [Mg++] >1.0mM 
is probably that the different contacts of GppNHp made in the guanine
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nucleotide binding site of Gs causing the activation rate of Gs to be slower than 
with GTP. These experiments also show the central role of Mg++ binding in 
the activation of Gs.
That Gs exists in three quite different conformations during its 
activation cycle can be seen from the hydrodynamic behavior of the purified 
protein by density gradient centrifugation (Codina et al, 1984). The GppNHp 
bound form sediments as 4S, the GppNHp+Mg++ form at 3S, and the 
dissociated as, form as 2S. The 3S form cannot normally be detected since is 
rapidly converted to 2S, although it can be if the temperature is lowered to 4 
degrees Celsius (Codina et al, 1984). The 3S form rapidly breaks down to 
the 2S form, because the 3S form is essentially an unstable intermediate in 
the process of forming the 2S dissociated a s+py from the 4S a spy species of 
G s. This behavior of Gs was believed to demonstrate that Gs undergoes 
dissociation as part of its route to the attainment of an activated state, at least 
as activated by GppNHp and Mg++.
The catalytic unit C also contains a Mg++ binding site (Somkuti et al,
1981). According to this data, the allosteric binding site for Mg++ appears to 
be essential in that the site must be occupied in order for A-Rs to activate Gs. 
This allosteric site appears to be quite distinct from the MgATP binding site.
It has been estimated that since the deactivation rate is 15 to 20 times 
faster than the activation rate,ie Kon is 0 .5 -1 .5m in'1 while Koff is 13- 
15m in'1, there is only 5 to 7% of Gs which is active even in the presence of 
hormones and GTP (Levitzki et al, 1977). Concerning the activation of Gs, 
Levitzki has shown by kinetic analysis and physical co-purification of Gs 
with C (Arad et al, 1984) that Gs remains tightly bound to C and therefore 
to the membrane throughout the activation cycle. Also it appears that the 13 
subunit  ^ remains bound to a s during the entire activation-deactivation 
cycle of Gs. This has been demonstrated by the stoichiometric co-purification
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of GppNHp preactivated adenylate cyclase as a complex of a sGppNHp*B*C 
from turkey erythrocyte membranes (Bar-Sinia et al, 1990) and bovine 
brain membranes (Marbach et al, 1990). However high salt concentrations 
do promote the dissociation of B from a s*C. It has been shown that the 
dissociation of apy depends on the nucleotide bound (Huff & Neer, 1986), 
with GTPyS causing complete dissociation and GTP causing no dissociation at 
all. These results imply that the mechanism of Gs activation involving 
dissociation of a spy may be incorrect and consequently the inhibition of Gs by 
Gj cannot be due to the release of free By.
1.3.9 Inhibition of adenylate cyclase by Gj and the role of Gj in 
regulation of adenylate cyclase.
The mechanism by which G inhibits adenylate cyclase is not yet 
resolved, partly because, in theory, there are a number of ways in which this 
can be achieved. In practice more than one way probably operates in any case. 
The potential mechanisms to inhibit adenylate cyclase include (i) direct 
action of aj upon adenylate cyclase or its associated components necessary for 
activation and (ii) Involvement of By exerting effects directly upon C subunit 
or associated components. This latter possibility is made more likely by the 
relatively high affinity of py for a s compared with aj (Sternweis, 1986; 
Pang & Sternweis, 1989) and also the large excess of Gj over Gs, presumed 
by some, to occur in most membranes (Gilman, 1987).
It has been shown in S49 eye" cells, which lack Gs and its mRNA, that 
there is direct effect of Gj upon the C subunit, since both Rj linked hormones 
and GTP still inhibit adenylate cyclase (Hildebrandt et al, 1982; Jacobs et 
al, 1983). Studies on the wild type S49 cell line show that in the case of 
forskolin-stimulated adenylate cyclase, By inhibitsadenylate cyclase activity 
to the same extent as somatostatin and such effects are non-additive when py 
was added together with somatostatin (Katada et al, 1984). This would then
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tend to support By as the mediator of somatostatin action. However 
Hildebrandt & Kohnken (1990) have shown that while somatostatin and By 
are equally effective in inhibiting forskolin-stimulated adenylate cyclase in 
wild type S49 cells as found by (Katada et al, 1983), By are much less 
effective than somatostatin at inhibiting isoproterenol-stimulated adenylate 
cyclase. The By complex only inhibited isoproterenol-stimulated adenylate 
cyclase at very high concentrations. In addition, somatostatin served as a 
mixed inhibitor of isoproterenol stimulated adenylate cyclase while By was a 
simple non-competitve inhibitor. Thus By and somatostatin appear to inhibit 
adenylate cyclase by different mechanisms, at least when stimulated by an 
Rs-linked hormone. Thus the authors propose that aj mediates Rj-stimulated 
inhibition of Rs-stimulated adenylate cyclase while By probably function to 
inhibit basal activity of adenylate cyclase (Hildebrandt & Kohnken, 1990).
It is also relevant that in a reconstituted system of purified 
components B-AR, Gs, C and Gj the fold stimulation of adenylate cyclase 
activity by isoproterenol was only 1.3 fold over basal (in the absence of Gj) 
but when Gj was included this increased to 7-8 fold (Cerione et al, 1985). 
It was found that a ratio of 4-5 Gj molecules to every Gs was required to 
achieve an increase in the fold activation reported. This may well relate to an 
overall excess of Gj to Gs of 4-10 times, as found in purification studies 
(Codina et al, 1984). Thus it appears that Gj might serve more than one 
function if this phenomena was to occur in vivo since Gj would be required 
for maximal activation of activity apparently by suppressing the basal 
activity of adenylate cyclase, ie eliciting a tonic inhibition of adenylate 
cyclase.
In eye" membranes Gj is a simple non-competitive inhibitor of Gs- 
GTPyS added exogenously. However Gs activated by GTPyS, which is thought to 
be in the dissociated state of free a s, is probably quite resistant to inhibition 
by By (Northup et al, 1983). Cholera toxin substantially reduces the
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affinity of By for a s (Kahn & Gilman, 1984) and cholera toxin-catalysed 
ADP-ribosylation of adipocyte membranes in presence of GTP reduces the 
effectiveness of Rj linked inhibition mediated by PIA by some 35% (Owens 
et al, 1985). Under these conditions there is little ADP-ribosylation of Gj 
(Milligan, 1987) therefore this reduction in PIA mediated inhibition 
probably reflects an alteration in the ability of adenylate cyclase system to be 
inhibited rather than any ability of Rj to generate the inhibitory species. 
Thus, in adipocytes, ADP-ribosylation of Gs may well reduce its ability to be 
inhibited by Rj receptor means. Since ADP-ribosylation is known to reduce 
the affinity of Gs for By then the reduction in effectiveness of Rj-mediated  
inhibition in this system may well be due a decreased capacity of By to inhibit 
adenylate cyclase because of reduced affinity between a s and By. However 
others (Toro 1987) have claimed that Rj mediated inhibition is not sensitive 
to cholera toxin mediated ADP-ribosylation of Gs. However one of the 
strongest arguements against By playing a direct role in the Rj mediated 
inhibition of adenylate cyclase is that By seem to be functionally 
interchangable between different G-proteins. Thus any time a G-protein is 
activated, adenylate cyclase would be inhibited. This is then a rather 
unsatisfactory biological non-specificity.
Another mechanism by which Gj might inhibit adenylate cyclase is 
would involve Gj interaction with Rs. Evidence shows that Gj will interact 
with B-AR in reconstituted systems in which it has been shown (Asano et al,
1988) that B-AR will stimulate GTPase activity of Gj. However more direct 
evidence has recently been obtained since Marbach et al (1988) have 
demonstrated a direct interaction between Gj and B-AR in S49 lymphoma 
cells. This interaction requires the presence of Gs since in does not occur in 
eye' S49 cells or in turkey erythrocyte membranes which lack Gj. The 
interaction was inferred by showing that Pertussis toxin catalysed ADP-
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ribosylation of Gj in membranes results in a 3 fold reduction in affinity for 
isoproterenol. This interaction could only be demonstrated by utilising an 
improved method of ligand binding studies to detect the interaction of B-AR 
with Gj (Marbach et al, 1988).
Antagonists of the 3-opiate receptor have been found which exhibit 
negative intrinsic activity (Costa & Herz, 1989) and for this to occur it has 
been suggested receptor catalysed partial activation of Gj may occur due to 
unoccupied receptors, others have arrived at similar conclusions (Sunyer et 
al, 1989). Evidence for an activity of unoccupied receptors in stimulating 
G-proteins also comes from reconstitution of a 2-AR with Gj+C showing that 
even in absence of a-adrenergic agonist the empty a 2-AR will activate Gj 
(Cerione et al, 1986). Similarly the same process has been shown for the 
B-AR, GS,C reconstituted system (Cerione et al, 1985). Antagonist affinity 
has been found to be modulated by GTP or its analogs for mAch-receptor 
(Burgisser et al, 1982), D2-dopamine receptor (De lean et al, 1982) and 
the A1-adenosine receptor (Green et al, 1984). In these cases the antagonist 
must be active in promoting the dissociation of R*G which requires empty 
receptors to be able to activate G-proteins.
Tonic, receptor-independent, inhibition of adenylate cyclase by Gj has 
been observed in a number of systems including fat cell membranes (Cooper 
et al, 1979). This was determined by virtue of the inhibition of adenylate 
cyclase seen at high concentrations of GTP in the biphasic dose response curve 
of isoproterenol stimulated adenylate cyclase to GTP. The tonic inhibition of 
adenylate cyclase can also be seen by using low concentrations of GppNHp 
upon forskolin stimulated adenylate cyclase in adipoctye membranes (Begin- 
Heick, 1985), hepatoctye membranes (Houslay, et al 1988), and platelet 
membranes (Spence & Houslay, 1989). Tonic inhibition of adenylate cyclase 
by Gj could occur by at least two mechanisms: either by empty-receptor
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catalysed activation of Gj or by an intrinsic basal activity of Gj. However, 
since empty receptor activation of Gj seems to be a real possibility, it is 
interesting to note that 3-opiate antagonists which display negative intrinsic 
activity do so only at low [Na+]. At high concentrations of Na+ tonic inhibition 
is lost but that mediated by PIA acting upon Rj in adipocyte membranes is not 
(Cooper 1982). Thus it is possible to both divorce the two modes of 
inhibition by selectively inhibiting one and not the other. It has been noted 
that Na+ promotes the activation of adipocyte adenylate cyclase by GTP (Katz 
et al, 1981). This latter effect could be because high Na+ has abolished the 
tonic inhibition by GTP, resulting in greater stimulation by GTP.
In lipid vesicles exogenous py added will inhibit GTPyS-stimulated but 
not isoproterenol stimulated adenylate cyclase (Cerione et al, 1985). One 
possibility is that active a s remains associated with B-AR, however this is 
difficult to reconcile with the demonstrated ability of a single B-AR to 
catarlytically activate many G-proteins (Pederson & Ross 1982). An 
alternative may be that a s-GppNHp and Py are evenly distributed but that 
a s-G TP+py formed using stimulation by isoproterenol+GTP are locally 
concentrated around B-AR. In this case more free as may be needed to activate 
B-AR because of the higher local concentration of py and in consequently the 
susceptibility to inhibition is lost.
1.4 FEATURES OF Rs AND Rj OF THE ADENYLATE CYCLASE SYSTEM  
AND COMPARISON WITH RECEPTORS FROM OTHER SIM ILAR  
SIGNAL TRANSDUCTION SYSTEMS.
1.4.1 General structural features.
Rhodopsin and B-AR are the most well characterised G-protein linked 
receptors known. Thus far, all receptors coupled to G-proteins appear to 
share common tertiary structural features, most notably the seven 
transmembrane spanning helices. Each receptor is approximately 40-50KD, 
approx 350-500 amino acid and probably forms seven transmembrane
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regions linked by 3 cytoplasmic and 3 extracellular loops (Wang et al,
1989). The extracellular N-terminal tail may contain one or more 
glycosylated residues and the intracellular C-terminal tail has several serine 
and threonine residues that are potential or demonstrated sites of 
phosphorylation. The transmembrane sequences are unusual in having many 
proline and glycine residues. These may form 'kinks' in the helices that help 
form the binding pocket buried deep within the transmembrane regions. They 
may also play a part in transmitting to the cytoplasmic surface of the 
receptor the conformational change induced by ligand binding (Dolhman et 
al, 1987; Chambre & Deterre 1989). The transmembrane residues, 20-25 
amino acid for each helix, are the most conserved amino acid between 
different receptor molecules (Lefkowitz et al, 1989).
1.4.2 Ligand recognition
Ligand recognition also seems to show, albeit unexpectedly, some 
common structural features. Negatively charged acidic residues in the 
putative intramembrane binding pocket serve as counterions for positively 
charged retinal, acetylcholine, or adrenaline (Applebury & Hargrave 1986).
Most of the extramembrane regions of the 8-AR can be removed by 
proteolysis without altering ligand binding, indicating that the ligand binding 
domain must lie within the core of the protein (Rubstein et al, 1987).
Similarly retinal interacts with opsin through the formation of a 
Schiff base with Lys296 in the 7th transmembrane helix. Biophysical studies 
suggest that the bound chromophore in rhodopsin is buried approximately 
30% into the membrane bilayer (Chambre & Deterre, 1989).
In the case of the B-AR, the protonated amine group of catecholamines 
is located to Asp113, as substitution to Asn results in a 10,000 fold decrease 
in affinity for adrenergic agonists. In the B-AR, Asp79 also seems to be 
involved in agonist binding, however unlike Asp113, Asp79 is not involved
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with antagonist binding. The residues in the ml muscarinic acetylcholine 
receptor corresponding to Asp113 and Asp79 of G-AR are Asp105 and Asp71 
respectively (Strader et al, 1989) showing that some of the contacts are 
made in the binding pocket of the ml muscarinic receptor are similar to 
those made in the G-AR.
Molecular replacement analysis has been less succesful in 
determining amino acid responsible for G1 and G2 receptor subtype 
selectivity. This is determined by contacts made to the substitution on the 
amine group If helix 4 of G^AR is changed to predominantly a, G2-like 
form, then the affinities of the G-j-AR became more like those of G2-AR  
(Frielle et al, 1988). Thus a G^AR can be turned effectively into a G2-like 
AR by replacing helices 4 and 5 of G^AR with those of G2-AR. In contrast 
smaller helix replacements or single amino acid replacements failed to affect 
subtype specificity. Thus it appears G-j-AR and G2-AR differences cannot be 
attributed to a single amino acid contact which is any different between G^ 
AR and G2 -AR, rather this recognition difference arises from the 
conformation of the receptor helices which is controlled by sequences within 
the transmembrane helices 4 and 5 (Dixon et a/,1989 ).
Mutagenesis of the highly conserved Asp130 in the putative third 
transmembrane helice of the human G-AR to Asn results in a receptor which 
is completely unable to stimulate adenylate cyclase (Fraser et al, 1988). 
However, somewhat paradoxically, this receptor is still responsive to 
guanine nucleotide effects on agonist affinity in membranes. The quantitative 
effects were somewhat different in that whereas in wild type G-AR containing 
membranes 100pM GppNHp caused 5 to 10 fold shifts to the right in 
competition studies of 125l-CYP/isoproterenol, the shift was only 3-5 fold 
in the mutant receptor. In addition the Hill co-efficient nHiu changed from 
0.5-0.66 to 0.86-1.0 for the wild type receptor, but in the case of the
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mutant the co-efficient nHiu was unchanged. Examination of the GppNHp dose 
response curve of % 125I-CYP bound in the presence of 35pM 125I-CYP and 
10pM isoproterenol showed that the K0 5 for the mutant B-AR was much 
higher than than that for wild type. These experiments thus separate the two 
effects of Gs activation and GTP effect on agonist binding. In cells the affinity 
of mutant receptors for agonist is much higher and they show only a single 
class of sites but the affinity for antagonist is unaltered.
1.4.3 G-protein recognition
Receptor recognition of G-protein seems to involve both the loop that 
links the 5 and 6 transmembrane domains, i.e the 3rd cytoplasmic loop, and 
part of the C-terminal domain (Kubo et al, 1988; Kobilka et al, 1988; 
O'Dowd et al, 1989) with positively charged residues possibly playing a 
major role (Ross, 1989). This agrees with the experiments showing that 
proteolytic cleavage within the 3rd cytoplasmic loop of rhodopsin disrupts its 
ability to couple to transducin (Findlay & Pappin, 1986). Mutations in the 
B-AR which uncouple it from Gs activation only reduce the maximal 
stimulation of adenylate cyclase by isoproterenol and do not affect the K0 5 
(Strader et al, 1987). It seems that regions of the N- and C-terminal ends 
of the 3rd cytoplasmic loop of B-AR are essential for coupling to Gs. However 
these are unlikely to be the only contacts between Rs and Gs.
However using proteolysis of purified B-AR from erythrocytes, 
Rubenstein et al, (1987) showed that most of the 3 rd cytoplasmic 
intracellular loop and the C-terminal tail are not required in any way for 
functional coupling to Gs. Also most of the putative extracellular hydrophilic 
domains of B-AR can be deleted without affecting coupling to Gs. The question 
then posed is what is the purpose of these domains: for example do they have a 
role in B-AR desensitization ?
Another approach to the mapping of domains of the B-AR which 
interact with Gs is the use of peptides corresponding to portions of the known
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sequence of B^AR to inhibit isoproterenol stimulated adenylate cyclase 
(Palm et al, 1989).
1.4.4 Antagonist binding.
An antagonist must bind more strongly to the active conformation of 
its receptor, otherwise many binding events would be unproductive. This 
state is the conformation of R which binds most tightly to the 'transition' 
state, apy with no guanine nucleotide bound. If a guanine nucleotide is then 
added it binds to the vacant site on a s , the transition state is lost, the 
association R*GS is weakened and with it the high-affinity binding of A to R. 
The analogous phenomenon for photoreceptors is the decreased stability of the 
active form of rhodopsin (meta rhodopsin II) in presence of GTP (Pfister et 
al, 1983). Antagonist receptors cannot bind more tightly than empty 
receptors to the G transition state or they would activate G. An antagonist may 
simply sterically block the binding of agonist but it may also bind more 
tightly to the inactive form of G and will exhibit negative intrinsic activity 
and thus inhibit basal turnover of G (Costa & Herz 1989). When the 
antagonist occupied receptor binds more tightly to the inactive (non­
transition state) forms of R, GTP then stabilizes this antagonist binding. This 
appears to be true for 3-opoid, D2 -dopaminergic, A 1-adenosine and 
muscarinic receptors ( Burgisser et al, 1982).
1.5 REGULATION OF OTHER G-PROTEIN COUPLED EFFECTORS AND 
COMPARISON TO ADENYLATE CYCLASE.
1.5.1 Why use G-proteins?
The types of events controlled by receptors and the time scale over 
which they elicit their actions vary enormously. Thus activation is seen 
within milliseconds in the case of acetylcholine's ability to cause postsynaptic 
depolarisation. In contrast the effects that a growth factor, involving protein 
tyrosine kinase activation dependent activation, are much slower to elicit an
2 6
end result. Slow dissociation of A from R would provide high affinity binding 
and consequently a sensitivity to low concentrations of A, but would 
inevitably leave R insensitive to rapid changes in concentration of A. For G- 
protein linked R there are additional problems stemming from the agonist 
being bound to the receptor for too long, thus the interaction with G becomes 
inefficient. Active R will initially collide with only inactive G but as more of 
G is activated with time, an increasing fraction of collisions will be with 
already active G.
The conflict between responding rapidly and still maintaining 
sensitivity to low concentrations of agonist can therefore be satisfied by 
having receptors of relatively low affinity, hence fast dissociation rates, but 
to have so many spare receptors that maximal response can be evoked when 
only a small fraction are occupied so that sensitivity to low agonist 
concentrations is retained. In guinea pig ileum occupancy of less than 0.25%  
of muscarinic cholinergic receptors by acetylcholine is sufficient to cause 
half maximal contraction (Kenakin 1984).
The discrepancy between curves for receptor occupancy and certain 
responses, arises whenever one saturatable event controls the next 
saturatable step in the sequence (Strickland & Loeb 1981; Kenakin 1984). 
Thus the inclusion of G-proteins into the signalling sequence exaggerates the 
discrepancy between occupancy and response curves. Spare receptors 
therefore allow cells to respond to low agonist concentrations without losing 
sensitivity to rapid changes in agonist concentration. A change in receptor 
number can thus substantially alter sensitivity of adenylate cyclase without 
preventing full response.
G-proteins provide a means to enhance temporal sensitivity without 
sacrificing sensitivity to low agonist concentrations. They essentially, speed 
up the dissociation of agonist from R by virtue that dissociation of Gs from A-
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Rs*Gs converts A*RS to low affinity, therefore dissociation rate increases so 
that A leaves Rs, then Rs is back in a high affinity form to seek out and bind 
new agonist. Thus the recycling of R is coupled to the activation of G.
1.5.2 Rhodopsin-transducin-cGMP-phoshodiesterase system.
As regards the particular functional roles within a G-protein of the 
individual a,p and y subunits the best resolved case is that of transducin. In 
retinal rods free a t-GTP activates cGMP-PDE by binding to the small 
inhibitory subunit and relieving the inhibition upon the cGMP-PDE (Fung & 
Griswald-Penner, 1989; Chabre & Deterre, 1989). In other signal 
transduction pathways the relative roles of a,p and y are less clear.
In comparison with the dissociational activation of Gs, when the a t of 
transducin binds GTP, but not GDP, its affinity for Py is substantially reduced 
and the a tpy dissociates into Py and a t-GTP (Navon & Fung 1987). A single 
activated rhodopsin can activate a number of a tPy, since individual py can 
recycle between many subunits. Thus the transducin-cGMP-PDE signal 
transduction system like that of the adenylate cyclase system is able to 
achieve signal amplification.
Recently the y subunit of transducin has been found to be farnesylated 
(Fukada et al, 1990). This modification appears to be essential for full GTP 
binding activity of holomeric transducin. The more active, farnesylated, form 
runs at 6kD rather than 8kD for the less active non-farnesylated form since 
bovine brain y subunit was found to exist as in two forms in native ROS 
membranes (Fukoda et al, 1989) which can be separated by electrophoresis 
and identified by a common antigen site. A similar covalent modification may 
occur in the other y subunits of different G-proteins. It is of interest that the 
GTP binding proteins p21ras which cannot bind p# subunits is itself 
farnesylated (Hanock et al, 1989), (Casey et al, 1989), (Schafer et al,
1989).
1.5.3 Rp>Gp-phospholipase C system
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There are multiple PLC isoenzymes some of which appear to be 
regulated in a G-protein dependent fashion, Gp, (Fain, 1990). In some 
systems Gp appears to be a Pertussis toxin sensitive protein (presumably 
one of a j1 ,2 ,3  or a 0 1 or 2) as in neutrophils stimulated by fMLP 
(Nakamura & Ui, 1985). In other systems such as hepatocytes stimulated by 
vasopressin Gp is Pertussis toxin insensitive (Martin et al, 1986). In 
Xenopus  oocytes activated a 0 appears to stimulate PLC (Moriarty et al,
1990).
In contrast to the regulation of adenylate cyclase there is no good 
evidence for the existence of an inhibitory G-protein for the PLC system. 
However a Pertussis toxin insensitive inhibition of pituitary cell PLC by 
dopamine receptors has been observed (Enjalbert et al, 1986). It is of note 
that turkey erythrocyte I3-AR*G*C system, contains no Gj and therefore has 
no means to achieve receptor-mediated inhibition of adenylate cyclase. Thus 
regulation of adenylate cyclase in turkey erythrocytes has some analogy to the 
regulation of PLC in mammalian systems.
There is a family of low molecular weight guanine nucleotide binding 
proteins, the p21 proteins  ^which are encoded by the genes H-ras, K-ras, N- 
ras and others (Barbacid, 1987). The function of these proteins is uncertain 
but they may be regulated by cell surface receptors and thereby control the 
activity of effector enzymes vide infra. It has been reported that p21ras 
proteins coupled bombesin receptors to PLC (Wakelam et al, 1987).
1.5.4 R-G-phospholipase A2 system
Phospholipase A2 is an effector enzyme, which when hormonally 
stimulated, hydrolyses phosphatidyl choline to arachidonic acid and 
lysophosphatidyl choline. In mast cells (Bokoch & Gilman, 1984) and 
neutrophils (Okajima & Ui, 1984) stimulation of PLA2 is Pertussis toxin 
sensitive. The identity of the G-protein involved is unknown.
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1.5.5 The dihydropyridine-sensitive, voltage gated Ca+ + - 
channel(s)
For Ca++ channels a s-GTPyS activates the channel protein in heart 
tissue membranes (Yanati et al, 1987). In addition PKA seems to activate 
the channel by phosphorylation (Yanati et al, 1987). The stimulation of L- 
type Ca++channels in guinea pig ventricular myocytes occurs by potentiation 
of high activity gating modes (Yue et al, 1990).
G0 has been found to be capable of inhibiting the channel by direct and 
indirect means. In chick dorsal root ganglia G0 may directly inhibit the 
channel via a-adrenergic receptors and GABAB-receptors (Holz et al, 1986; 
Rane et al, 1986). In these same cells the inhibitory effect can also be 
mimicked, in Pertussis toxin-treated cells, by the addition of phorbol esters 
(Rane et al, 1986). Thus activation of PKC via stimulation of G0 may be 
another route of inhibition of the Ca++ channel.
1.5.6 Signal transduction of growth factor receptors exhibiting 
tyrosine kinase activity
G-proteins are not generally believed to couple to growth factor 
receptors possessing protein tyrosine kinase activity. This has been in part 
due to the possibility that effector activation was mediated directly by the 
PTK activity however recent results may indicate otherwise.
Recently  stim ulation of T -ce ll activation  by PHA, 
phytoheamagglutinin, has been shown to activate p21ras (Downward et al,
1990). This is the first time that the activity of p21ras has been shown to 
be activated by a receptor. Activation of p21ras appears to be due to a 
decrease in the GTPase activity of the p21ras such that a larger number of 
the molecules exist in the active GTP-bound form rather than the GDP-bound 
inactive form. The mechanism of activation of p21ras is not known however 
PKC appears to be involved in the signal transduction mechanism. It is
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suggested that activation of p21ras involves inhibition of GAP thereby 
leading to decreased inhibition of p21ras. GAP (Ellis et al, 1990), or 
GTPase activating protein, stimulates the GTPase activity of p21ras thereby 
increasing the number of p21ras molecules in the GDP-bound inactive state.
It is interesting to note that a GTPase activating protein, called GAP- 
43, has been found to interact with G0 (Strittmatter et al, 1990). The 
protein GAP-43 has been shown to be a peripheral membrane protein. This 
protein is also known as B50 or neuromodulin. GAP-43 stimulates the 
binding of GTPyS to G0 by some 2 fold (Strittmatter et al, 1990). Other 
activities of GAP-43 include binding of calmodulin, inhibition of PIP kinase 
and ability to be a substrate for PKC. It is the N-terminal sequence of GAP- 
43 which stimulates binding of GTP to G0 . The N-terminus of GAP-43 
contains a 10 amino acid sequence possessing a consensus sequence found in 
the cytoplasmic loop of G-protein linked receptors.
In light of the findings of Downward et al (1990) it is worthy of note 
that a somewhat similar story emerged sometime ago when Kamata & 
Feramisco, (1984) reported that they had found that EGF could stimulate the 
phosphorylation and GTP binding of p 2 ic_H' ras in membranes from Ha-NRK 
cells (non-producer line of rat kidney cells transformed by Harvey murine 
sarcoma virus).
Concerning the involvement of p21 proteins in signal transduction, 
the p21ras protein has been found to associate with aggregated receptors cell 
surface immunoglobulins, co-capp, in activation of B-cells as shown by 
immunoflorescence (Graziadei et al, 1990). This represents further 
evidence that the p21 proteins mediate in cell surface receptor 
transmembrane signal transduction processes.
1.5.7 Adenylate cyclase in yeast (S.cerevisae)
Studies on this system are important in that it bears a considerable 
degree of homology to the mammalian system.
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As with mammalian adenylate cyclase, Mn++ stimulates the C subunit 
directly without any involvement of G-protein. In yeast the functional 
homologue of Gs appears to be the product of the RAS2 gene which is highly 
homologous in terms of sequence similarity to mammalian ras proteins 
(Broek et al, 1985). However the catalytic unit (Kataoka et al, 1985), 
CDC35, at 220kD is somewhat larger than its mammalian counterpart of 
120-150kD.
The functional equivalent of Rs is probably CDC25, however this 
molecule does not appear to contain protein sequences which would cause it to 
possess transmembrane domains like those of classical Rs. However sequence 
homology with ligand binding domain of cytochrome P-450, suggests that 
CDC25 possess a binding domain for a yet unidentified ligand. CDC25 does act 
upon RAS2 in an analogous manner to Rs upon Gs in that CDC25 catalyses 
guanine nucleotide exchange of RAS2. In membranes prepared from mutant 
yeast lacking RAS2 and RAS1, mammalian p21H' ras can reconstitute 
adenylate cyclase stimulation (Toda et al, 1985). Identification of the 
domain of CDC35 with which CDC25 interacts could help to identify the 
effector of p21ras proteins. RAS1 gene can transform NIH 3T3 cells 
provided that the C-terminus is replaced with that from p21H' ras (DeFeo- 
Jones et al, 1985). The partially purified catalytic unit of adenylate cyclase 
can be stimulated by purified RAS2 (Field et al, 1988) and also RAS1 but to 
a much lesser extent (Broek et al, 1985).
Yeast adenylate cyclase is negatively regulated by IRA-1 and IRA-2 
gene products and recently (Tanaka, 1990a) it has been shown that these two 
proteins have significant sequence homology to the product of the human 
neurofibromatosis type-1 (NF-1) gene. NF-1 encodes a tumor suppressor 
gene encoding a large protein as is the case for IRA-1 (2938 amino acid) and 
IRA-2 (3079 amino acid), (Tonaka et al, 1990b) Both IRA-1 and IRA-2
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exhibit regionalised but significant homology to mammalian GAP and 
mammalian GAP can suppress the phenotype of IRA mutants (Tanaka 1990a) 
suggesting that IRA-1 and IRA-2 may be functionally analogous to GAP. The 
homology of GAP to IRA-1 and IRA-2 has been localized to a small region in 
the middle, 1451-1780 amino acid for IRA-1 and 1597-1925 amino acid 
for IRA-2, of these proteins (Tonaka 1990a).
Two mammalian G-protein homologs have been found in S.cerevisae, 
GP1 a (encoded by GPA1) and GP2a (encoded by GPA2) of Mr 54075 and 
50516 respectively (Nakafuku et al, 1987; Nakafuku et al, 1988). The 
deduced amino acid sequences of GP1a and GP2a are highly homologous with 
those of rat brain otj and aQ. GPA1 is a haploid specific gene, only expressed 
when cells are involved in mating factor signal transduction. However GPA2 
is expressed in both haploid and diploid cells, and may be involved in the 
regulation of cAMP levels in yeast (Nakafuku et al, 1988). The level of 
cAMP regulates progression through the cell cycle, acting as an indicator of 
nutritional status of environment.
Analogs of 6 and y of mammalian G-proteins may have been found 
(Whiteaway et al, 1989) since the STE4 and STE18 genes of yeast encode 
gene products with significant sequence homology to 8-subunit and y-subunit 
respectively. It has been suggested (whiteaway et al, 1989) that STE4 and 
STE18 are the py subunits of GPa1. Expression of STE4 and STE18 is limited 
to haploid cells, suggesting the existence of another set of genes encoding 
potential py subunits of GPa2 which is present in both haploid and diploid 
cells. Thus STE4 and STE18 are probably specifically employed in the mating 
factor signalling system.
STE4 gene product has been found to be phosphorylated on serine 
residues (Cole & Reed, 1990). Thus phosphorylation of G-proteins occurs in 
yeast, holding the possibility that this is also used as a mechanism to regulate
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their functioning as is the case for Gj proteins in mammalian cells. Cells 
loaded with 32P show phosphorylation of RAS2 and RAS1 exclusively on 
serine residues. At least two tryptic phosphopeptides have been which can be 
dephosphorylated by alkaline phosphatase (Cobitz et al, 1989). However it 
appears that neither RAS proteins can serve as substrates for PKC but that 
RAS2 can be phosphorylated by PKA and that this modification decreases its 
ability to activate CDC35 (Resnick & Racker, 1988). Interestingly 
phosphorylation of a platelet 22kD GTP binding protein by PKA, smg p21, 
has been reported (Hoshijima et al, 1988) in a cell free system. Among the 
mammalian small molecular weight proteins p 2 lc' K' ras has been shown to 
be phosphorylated by PKC and PKA (Ballester et al, 1987) and p 2 iv' H' ras 
by PKC (Jeng et al, 1987).
At least 15 smg molecules have been separated from bovine brain 
membranes. The smg include ras; rh o ’,ra l;R -ras;yp t1  ;rab2; and a r t  
gene products (Barbacid 1987; Maduale & Axel 1985; Chardin & Tavitian 
1986; Lowe et al, 1987; Haubruck et al, 1987; Touchot et al, 1987; 
Sewell et al, 1988). However these proteins may not be involved in signal 
transduction. The ypt1 gene product has been implicated in secretory 
phenomena (Segev et al, 1988). The rho  p20 is known to be ADP- 
ribosylated by botulinum toxin (Kikuchi et al, 1988) and this toxin 
inhibits neurotransmitter release from cholinergic nerves. However smg21 
has sequence similarity in its C-terminal tail to the corresponding region of 
p 2 i ras proteins (Kawata et al, 1988) which is the putative effector 
domain as deduced by comparison with the effector domain of the GTP binding 
protein EF-Tu. It seems most likely that many of these smg are not involved 
in transmembrane signal transduction. However the fact that both p21ras 
proteins which may be involved in transmembrane signal transduction like 
their yeast counter parts are potentially subject to phosphorylation may have 
important clues to the elucidation of the role that phosphorylation plays in
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the regulation of conventional G-proteins within mammalian systems such as 
adenylate cyclase system. Thus there may be important parallels to draw with 
mammalian systems.
The human 62-AR together with mammalian Gs can when expressed in 
yeast can stimulate the endogenous adenylate cyclase, ie CDC35 (King et al, 
1990). This approach provides a valuable new method to assess signal 
transduction.
1.6 SPECIFICITY IN R-G INTERACTIONS & G-E INTERACTIONS.
1.6.1 General points.
Obviously one of the major problems of research in G-protein signal 
transduction systems is specificity of interaction between receptor and G- 
protein and similarly between G-protein and effector. In the first part there 
are 80 receptors but only 12 known G-proteins with not much more than 15 
suspected G-proteins. In the second part it is now appreciated that the same 
G-protein can apparently couple to completely different effectors.
1.6.2 Fidelity of R-G interactions
The peptide hormone thrombin appears to stimulate two distinct G- 
protein GTPase activities in human platelet membranes (Houslay et al,
1986). It is suggested that thrombin couples through its receptor(s) to Gj 
and Gp. The novel activity of Gp was identified due to a lack of susceptibility to 
Pertussis toxin mediated inhibition. There are two possibilities: either there 
is one thrombin receptor coupling to two G-proteins or two receptors each 
coupling to different G-proteins. It has been shown that purified mAch- 
receptor can be reconstituted with purified G0 or Gj such that muscarinic 
agonists will show guanine nucleotide sensitive binding like that of native 
membranes (Florio & Sternweiss, 1984). The 6-AR appears to be able to 
interact with Gj as well Gs (Marbach et al 1988).
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G s is known to be able to stimulate both Ca++ channels and the C 
subunit of adenylate cyclase (Yanati et al, 1987a). Similarly G0 appears to 
be capable of stimulating both PLC and inhibiting Ca++ channels directly 
(Holz et al, 1986; Rane et al, 1986).
1.7 DESENSITIZATION OF ADENYLATE CYCLASE AND OTHER G- 
PROTEIN LINKED SYSTEMS.
1.7.1 General points.
Prolonged exposure of cells or tissues to drugs/hormones such as 
catecholamines leads to a state of refractoriness to further stimulation by 
that agent, known as homologous desensitization. However the desensitization 
can also become heterologous such that it affects signalling through any 
receptor linked to the same G-protein/effector.
1.7.2 Desensitization of the B-AR system .
Adenylate cyclase can become desensitized to a wide variety of agonists 
in a number of cells, however probably the best characterised is that of the 
6-AR. This process involves alterations at a number of points including an 
increase in the rate of transcription of cAMP-PDE (Swinnen et al, 1989). 
However this change in itself is not sufficient to reduce cAMP levels to the 
extent seen, since desensitization still occurs in presence of cAMP-PDE 
inhibitors, nor is it rapid enough. Two potential mechanisms to explain rapid 
effects of desensitization have been popular in the past: phosphorylation of 
6-AR and secondly the internalisation of the 6-AR. However although 
internalization can be rapid, several lines of evidence suggest this is not 
important in achieving rapid desensitization. Firstly, internalisation can be 
blocked by the use of concanavalin A or phenylarsene oxide without disrupting 
rapid desensitization. (Waldo et al, 1983). Also the onset of desensitization 
has been detected before internalisation. Thus in frog and turkey erythrocytes 
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desensitized membranes can be isolated and B-AR stimulated adenylate 
cyclase and GTPase activities determined. Using this approach it has been 
shown that the reduction in adenylate cyclase stimulation is paralleled by an 
equivalent reduction in GTPase stimulated by B-AR agonists (Pike & 
Lefkowitz, 1980). Purified B-AR, 64kD, can be phosphorylated in vitro by 
purified PKA to a stoichiometry of 2 mol phosphoserine/ mol of receptor and 
isoproterenol increases the rate of phosphorylation by 2-3 times (Benovic 
et al, 1985). In, S49 kin" cells which lack PKA activity, the B-AR can still 
be phosphorylated and this led to the discovery of B-AR kinase, called B-ARK 
(Benovic et al, 1986).The B-ARK gene has been cloned (Benovic et al,
1989) and from this a multigene family of similarly functioning receptor 
kinases has been predicted. The cDNA was expressed in COS cells, and shown 
to contain encode a 689 amino acid (80kD) protein which shows only 33% 
homology to catalytic domains of PKC and PKA this being restricted to the 
putative catalytic domain of 239 amino acid. The lack of homology to 
previously known protein kinases suggests this may be the first member of a 
distinct family of protein kinases and indeed a second member of this family 
has been found with 85% homology to B-ARK by screening of a bovine cDNA 
library. Northern blot analysis shows that B-ARK is apparently expressed 
most highly in brain, spleen, heart and lung which have a high sympathetic 
input suggesting B-ARK is involved in modulating activity of synaptic 
receptors. This may be an important fact since the substrate specificity of B- 
ARK is not resolved since it also acts upon muscarinic receptors and a2-AR 
(Kwatra et al, 1989). In the rhodopsin system, phosphorylation of the 
visual receptor by purified rhodopsin kinase by itself resulted in little 
deactivation (Uhl et al, 1990). Phosphorylation allows the binding of 
arrestin, 48kD, to inhibit competitively the binding of transducin to 
rhodoposin (Wilden et al, 1986). A cDNA possessing 59% identity to retinal 
arrestin, the protein which is intimately involved with the deactivation of
transducin, has been found. High levels of phosphatase activity appear to be 
associated with subcellular vesicles containing internalized B-AR (Sibley et 
al, 1986). The phosphatase associated with this compartment reversed the 
desensitization. Duck erythrocyte B-AR desensitization can be reversed in 
isolated desensitized membranes by alkaline phosphatase treatment (Stadel 
et al, 1988). A protein, termed B-arrestin, possessing 59% sequence 
homology to arrestin, the protein intimitly involved in deactivation of 
transducin activation, has been identified in non-retinal tissue (Lohse et al,
1990). By Northern bloting B-arrestin demonstrates a similar tissue 
distribution to B-ARK, implying the possibility that this protein may be the 
functional analog of arrestin, in the B-AR system.
High levels of phosphatase activity appear to be associated with 
subcellular vesicles containing internalized B-AR (Sibley et al, 1986). The 
phosphatase associated with this compartment reversed the desensitization.
Duck erythrocyte B-AR desensitization can be reversed in isolated 
desensitized membranes by alkaline phosphatase treatment (Stadel et al,
1988).
In contrast to shorter term desensitization there is little evidence that 
phosphorylation by either B-ARK or PKA is important in the mechanism of 
long term desensitization. Mutations in the two sites of phosphorylation by 
PKA, of the human B2-AR, from Ser to Ain has been conducted (Hausdorff et 
al, 1989). The mutant receptor was stably expressed in a cell line and found 
to show no impairment to internalization, or its ability to couple t o a ^ e n y l a t e  
Icyciasestimulation but was unable to undergo phosphorylation and desensitization.
Thus mutant B2-AR exposed to isoproterenol for several hours 
ultimately desensiiize to an equivalent degree to normals (Strader et al,
1987). This data implies that phosphorylation is important for short term 
desensitization but is relatively unimportant in the mechanism of long term
3 8
desensitization. In S49 eye' cells there is very little down-regulation of B- 
AR (Mahan et al, 1985). In addition mutant receptors that show impaired 
coupling to Gs also show impaired down-regulation. However in H21a S49 
cells, which lack coupling between Gs and B-AR , there is still normal agonist 
induced internalization. Long term exposure to agonists seems to reduce the 
mRNA for B2-AR this being due to a decrease in the stability of the mRNA 
rather than an alteration in rate of transcription (Hadcock et al, 1989).
1.7.3 Glucagon desensitization of hepatocyte adenylate cyclase 
system in chick hepatocytes.
Exposure of chick hepatocytes to glucagon results in the rapid onset of 
heterologous desensitization as measured by decreased response of adenylate 
cyclase to NaF stimulation. An interesting feature of this heterologous 
desensitization is that it is rapidly reversible under conditions where 
homologous desensitization is retained (Premont & Iyengar 1989). 
Degradation and de novo synthesis would be too slow to account for this 
process. Reconstitution of Gs activity into S49 eye' cell membranes shows 
that Gs activity is reduced 25% following glucagon treatment (Premont & 
Iyengar 1989). Addition of purified Gs to desensitized chick membranes 
results in partial restoration of glucagon responsiveness. The extent of this 
restoration of NaF stimulated adenylate cyclase activity was some 10-15%. 
Resorting to 8-Bromo-cAMP treatment of intact non-desensitized cells 
results in a 15-20% loss of NaF-stimulated activity which could not be 
restored by the addition of purified Gs to membranes. Some experiments 
appear to show that incubation of control membranes but not desensitized 
membranes with PKA, results in decreased activity of adenylate cyclase 
(Premont & Iyengar 1990). The effect seems to be more pronounced in S49 
kin' cell membranes. Experiments indicate that By are not phosphorylated 
(Premont & Iyengar 1990).
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1.7.4 Glucagon desensitization in Rat hepatocytes.
Exposure of rat hepatocytes to glucagon results in desensitization, t0 5 
1.5-2.0 min and K0 5 glucagon 0.4nM (Houslay et al, 1990) with no change 
in receptor number or response of membranes to NaF. The addition of cAMP- 
PDE inhibitors has no affect on the t0 5 for desensitization and stable analogs 
of cAMP such as dibutryl-cAMP and 8-bromo cAMP do not elicit 
desensitization. Therefore the process of desensitization appears to be cAMP 
independent. Desensitization appears to involve a different population of 
glucagon binding receptors to those which stimulate adenylate cyclase since 
the Kq 5 for desensitization is 0.4nM while the K0.5 for stimulation of 
adenylate cyclase is 8nM. In support of this theory, TH-glucagon, an analogue 
of glucagon which does not stimulate adenylate cyclase, causes glucagon 
desensitization in hepatocytes. Apparently both glucagon and TH-glucagon can 
stimulate the production of inositol polyphosphates in hepatocytes. As the PKC 
activating phorbol ester TPA was found to be capable of eliciting glucagon 
desensitization and also hormones capable of producing diacyglycerol 
intracellularly. This causes uncoupling of glucagon receptors from Gs , 
probably through the phosphorylation of one of these components.
1.8 INSULIN RESISTANCE/DIABETES/OBESITY.
1.8.1 Type 1 (IDDM)
Human insulin dependent diabetes mellitus (IDDM) is clinically 
characterised by the abrupt onset of symptoms such as hyperinsulinaemia, 
ketosis, hyperglyCftGrtHt* and glycosuria.In order to sustain life, daily 
injections of insulin are required. This class of diabetes mellitus was 
classically diagnosed in juveniles and is often therefore known as juvenile 
onset diabetes.This classification however is not strictly true because 
diagnosis of this disease has been made within a wide range of groups.
Factors associated with the onset of this form of diabetes include 
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abnormal immune response (islet cell antibodies are often present at 
diagnosis), genetic inheritance (genes on chromosome 6 suggested) and viral 
infection. Chemically induced destruction of 13-cells of pancreas has been 
demonstrated to mimic type 1 diabetes. Streptozotocin (2-deoxy-2-(3- 
m ethyl-3-nitrosoureido)-D-glucopyranose) and alloxan (2 ,4 ,5 ,6-te tra  
oxohexahydropyrimidine) have been used in rats. Streptozotocin accumulates 
in the 3-cells of the pancreas. STZ has an LD5Q of 138mg/kg when 
administered to rats by intravenous injection. One theory is that DNA is 
damaged by generation of carbonuim ions (CH3*) and subsequent repair by 
poly-ribose synthetase to repair the damage leads to NAD depletion and hence 
cell death (Uchigata et al, 1982).
1.8.2 Type 2 (NIDDM)
This type has been termed maturity onset diabetes but the method of 
classification is not strictly correct because NIDDM may develope at any age 
but is most likely to develope at 40 and over. Statistics show that 60-90% of 
all NIDDM patients are obese and treatment in many cases, is restricted to 
diet alone. In other cases controlled diet together with sulphonylurea or 
biguanide therapy is administered. Clinical diagnosis of NIDDM in absence of 
readily observable symptoms is generally made by oral glucose tolerance test 
(OGTT).
1.8.3 The Zucker rat.
The obese Zucker rat appeared as a spontaneous genetic obese condition 
in the laboratory of Comparative Pathology, Stow,Massachusett,USA in 
1961 .(Zucker & Zucker 1961). Obese (fe/fe)progeny were observed at a 
25% incidence/litter the condition being due to a single recessive gene.
Obesity is observable within 3 weeks and food intake is significantly 
increased in these animals. The fatty acid level is 10 times that found in lean 
(Fa/Fa) littermates and is milky in appearance. Even when food intake is
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restricted fa/fa  rats are still obese in comparison with their lean (Fa/Fa) 
litermates.
Hyperinsulinaemia is present in fa/fa  animals before obesity is 
observed and plasma insulin concentration appears to be dependent on the age 
of the rat. In contrast circulating glucagon levels are decreased in obese 
animals (Eaton et al, 1976). Interestingly Clark et a /,(  1983) have 
identified the presence of insulin-resistance, as assessed by oral glucose 
tolerance test and the lowering of body fat & triglyceride when compared to 
obese normoglycaemic rats. This condition appeared after 6 months and 
surprisingly occurred more in males than females. It has been (Geurre-Milo 
et al, 1985) suggested that insulin stimulated glucose transport is enhanced 
in fa/fa animals.
1.8.4 The db/db diabetic mouse
The db gene is inherited as an autosomal recessive trait (Coleman & 
Hummel, 1967). The db/db animals exhibit abnormally high deposition of 
fat, by 4 weeks of age, followed by hyperglcaemia and polyuria. Blood sugar, 
non-fasting, from control mice did not exceed 200mg/100ml at any age but 
in contrast db/db  mice at 10 weeks of age exhibit levels not less than 
300mg/100ml.
1.8.5 The ob/ob obese mouse
The ob/ob syndrome is the result of a mutation in one gene located on 
chromosome 6. The consequences of this mutation are numerous. In addition to 
hyperglcemia, hyperinsulinemia, and extreme resistance to insulin (Herberg 
& Coleman, 1977; Bray & York, 1979) this animal model of obesity is 
characterised by the extreme resistance of its adipose tissue to the action of 
lipolytic hormones vide infra.
1.9.1 INSULIN RESISTANT SYSTEMS SHOWING IMPAIRED 
CATECHOLAMINE STIMULATION OF ADENYLATE CYCLASE IN
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ADIPOSE TISSUE
A number of rodents which exhibit insulin resistance show impaired 
catecholamine stimulation of lipolysis and all of these are obese. There is a 
strong correlation between intracellular concentration of cAMP and the rate 
of lipolysis (Londos et at, 1984). The bodies of these animals show 
increased amounts of adipose tissue and in some this is extreme. These include 
the genetically obese ob/ob mouse (Begin-Heick 1985); the genetically 
obese diabetic mouse db/db  (Levilliers et al, 1978), the Toronto-KK 
mouse (Kupiecki and Adams 1974), the New Zealand obese mouse (Kupiecki 
and Adams, 1974). The ob/ob mouse; the db/db mouse; Toronto-KK; New 
Zealand obese mouse; and the high fat diet fed rat (Gorman et al, 1973) all 
show decreased stimulation of adenylate cyclase by catecholamines.
1.9.2 Adenylate cyclase defect in ob /ob  mouse adipocytes
The adenylate cyclase defect has been best characterised in the ob/ob 
mouse. From such studies there is no doubt that a severe defect in the 
stimulation of adenylate cyclase by catecholamines exists in the adipocytes of 
ob/ob mice but the presence of a corresponding defect in catecholamine- 
stimulated lipolysis has been refuted (Sheperd et al, 1977). However, more 
recent evidence suggests otherwise (Dehaye et al, 1985) as does earlier 
evidence (Dehaye et al, 1977; Jolly et al, 1978). It is also of note that 
lipogenesis is reported to be increased in ob/ob adipose tissue (Winand et 
al, 1973).
The cAMP-phosphodieterase activity has been shown to be elevated in 
ob/ob adipocytes (Begin-Heick 1977; Dehaye et al, 1977; Sheperd et al, 
1977; Kaplan et al, 1973). Thus impaired stimulation of lipolysis in this 
system by catecholamines could be due to increased degradation of cAMP by 
the cAMP-PDEs. However the addition of methylxanthine cAMP-PDE  
inhibitors could not restore sensitivity or the capacity to respond to lipolytic 
hormones in adipose tissue of ob/ob mice. Thus there must be a significant
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defect at the level of cAMP generation by adenylate cyclase.
Dibutryl cAMP is able to elicit similar lipolytic responses in lean and 
obese adipocytes (Herberg et al, 1970; Begin-Heick & Heick 1977). This 
implies that the capacity of TAG lipase, the pacemaker enzyme of 
triacylglycerol hydrolysis, is similar in lean and obese mice and hence the 
defect must lie at the steps controlling the production of cAMP.
It has however been reported (Kahn et al, 1973; Begin-Heick,
1980) that there is no decrease in the number of 6-AR receptors and that 
there is no apparent defect in the number of catalytic units. Thus the 
defect(s) in stimulation of adenylate cyclase probably lie at the level of 6-AR 
receptor coupling to Gs or at the level of activation of adenylate cyclase by Gs. 
It has (Begin-Heick, 1985) been shown that membranes from ob/ob mice, 
as opposed to their lean littermates (+/?), show tonic inhibition of adenylate 
cyclase as mediated by Gj. However others (Greenberg et al, 1987) have 
shown that Rj mediated inhibition appears to be still perfectly intact in 
ob/ob membranes. Thus its seems that, in ob/ob adipocytes tonic inhibition 
by Gj upon adenylate cyclase is abolished, whilst in contrast agonist occupied 
receptor mediated inhibition is still perfectly functional. A question arises as 
to what the consequences of the above alterations in Gj activity might have on 
the regulation of adenylate cyclase by Rs linked agonists. To this end Begin- 
Heick proposed a theory to link the loss of tonic inhibition by Gj with the 
reduced stimulation of AC by 6-AR agonists. Since it is believed that the 
amount of Gj greatly, 10-30 fold, exceeds that of Gs (Bokoch et al, 1984) 
then if there was some perturbation of Gj which weakened the association of 
otjpY such that the free Py concentration within the membrane increased. The 
increased free concentration of py would by mass action tend to inhibit the 
dissociation of a spy thereby decreasing the effectiveness with which 6-AR 
can activate adenylate cyclase.
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It has been shown that the B-AR response of lean mice is mostly due to 
B^ARs but that of obese is more typical of B2-AR response (Begin-Heick,
1981). The significance of this may be that B2 -receptors may be less 
effectively coupled to the activation of adenylate cyclase, hence helping to 
explain the loss of responsiveness to catecholamines. In support of this latter 
possibility are the observations made with differentiated 3T3-F442A  
adipocytes (Feve et al, 1990). These latter cells are responsive to 
catecholamines, however if these same cells are exposed for long periods of 
time to glucocorticoids then they subsequently exhibit a reduced 
responsiveness to stimulation of adenylate cyclase by isoproterenol. This 
latter effect is associated with the switch of predominantly B-j-ARs in the 
more responsive cells to predominantly B2-ARS in the less responsive cells.
1.9.3 Adenylate cyclase defect in db/db adipocytes.
The only data on the regulation of adenylate cyclase in adipoctes of 
db/db  mice, show; that their is no apparent defect at the level of the 
catalytic unit of adenylate cyclase itself (Laudat & Pairault 1975; Levillier 
et al, 1978). The type of G-protein lesion seen the ob/ob  (above) is not 
seen in the db/db mouse (Begin-Heick & Coleman, 1988).
1.9.4 Regulation of adenylate cyclase in hepatocytes from animal 
model systems of type II diabetes mellitus (NIDDM).
The main characteristics of hepatic metabolism in the Type II diabetic 
state are increased lipogenesis, leading to triglyceride accumulation, and an 
enhanced hepatic glucose output which contributes to the observed 
hyperglycaemia (DeFronzo, 1988). As for IDDM, several animal models of 
NIDDM have been investigated to determine whether these effects can be 
explained by alterations in the regulation of adenylate cyclase activity. This 
possibility has been studied in several animal models of obesity and NIDDM 
including the genetically obese (fa/fa) Zucker rat (Houslay e ta !., 1989),
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the genetically obese (ob/ob) mouse (B6gin-Heick & Welsh, 1988).
In hepatocyte membranes prepared from obese Zucker rats, there 
seem to be two defects affecting adenylate cyclase regulation (Houslay et al.,
1989). Firstly, there is an abolition of the ability of GppNHp to inhibit 
forskolin-stimulated adenylate cyclase activity in membranes from obese 
animals, although the amounts of GjOt-2 are similar in lean and obese 
membranes as determined by immunoblotting and pertussis toxin-catalysed 
ADP-ribosylation studies (Houslay et al., 1989). As with the stz-diabetic 
system, P2 y purinergic receptor-mediated inhibition of cyclic AMP 
accumulation persists in the obese state (Murphy & Houslay, unpublished 
data). There is also a defect in the ability of glucagon to stimulate adenylate 
cyclase activity, as hepatocyte membranes from obese animals exhibit a ten­
fold higher K0 5 value for glucagon activation of adenylate cyclase. However, 
the specific activities produced at maximal glucagon concentrations are the 
same in lean and obese rats (Houslay et al., 1989). The reduced efficacy of 
hormonal activation was attributed to a 50% reduction in expression of the 
two forms of Gsa expressed in hepatocytes, as determined by cholera toxin- 
catalysed ADP-ribosylation (Houslay et al., 1989).
Another study employing sucrose-purified liver plasma membranes 
from lean and genetically obese (ob/ob) mice gave similar but not identical 
findings to those in obese Zucker rats (B6gin-Heick & Welsh, 1988). Gj 
function was shown to be abolished but this was claimed on the basis that a2- 
adrenergic receptor-mediated inhibition was lost unlike Zucker rat 
hepatocytes. This was associated with an enhanced ability of isoproterenol, 
but not glucagon, to stimulate adenylate cyclase activity in the presence of 
GTP (B6gin-Heick & Welsh, 1988). Whether these changes in regulation are 
related to the reduced cholera toxin-catalysed labelling of Gsa and increased 
pertussis toxin-catalysed labelling of Gjtx observed in liver membranes from 
obese animals compared with leans is unknown (B6gin-Heick & Welsh,
4 6
1988).
1.9.5 Adenylate cyclase regulation in streptozotocin  
diabetes/type I diabetes mellitus (IDDM)
Type I diabetes mellitus (IDDM) arises due to the inability of the 8- 
cells within the islets of Langerhans in the pancreas to secrete insulin: the 
consequences of this state for whole body metabolism have been recently 
reviewed (Taylor & Agius, 1988).
1.9.5.1 Liver tissue
Evidence suggests that the hyperglucagonaemia associated with IDDM 
is responsible for the increased hepatic glycogenolysis, gluconeogenesis and 
ketogenesis in diabetic patients (Unger & Orci, 1981; Johnson et al.,
1982). In both genetic (BB/W or rats) and chemically-induced  
(streptozotocin [stz] or alloxan) rat models of IDDM, these changes are 
associated with an increase in hepatic cyclic AMP concentrations (Pilkis et 
al., 1974; Appel et al., 1981). Several groups have attempted to ascertain 
whether this increase in cyclic AMP content is attributable to defects in the 
adenylate cyclase signalling complex, with variable results being obtained 
(Allgayer et al., 1982; Dighe et al., 1984; Gawler et al., 1987; Lynch et 
al., 1989).
Most groups have shown there to be an increase in the ability of 
glucagon to stimulate adenylate cyclase in plasma membranes prepared from 
either whole liver (Allgayer et al., 1982; Lynch et al., 1989) or 
hepatocytes (Gawler et al., 1987). However the mechanisms by which this 
phenomenon occurs are still controversial. Lynch et al. (1989) claim that 
liver plasma membranes prepared from streptozotocin-induced diabetic 
animals and BB rats contain increased amounts of Gsoc-subunits compared 
with normal controls as assessed by immunoblotting and cholera toxin- 
catalysed ADP-ribosylation. This results in an enhanced activation of
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adenylate cyclase activity by cholera toxin, [AIF4 ]" and GTPyS as well as 
glucagon (Lynch et al., 1989). Also, inhibition of adenylate cyclase by 
angiotensin II in isolated membranes and intact hepatocytes was unchanged in 
streptozotocin-induced diabetic animals and slightly increased in BB rats 
compared with normal controls (Lynch et al., 1989). These results 
appeared contradict the earlier findings of Gawler et al. (1987) who 
attributed the enhanced activation of adenylate cyclase activity by glucagon in 
hepatocyte plasma membranes to a loss of functional Gj activity relieving a 
tonic inhibitory effect on stimulation, thereby sensitising the response to 
glucagon. However, Bushfield et al (1990), have now explained this 
discrepancy. The reason for this is that Gawler et al (1987) used a 
hepatocyte preparation consisting of pure parenchymal cells, wheras Lynch 
et al (1989) studied 'whole liver' containing a mixture of cell types. Thus it 
was shown (Bushfeild et al, 1990) that streptozotocin diabetes causes cell- 
specific changes in Gj expression., a 70% reduction in the expression of Gjtx- 
2 and Gjtx-3 Associated with this was the a phosphorylation of Gja-2 in 
streptozotocin-diabetic hepatocytes causing an abolition of the ability of 
GppNHp to inhibit forskolin-stimulated adenylate cyclase activity (Gawler 
et al., 1987; Bushfield et al., 1990). This loss of Gj function accounted for 
amplification of glucagon action, a fact confirmed by mimicking it in 
hepatocytes from normal animals treated with pertussis toxin. However, 
whilst guanine nucleotide-mediated inhibition was abolished, P2y purinergic 
receptor-mediated inhibition of cyclic AMP accumulation in streptozotocin- 
diabetic hepatocytes persists, albeit to a lesser extent commensurate with the 
reduction in expression of Gja-subunits (Bushfield et al., 1990c).
1.9.5.2 Adipose tissue
The reduction in plasma insulin concentrations associated with IDDM 
results in the mobilization of fatty acids from adipose tissue due to the
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concommitant reduction of insulin’s anti-lipolytic effect and the enhanced 
action of lipolytic hormones (Williamson et al., 1989). The latter effect 
presumably accounts for the elevated cyclic AMP content of streptozotocin- 
diabetic rat adipocytes (Ciappe de Cingolani, 1983). As with hepatocytes, 
different groups have attempted to characterize possible defects in the 
regulation of adenylate cyclase which could explain the observed increase in 
lipolysis (Kissebah & Fraser, 1972; Zumstein et al., 1980; Chiappe de 
Cingolini, 1986; Strassheim et al., 1990).
Several investigators have noted either an increased sensitivity (La 
Casa et al., 1983) or increased stimulation of adenylate cyclase in response 
to catecholamines (Chiappe de Cingolini, 1986; Strassheim et al., 1990). 
W hereas Chiappe de Cingolini (1986) attributed the enhanced  
responsiveness to an increase in the number of 6-adrenergic receptors, 
Strassheim et al. (1990) demonstrated that the tonic inhibitory effect of Gj 
was abolished in adipocyte membranes from streptozotocin-diabetic animals, 
which in this respect resemble hepatocyte membranes (Gawler et al., 
1987). Similarly, receptor-mediated inhibition of adenylate cyclase by PIA, 
PGE.J and nicotinic acid persists, and is even slightly enhanced in 
streptozotocin-diabetic animals (Strassheim et al., 1990). These changes 
were also accompanied by a 2-fold increase in expression of Gja-3, although 
the authors claim that it is the phosphorylation and inactivation of GjCt-2 
which causes the abolition of guanine nucleotide-mediated inhibition 
(Strassheim et al., 1990).
Human studies on IDDM patients failed to show any alteration in their 
ratios of expression Gja-2 to Gsa compared with non-diabetic controls as 
determined by Western blotting (Ohisalo et al., 1988) but functional 
studies have not been carried out to ascertain whether there was any 
alteration in adenylate cyclase regulation. However the number of patients 
studied was really too few to draw any conclusions.
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1.10 ALTERATION IN SIGNAL TRANSDUCTION ELEMENTS OTHER 
THAN ADENYLATE CYCLASE IN INSULIN RESISTANT STATES.
1.10.1 Human obesity
The rate at which insulin stimulates glucose disposal in human obese 
subject is much slower than in normal subjects (Molina et al, 1989). 
Insulin is thought to stimulate glucose transport by two mechanisms. Firstly 
by recruitment of transporters from an intracellular pool to the plasma 
membrane (Kono et al, 1982) and secondly by increasing the intrinsic 
activity of the recruited carriers (Simpson & Cushman, 1986). Human 
obesity is associated with a decrease in the number of low-density 
microsomal glucose transporters. However the decrease in basal and insulin 
stimulated glucose transport cannot entirely be explained by decreased 
number of glucose transporters, suggesting an impairment in intrinsic 
activity of the glucose transporters (Garvey et al, 1988). It appears that 
the defect in activation of intrinsic activity, the second stage, is not due to a 
binding defect of insulin to receptor but a post receptor defect.
1.10.2 Glucose transporters in obese and lean Zucker rats.
The skeletal muscle, the primary site of glucose disposal in normal 
rats, of 36 week old fa/fa rats shows impaired insulin stimulation of glucose 
transport (Crettaz et al, 1980). The level of the GLUT-4 glucose 
transporter is similar in lean and obese animals, however exercise of fa/fa 
animals increases the level of the GLUT-4 transporter. However in contrast, 
the white adipose tissue of fa/fa rats shows increased glucose transport and 
increased glucose oxidation (Ezaki 1989).
Insulin activates glucose transport in heart and brown adipose tissue 
in the same or very similar manner as in adipocytes. In these tissues, the 
second activation step involves an increase in affinity for glucose and
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occurrence of positive co-operativity (Zaninetti et al, 1989). In fa/fa  rat 
heart tissue insulin stimulation of the second step was decreased, while 
affinity for glucose was unaltered (Zaninetti et al, 1989).
1.10.3 Alteration in PKC signalling in insulin resistant 
animals.
The ability of phorbol esters, which activate PKC by mimicking the 
action of diacylglyceroi, to inhibit glycogen synthase a in heart tissue of 
fa/fa rats is significantly impaired (Van de Werve et al, 1987).
The liver tissue of rats starved for 3 days shows impaired activity of 
the IR protein tyrosine kinase and hence insulin action (Karasik et al,
1990). The protein tyrosine kinase activity of IR, decreases by 45% and this 
decrease can be reversed by alkaline phosphatase treatment of membranes. 
Tryptic removal of the C-terminal region of IR B-subunit, which functions 
to inhibit the kinase activity, similarly restored kinase activity of the IR 
from starved rats to normal. A two fold increase in PKC activity was found in 
cytosol and membrane extracts of liver from starved rats. A parallel increase 
in PKC was demonstrated by immunoblotting for PKC itself. Thus the 
decreased activity of IR in starved rats may be due to increased activity of 
PKC (Karasik et al, 1990).
1.11. INSULIN RECEPTOR .
1.11.1 General points.
The mature human IR is a heterotetramer a2B2. The a  subunit is 719 
or 731 amino acids the B is 620 amino acids. The a precusor is 1355 amino 
acids (Ebina et al, 1985). The a and B subunit are generated from the 
proteolytic cleavage of a single chain precusor 1355 amino acids, this occurs 
during transfer from ER to plasma membrane. After cleavage of the precusor 
the nascent a and B subunits are glycosylated on asparagine (N-linked) and 
possibly serine/threonine (O-linked) residue. Thus the a  and B subunits
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have apparent Mr of 135 and 95 KD respectively,ie greater than their 
weights predicted from cDNA. In the absence of a subunit the 3 PTK is 
constitutively active, suggesting the a subunit inhibits the PTK and that the 
IR is activated by removing the negative affect of a upon 3 PTK activity (Ellis 
et al, 1987).
The IR is a protein tyrosine kinase phosphorylating tyrosine residues 
on target proteins (Czech, 1985). Site directed mutagenesis studies have 
revealed a close relationship between PTK activity and insulin action.(Ellis 
et al, 1986; Ebina et al, 1987; Herra et al, 1985; Morgan & Roth 1987; 
Russell et al, 1987). A number of putative endogenous substrates have been 
found, mostly of high molecular weight (Rees-Jones et al, 1984; White et 
al, 1985; Kadowaki et al, 1985; Standtmauer & Rosen 1986; Accili e t 
al, 1986; Sadoul et al, 1986). Some of these putative substrates are 
cytosolic, cytoskeletal and some are plasma membrane associated.
Despite a high degree of structural characterization of the IR 
virtually nothing at all is known about the next step in the signal 
transduction process after activation of the PTK of the 3 subunit.
However the metabolic actions of insulin upon target enzymes is much 
better characterised. Insulin controls metabolism of skeletal muscle, cardiac 
muscle, hepatocytes and adipocytes essentially by stimulating anabolic 
metabolic pathways and inhibiting catabolic pathways (Czech, 1977; Denton 
et al; 1981). This is achieved intern by controlling the phosphorylation 
state of the relevant pacemaker enzymes. This must be at least impart, 
achieved by controlling the levels of metabolically important second 
messengers such as cAMP. Insulin stimulates the activity of glycogen 
synthase in hepatocytes while a 1-agonists inactivate the enzyme (Thomas et 
al, 1985). Insulin antagonizes the action of glucagon in hepatocytes by 
reducing the concentration of cAMP largely by activation of cAMP-PDE 
activity (Houslay, 1986). However insulin antagonism of a 1-agonists
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inhibition of glycogen synthase appears to occur at the level of elevation of 
intracellular Ca+ + (Thomas et al, 1985).
Previous reports of the purification of low molecular weight chemical 
entities capable of mimicking insulin action (Saltiel & Cuatrecasas, 1986) 
have not been verified.
A number of reports have hinted at the potential G-protein 
involvement in the signal transduction process. Insulin has been reported to 
phosphorylate Gj and G0 (Krupinski et al, 1988). These experiments were 
performed in reconstituted phospholipid vesicles and its was also inferred 
that the presence of Gj and G0 increased the proportion of IR incorporated into 
the vesicles implying the possibility of some stabilizing interaction. Insulin 
has been reported to be able to inhibit the Pertussis toxin catalysed ADP- 
ribosylation of G-proteins (Rothenberg & Kahn, 1988). Insulin, as well as 
glucagon, has been reported to be able to attenuate the ability of cholera toxin 
to activate adenylate cyclase in hepatocytes (Irvine & Houslay, 1988).
1.11.2 Exon-intron organization of hIR gene
The hIR gene is located on the distal, short arm of chromosome 19 in 
the region of bands p13.3-p13.2 (Yang-Feng et al, 1985). The LDL- 
receptor gene is also in this region. The approximately 13,000 bp of the hIR 
is composed of 22 exons and 21 introns. The exons range in size from 36bp to 
>2500bp . All of the introns interrupt protein coding regions. The 
organization appears to reflect the organization of the protein, since many of 
the exons code for structural or functional domains of the receptor.
Exon 1 signal peptide
Exon 2 insulin binding
Exon 3 highly cysteine rich domain, may bind insulin.
Exon 6 located at interface between adjacent a-subunits in 
heterotetrameric a 2 32 form of hIR and contribute to co-operative site-site
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interactions (Kadowaki et al, 1989).
Exon 11 the smallest only 36bp in size, alternate splicing of this exon 
results in synthesis of hIR proteins having a-subunits with different C- 
terminal sequences (Seino & Bell, 1989).
Exon 12 codes the tetrabasic amino acid sequence Arg-Lys-Arg-Arg 
the cleavage site to generate separate a and B units from the 1355 amino acid 
precusor. It also encodes N-terminus of B-subunit, 20% of amino acid in 
this region of B are either serine or threonine, suggesting the N-terminus of 
B represents a region of o-linked oligosaccharide modification.
Exon 15 codes for membrane spanning region of B.
Exon16 encodes 22 amino acid segment that separates transmembrane 
and PTK domains.
Exon 17-21 encode for PTK domain, the tyrosine residues that are 
phosphorylated upon insulin binding are encoded by exon 20 
(Tyr1158,1162,1163) and exon 22 (Tyr1328 and 1334).
Exon 22 encodes for highly charged C-terminus of B.
These data suggest that exons encode functional/structural domains of hIR 
proteins and that the hIR gene like the LDL-receptor gene (Russel et al,
1989) is a mosaic constructed from exons recruited from other sources. The 
1355 amino acid precusor is derived from a precusor containing 27 amino 
acid serving as the signal peptide there can be two precusors, 1370 or 1382 
these could be expressed tissue specifically and be possibly developementally 
regulated by alternative splicing of exon 11, which encodes for a 12 amino 
acid segment at the C-terminal end of the a-subunit. Brain and spleen almost 
exclusively express the 719 amino acid a  subunit, whereas other tissues 
including placenta, liver, kidney and adipose tissue express a-subunits of 
both 719 aa and 731 amino acid a subunit.
1.12.1 GENETIC DEFECTS OF INSULIN RECEPTOR IN HUMAN
54
INSULIN RESISTANT PATIENTS.
Recent studies have identified more than 8 different mutations of the 
insulin receptor, in one or both of the IR alleles of individuals with the 
syndromes of acanthosis nigricans, leprechaunism and Rabson-Mendenhall 
syndrome (Taylor 1985).
In the a  subunit alone 4 different defects alone are known.
(i) A mutation in a, exon 3, Leu233 to Pro,in a person of Dutch orgin 
results in delayed transport to the cell surface.
(ii) A mutation in a , Phe382 to Val, exon 5, a person of Venezuelan 
orgin, resulting in delayed transport to the membrane surface.
(iii) A mutation in a , Lys460 to Glu and Gin672 to amber (TAG 
translation termination codon), exons 6 & 10, in an American, exhibits a 
truncated a subunit and qualitative abnormalities in insulin binding. This 
person is a compound heterozygote expressing different a-subunit mutations. 
There is a nonsense mutation in the codon for amino acid 672 of the 
paternally derived allele, which results in the synthesis of a truncated 671 
amino acid fragment of a such a molecule would be secreted from the cell but 
biologically inactive. The maternally derived hIR allele has a missense 
mutation Lys460 to Glu that results in the expression of a protein with 
qualitative abnormalities in insulin binding, including increased stability of 
the insulin-IR complex. Such a mutation might impair the release of insulin 
in the acidic endosome after internalization of the insulin-IR complex and 
thereby affect IR recycling. Cells from the patients mother which express 
both normal Lys460 and mutant Gly460 IR, also exhibit qualitative 
abnormalities in insulin binding similar to the patient, however the mother 
was neither insulin resistant nor diabetic. By contrast the father who 
expresses both the normal IR and the truncated molecule, was moderately 
insulin resistant with impaired glucose tolerance although not overtly 
diabetic.
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(iv) A mutation in a Arg735 to Ser, exon 12, in a Japanese subject, 
shows a defect in the processing of the receptor since the mutant IR is fully 
glycosylated but exists as the uncleaved proreceptor on the cell surface 
(Yoshima et al, 1988). this mutant IR can bind insulin and undergo insulin 
stimulated autophosphorylation but only at high concentrations of insulin and 
only partially as well. Thus the IR aquires normal insulin affinity only after 
proteolytic separation of a  and IB subunits.
Three mutations in the 8 subunit that represent post-binding defect 
in insulin action have been found. All are associated with decreased PTK 
activity or decreased autophosphorylation.
(i) A mutation in Gly1008 Val, exon 12, of a Japanese subject, 
exhibits decreased PTK activity. This Gly1008 is a conserved glycine that is 
part of ATP binding site of all protein kinases. The dominant negative 
character of these mutations may be due to the fact the IR is a heterotetramer 
and that heterotetramers formed from 2 mutant subunits will result in 50% 
mixed(ie mutant with non-mutant) As a consequence only 25% will be fully 
active.
Along with nucleotide substitutions that result in the expression of an 
abnormal protein, silent substitutions in the coding region of the hIR gene and 
mRNA but not the protein have been described (Ebina et al, 1985), 
(Kadawaki et al, 1988), (Seino et al, 1989). A nonsense mutation causing 
reduced levels of hIR mRNA has been described (Kadowaki et al, 1990). The 
patient has a inherited form of insulin resistance, leprechaunism  
(leprechaunism/Minn-1) which is associated with extreme insulin 
resistance and growth retardation. A nonsense mutation in the paternal allele 
of patients insulin receptor gene. An opal chain termination codon (TGA) is 
substituted for the codon (CGA) for Arg897 located in the intracellular 
domain of the G-subunit. This nonsense mutation causes a reduction in the
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level of the mRNA derived from paternal allele.
Several restriction length polymorphisms have been reported at the 
hIR locus, these all appear to be located within introns (Seino et al, 1990).
1.12.2 Animal model systems
The liver tissue of starved rats show increased activity of PKC and 
this has been linked to decreased autophosphorylation of the IR (Karasik et 
al, 1990). The protein tyrosine kinase activity of the IR is decreased in 
adipocytes from rats fed on a high fat diet (Watari et al, 1988), 
streptozotocin diabetic rats (Kadowaki et al, 1984) and a number of other 
insulin resistant systems (Reddy & Kahn 1988). Therefore defective protein 
tyrosine kinase activity of the IR 8-subunit appears to be a common defect in 
tissues exhibiting insulin resistance.
1.13. REGULATION OF ADENYLATE CYCLASE IN PATHOLOGICAL  
STATES OTHER THAN CLASSICAL INSULIN RESISTANCE STATES.
1.13.1 H yp othro id ism
The adipocytes of hypothyroid animals show impaired stimulation of 
adenylate cyclase in response to catecholamines and this is correlated to a 
decreased lipolytic response to catecholamines (Saggerson, 1986). Thyroid 
hormones exert a permissive effect on the responsiveness of heart, skeletal 
muscle and adipose tissue to B-AR agonists (Kunos, 1981). B-AR action in 
heart (McNiel & Brody, 1968) and adipose tissue (Malbon et al, 1978) is 
potentiated by hyperthyroidism and severely blunted by hypothyroidism. The 
number of B-AR receptors in rat heart (Willaims et al, 1977), in liver 
(Malbon, 1980), skeletal muscle (Sharma & Banerjee, 1978) and 
submaxillary glanci (Pointon & Banerjee, 1978) has been reported to be 
influenced by thyroid hormone status. These change in receptor number may, 
in part, explain the altered responsiveness to catecholamines. However
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adipocytes from hypothyroid rats show no change B-AR number (Malbon et 
al, 1978), (Goswami & Rosenberg 1978) and the amount of C subunit was 
also normal. Hybridization of hypothyroid membranes with S49 eye" 
membranes treated with NEM (devoid of Gs and functional C ) restore B-AR 
response to hypothyroid membranes (Malbon et al, 1985). This implies 
that the defective component is neither Gs, nor the membrane environment 
but, most probably B-AR. Thus the defect could be that B-AR is inactivated by 
such as some covalent modification such as phosphorylation or a change in B- 
AR subtype such that the is an increase in the proportion of the weakly 
coupled subtype and a corresponding decrease in the proportion of the 
strongly coupled subtype which accounts for the alteration.
The anti-lipolytic effect of adenosine acting through A1-adenosine  
receptors linked to Gj is increased in hypothyroid adipocytes by virtue of 
both sensitivity and responsiveness (Woodward & Saggerson, 1986), 
(Malbon, 1985). However hyperthyroidism has exactly the opposite effect 
(Rapiejko & Malbon, 1987).
Thyroid hormones also alter the response of adipocytes to insulin as 
well as catecholamines. Incubation of differentiated 3T3-L1 adipocytes in 
hypothyroid medium reduces isoproterenol stimulated cAMP accumulation, 
lipolysis and adenylate cyclase activity while increasing in particulate 
cGMP-inhibited PDE activity and that of soluble cAMP-PDE activity (Elks & 
Manganiello, 1985). In adipocytes from hypothyroid animals, catecholamine 
stimulated lipolysis can be restored to normal by incubating adipocytes with 
cGMP (Goswami & Rosenberg, 1985).
1.13.2 Hyperthyroidism
Hyperthyroidism is associated with a enhanced stimulation of 
lipolysis and cAMP accumulation by adrenaline in adipose tissue (Deykin & 
Vaughan, 1963), (Ichiwara et al, 1971), (Malbon et al, 1978). However 
an apparent paradox presents itself in that the stimulation of adenylate
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cyclase by isoproterenol, NaF or GppNHp is actually reduced in hyperthyroid 
membranes. The number of 6-ARs is increased by 25%, the number of Ar  
adenosine receptors is decreased by 65% but there is no change in the levels 
of any of the G-protein subunits (Rapiejko & Malbon, 1987). Isolated 
adipocytes from hyperthyroid animals do show increased accumulation of 
cAMP (Rapiejko & Malbon, 1987). If adenosine deaminase was included in 
the incubation medium for measurement of cAMP accumulation in the intact 
adipocyte then the accumulation of cAMP is lower in hyperthyroid than 
euthyroid cells (Rapiejko & Malbon, 1987). Thus the increased response of 
intact cells to B-AR agonists could be due to the decreased number of A ^  
adenosine receptors.
1.13.3 Adrenalectomy
Steroid hormones can modulate the abilities of several tissues to 
respond to hormones which regulate adenylate cyclase activity (Davies & 
Lefkowitz, 1984), including liver and adipose tissues (Fain, 1968; Exton et 
a l., 1972; Allen & Beck, 1972). Hence, one might anticipate that 
adrenalectomy will perturb the permissive regulation of adenylate cyclase 
activity by steroid hormones in their target tissues. This is observed in 
adipocytes where adrenalectomy of rats impairs the catecholamine- 
stimulated lipolytic response in adipocytes (Thotakura et al, 1982; Ros et 
al., 1989b). This study indicated that glucocorticoids regulate cyclic AMP 
production at the level of expression of Gsa and also the expression of 6- 
subunits, since adrenalectomy causes a reduction in the cholera toxin- 
catalysed labelling of the two forms of Gsa and a decrease in the expression of 
p-subunit mRNA species present in adipocytes (Ros et al., 1989b). A 
similar reduction in hormone-stimulated adenylate cyclase activity was also 
observed in reticulocytes and hepatocytes, although it is not known whether a 
similar mechanism is involved (Stiles et al., 1981; Garcia-Sainz et al.,
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Consistent with adrenalectomy causing a reduction in expression of 
Gsa, dexamethasone therapy of adrenalectomized animals enhances levels of 
G sa in adipocytes and restores the catecholamine-stimulated lipolytic 
response to some extent, although the slightly reduced forskolin-stimulated 
adenylate cyclase activity observed might indicate a lower intrinsic activity 
of the catalytic unit (Malbon et al., 1985). The fact that dexamethasone 
treatment of growth hormone-secreting cells causes increases in both 
cholera toxin-catalysed labelling of Gsa and forskolin-stimulated adenylate 
cyclase activity shows that the effects of steroids on the permissive 
regulation of adenylate cyclase activity are probably tissue-specific (Chang 
& Bourne, 1987). Consistent with this idea is the finding that both Gjcx-2 and 
Gsa mRNA levels are regulated by glucocorticoids in brain, unlike adipocytes 
where expression of Gja-subunits appears to be unaffected (Saito et al., 
1989; Ros et al., 1989b).
Glucocorticoids also induce a state of insulin resistance. Incubation of 
differentiated 3T3-L1 adipocytes with the glucocorticoid analog 
dexamethasone, results in an increase in both the number of 82-AR and the 
sensitivity of adenylate cyclase to catecholamines (Lai et al, 1982). 
Incubation of the 3T3-L1 adipocytes with dexamethasone for 48-72 hours 
had no effect on basal cGMP inhibited-cAMP-PDE activity, but reduced both 
the maximal increase inactivity produced by insulin and isoproterenol and 
the sensitivity to these agents (Elks et al, 1983; Elks et al, 1984). It is 
now known that both insulin and isoproterenol activate the cGMP-inhibited 
cAMP-PDE in adipocytes by phosphorylation of the enzyme (Anderson et al, 
1989; Degerman et al, 1990). These phosphorylations may be. mediated by 
protein kinase A in the case of isoproterenol and an insulin activated serine 
kinase in the case of insulin
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1.13.4 Alcoholism
Cultured lymphocytesfrom alcoholic subjects have altered cAMP signal 
transduction resulting in reduced stimulation of Rs-G s route (Nagy et al, 
1988). Decreased cAMP levels have been suggested to be of pathological 
significance in chronic alcoholism (Diamond et al, 1987). More recently 
studies of human platelets has confirmed that stimulated cAMP levels are 
significantly reduced in platelets from alcoholic subjects (Tabakoff et al,
1988).
1.13.5 Albright hereditary osteodystrophy (AHO)
Albright hereditary osteodystrophy is a disorder inherited as an 
autosomal dominant trait (Van Dop et al., 1984), and is characterized by 
symptoms which include round fac short stature, subcutaneous 
ossification and obesity (Levine et al., 1988). Most AHO sufferers also 
exhibit pseudohypoparathyroidism type la (PHP-la), a state characterized 
by mental retardation, impaired olefaction and a resistance to parathyroid 
hormone and other ligands capable of stimulating adenylate cyclase activity in 
many tissues (Farfel & Friedman, 1986; Weinstock et al., 1986; Levine et 
al., 1983a). Presumably this is due to the drastically reduced functioning of 
G sa detected in all tissues thus far examined from PHP-la sufferers (Downs 
et al., 1983; Farfel et al., 1982; Levine et al., 1983b). AHO patients with 
norm al horm one resp o n s iven ess  are  te rm ed  p s eu d o ­
pseudohypoparathyroidism sufferers (PPHP) (Albright et al., 1952).
The autosomal dominant nature of the PHP-la characteristics 
suggested that the molecular lesion is at the level of one of the Gsa genes in 
the human genome. Fibroblasts and erythrocytes from all AHO patients 
examined, whether PHP-la or PPHP sufferers, have reduced levels of Gsa  
protein compared with normal subjects and all but three of these also had 
correspondingly reduced levels of Gsa mRNA (Levine et al., 1988). The lack 
of any differences in the genomic DNA restriction maps between normal and
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AHO patients rules out the possibility of large deletions, substitutions or re­
arrangements within the Gsa gene being responsible for the observed reduced 
mRNA levels, but it does not exclude the possibility of small changes within 
the gene or its promoter region (Levine et al., 1988). At present it is not 
known whether Gsa mRNA synthesis or processing is defective in these 
individuals.
The nature of the defect in the three PHP-la patients in the study by 
Levine et al.{1988) with normal Gsa mRNA levels but reduced Gsa protein 
is also unknown.
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CHAPTER 2 
MATERIALS AND METHODS
2 MATERIALS & METHODS
2.1 CHEMICALS
Sigma Chemical Co.,
Poole, Dorset, U.K.
BSA
Cholera Toxin
Theophylline
PIA
Nicotinic Acid 
Prostaglandin E-j 
Isoproterenol 
ATP
Soya Bean Trypsin Inhibitor 
Non-ionic detergent NP 40 
Ortho-dianisidine 
Lubrol-PX
Boehringer (U. K.), 
Lewes, East Sussex, U.K.
Creatine Kinase
Creatine Phosphate
Dithiothreitol
Triethanolamine-HCI
T ris
GTP
Gpp(NH)p
May & Baker Ltd., 
Dagenham, Essex, U.K.
Hydrochloric Acid
Calbiochem, 
Cambridge, U.K.
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Forskolin
National Diagnostics, 
Aylesbury, Bucks, U.K.
"Ecoscint" Scintillation Fluid
Porton Research Products Ltd. Pertussis Toxin
Maidenhead, Berks, U.K.
Whatman Biosystems Ltd., DE-50 Cellulose
Maidstone, Kent.
Worthington Biochemical Corporation, Collagenase 
Freehold, New Jersey, U.S.A.
Glucagon was donated by Dr. W. W. Brommer, Eli Lilly & Co., IN, U.S.A.
All radiochemicals were from Amersam International pic, Amersham,Bucks, 
U.K.
All other reagents were obtained from B.D.H. Ltd., Poole, Dorset, U.K.
2.2 Animals
Male genetically obese (fa/fa) and lean (Fa/Fa) Zucker rats were 
obtained from Olac Ltd, Shaws Farm, Bicester, UK & killed by cervical 
dislocation at 20-25 weeks of age for the immediate preparation of white 
adipocytes.
Male C57BL/KsJ heterozygous ( +  /+ )  lean and homozygous 
(db/db) obese diabetic animals aged between 6 and 15 weeks were obtained 
from Olac Ltd. Oxon, U.K.
Diabetes was induced, in Sprague-Dawley rats (220-280g fed ad  
libitum), by a single interperitoneal injection of streptozotocin (75mg/kg
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of body weight; dissolved in 0.1M-citrate buffer, pH4.0). Animals were used 
within 3-4 days if the urinary glucose level reached 167-280nM, as 
deduced by the use of Boehringer Diabur Test 5000 strips or if blood glucose 
reached 175-250mg of glucose/dl of blood, as deduced by the use of Ames 
Dextrostix.
Animals were allowed ad libitum access to standard laboratory chow 
and water.
2.3 PREPARATION OF ISOLATED ADIPOCYTES
Adipocytes were prepared essentially as described by Rodbell 
(1964). Animals were killed by cervical dislocation before the white 
epididymal fat pads were removed and placed into pre-warmed (37 degrees 
Celsius) Krebs-Ringer-Henseleit buffer, pH 7.4, containing 3% (w/v) BSA 
(KRH/BSA). The KRH buffer had the following composition:- 25 mM HEPES,
1.2 mM MgS0 4 , 1.2 mM KH2P 0 4 , 5 mM KCI, 120 mM NaCI, 2 mM CaCI2 and 
20 mM glucose.
After fine chopping with scissors, the pieces of fat tissue were rinsed 
with KRH/BSA and placed into pre-warmed 100 ml glass conical flasks 
(pre-treated with dichlorosilane to prevent cell adhesion) containing 10 ml 
KRH/BSA supplemented with 2 mg/ml collagenase and 0.5 mg/ml soya bean 
trypsin inhibitor and placed in a shaking 37*C waterbath set at 120 cycles 
per minute. Each flask was then sealed with a "Suba-seal" (Gallenkamp & 
Co., Widnes, Cheshire, U.K.) and gassed continuously for between 45 and 60 
minutes in an atmosphere of 0 2 :C 02 (95%/5%).
After digestion the contents of the flasks were filtered through a 
plastic teastrainer and washed into a pre-warmed glass beaker. The contents 
of the beaker were then poured into prewarmed 50 ml plastic centrifuge 
tubes and centrifuged at 600 r.p.m. for 5 seconds in an MSE Centaur 2 bench 
centrifuge to float the adipocytes. Adipocytes were removed from the top of 
the solution using a plastic Pasteur pipette and allowed to settle in a glass
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tube where the rest of the KRH/BSA was removed using a syringe with the 
attached needle placed below the floating cells. The cells were then added to 50 
ml centrifuge tubes with 5 volumes of KRH/BSA and the procedure repeated 
twice more. Concentrated adipocytes from the last step were used for the 
subsequent membrane preparation .
2.4 Preparation of a crude membrane pellet from isolated 
adipocytes.
The preparation of membranes from adipocytes was performed by two 
different methods. Method 1 was used to prepare membranes used in all 
experiments described in chapter 3, while method 2 was used for preparation 
of membranes used in all experiments described in chapters 4 and 5. The 
reason being that at the time, I believed that method 2 yielded membranes in vMlcV\ 
adenylate cyclase was more more responsive to stimulation by glucagon and 
other peptide hormones. This latter reasoning was later found to be untrue, 
however I continued to use method 2 for the purposes of continuity in my 
studies described in chapters 4 and 5.
2.4.1 Method 1
Cells were added to a pre-warmed (37 degrees Celsius) plastic 50 ml 
measuring cylinder and pre-warmed buffered sucrose (0.25 M sucrose, 50 
mM Tris-HCI, 3 mM ATP, pH 7.4) added such that the volume ratio of cells to 
buffer was 1:3. This mixture was transferred to a 50 ml glass Potter- 
Elvejhem homogenizer and hand-homogenized at room temperature by 6 up- 
and-down strokes of a teflon pestle. The homogenate was then poured into 
chilled (4 degrees Celsius) 50 ml plastic centrifuge tubes and centrifuged at 
1500 gmax for 15 minutes at 4 degrees Celsius in the 8x50 rotor of a MSE 
21 centrifuge. After removal of the fat cake from the top of the tube, the 
supernatant was re-centrifuged at 15,000gmax for 15 minutes in the same
66
centrifuge at the same temperature. The resulting pellet was resuspended in 
chilled buffered sucrose by 5 up-and-down strokes of a teflon pestle in a 25 
ml glass Potter-Elvejhem homogenizer at 4 degrees Celsius and re­
centrifuged at 15,0Q0gmax at 4 degrees celsius for 15 minutes. The 
membrane pellet was resuspended in 1 mM Tris-HCI, 1 mM EDTA, pH 7.4, to 
a concentration of between 0.5 and 1 mg/ml. 100 pi aliquots were rapidly 
frozen, by placing metal rack carrying eppendorf tudes into refrigerator, for 
storage at -80 degrees celsius.
2.4.2 Method 2
Cells were added to a pre-warmed (37 degrees celsius) 50 ml 
measuring cylinder and pre-warmed buffered sucrose (0.25 M sucrose, 50 
mM Tris-HCI, 3 mM ATP, pH 7.4) added such that the volume ratio of cells to 
buffer was 1:3. This mixture was transferred to a 50 ml glass Potter- 
Elvejhem homogenizer and hand-homogenized at room temperature by 6 up- 
and-down strokes of a teflon pestle. The homogenate was then poured into 
chilled (4 degrees celsius) 50 ml plastic centrifuge tubes and centrifuged at 
1500 gmax  for 15 minutes at 4 degrees celsius in the 8x50 rotor of a MSE 
21 centrifuge. After removal of the fat cake from the top of the tube, the 
supernatant was re-centrifuged at 1 5 , 0 0 0 ^ ^  for 15 minutes in the same 
centrifuge at the same temperature. The resulting pellet was resuspended in 
chilled buffered sucrose by 5 up-and-down strokes of a teflon pestle in a 25 
ml glass Potter-Elvejhem homogenizer at 4 degrees celsius and re­
centrifuged at 15,000 g m ax  at 4 degrees celsius for 15 minutes. The 
membrane pellet was resuspended in 1 mM Tris-HCI, 1 mM EDTA, pH 7.4, 
homogenized as before, resuspended in the same buffer and centrifuged at 
48,300 gave, for 10min. The resulting membrane pellet was resuspended in 
same buffer, to a concentration of between 0.5 and 1 mg/ml, and 100 pi 
aliquots rapidly frozen for storage at -80 degrees celsius.
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2.5 Preparation of cyclic AMP binding protein fron bovine 
heart.
The protocol used was done as described by Rubin et al. (1974).
2.5.1 Homogenization of bovlneheart tissue
After removal of pericardium and fat tissue, the heart was chopped 
into small (1 inch) cubes and minced using a Moulinex electric blender. The 
minced heart was then mixed with 4 I of 40 mM potassium phosphate, pH
6.1, containing 2 mM p-mercaptoethanol and homogenized in a Waring 
blender for 1 minute in small batches. After centrifugation at 10,000gm ax  
for 10 minutes at 4 degrees celsius, the supernatant was retained and filtered 
under vacuum through Whatman No 54 filter paper using a Buchner funnel 
and flask. The remaining pellet from the centrifugation step was extracted 
twice more with one litre of the same buffer and the filtered supernatants 
pooled for the next stage.
2.5.2 Ammonium sulphate precipitation
The pooled supernatants were made up to 55% saturation by the 
addition of solid ammonium sulphate to a concentration of 320 g/l, the pH 
being maintained between 7 and 8 units by the addition of ammonium 
hydroxide. Protein precipitation was allowed to occur for 3 hours and 
precipitated material was collected by centrifugation at 10,000<7max for 10 
minutes at 4 degrees celsius. The pellet was then dissolved in 500 ml 50 mM 
Tris-HCI, pH 7.6, containing 10 mM NaCI and 4 mM B-mercaptoethanol. 
This solution was dialysed overnight against 5 I of 50 mM Tris-HCI, pH 7.6 
containing 10 mM NaCI, overnight to remove the remaining ammonium 
sulphate.
2.5.3 Pretreatment of DE-50 Cellulose
50 g of DE-50 Cellulose was added to 2 I of 0.5 M HCI and the mixture 
%
stirred for 30 minutes. The resin was then washed with distilled water until
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the pH rose to 4 units. The resin was stirred for 30 minutes with 21 of 0.5 M 
sodium hydroxide before washing with distilled water as before until the 
eluate was at neutral pH. The acid/alkali washing procedure was repeated 
once more and the resin finally equilibrated with 50 mM Tris-HCI, pH 7.6, 
containing 10 mM B-mercaptoethanol and 10 mM NaCI, such that the final 
slurry gave a (wet) settled volumerfinal volume ratio of 2 :1.
2.5.4 Absorption of cyclic AMP binding protein by DE-50 
cellulose
The dialysed preparation was stirred for 1 hour with 800 ml 
equilibrated DE-50 Cellulose under conditions where cyclic AMP-dependent 
protein kinase activity should be absorbed. After filtration of the resin under 
vacuum with Whatman No. 54 filter paper on a Buchner funnel and flask, the 
resin was washed with 3 I of 50 mM Tris-HCI, pH 7.6, containing 10 mM 
NaCI and 4 mM p-mercaptoethanol, for 45 minutes. The resin was collected 
by filtration and washed with the 50 mM Tris-HCI buffer, pH 7.6, containing 
10 mM NaCI and 4 mM p-mercaptoethanol, using a Buchner flask and funnel.
2.5.5 Isolation of the cyclic AMP binding protein
The combined filtrates were brought to 35% saturation with 119 g/l 
solid ammonium sulphate and the pH maintained between 7 and 8 units with 
ammonium hydroxide solution. After stirring for 1 hour, the precipitate was 
collected by centrifugation at 10,000gmax for 10 minutes at 4 degrees 
celsius and the resulting pellet discarded. The supernatant was brought to 
75% saturation by adding 258 g/l solid ammonium sulphate and after 
stirring for 1 hour and the precipitate was collected by centrifugation at 
10 .O O O g ^^  as before. The pellet from this step was resuspended in a 
minimal volume of 50 mM potassium phosphate buffer containing 4 mM 13- 
mercaptoethanol, pH 7.0. This final suspension was dialysed against the same 
buffer overnight at 4 degrees. The purified protein kinase was stored in 250
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pi aliquots at -80 degrees celsius and under these conditions was stable for 
between 6 and 9 months. Aliquots were never refrozen but could be used for 
up to 48 hours after thawing if stored between 0 and 4 degrees celsius.
2.6 Assay of adenylate cyclase activity.
This was done using either one of 2 methods:-
2.6 .1 . Determ ination of cyclic AMP form ation using a binding  
protein assay for cyclic AMP.
This method was based on that described by Heyworth & Houslay 
(1983). The first part of the procedure involves the adenylate cyclase assay
with subsequent analysis of cAMP formed using the binding protein.
Incubations were carried out in a final volume of 100 pi containing 30 mM 
Tris-HCI and 0.75 mM EGTA, pH 7.4, with 10 mM theophylline (a non- 
selective cyclic AMP phosphodiesterase inhibitor), 22 mM creatine 
phosphate, 1.0 mM ATP, 2 mM M gS04 and 1 mg/ml creatine kinase. In 
experiments using inhibitory ligands, 1 U/ml adenosine deaminase was 
included and theophylline was omitted from the reaction medium and replaced 
with 100 pM R o -20-1724, a non-m ethylxanthine cyclic AMP 
phosphodiesterase inhibitor. These alterations enhance inhibition by reducing 
the effects of adenosine accumulation in the reaction medium. Other 
components of the reaction mixture were added at the final concentrations 
specified in figure legends and tables.
Reactions were initiated by the addition of 2-10 pg of adipocyte 
membrane protein, followed by incubation or 30 minutes at 30 degrees 
celsius over which time periods cyclic AMP production was linear. Reactions 
were terminated by incubation in a boiling waterbath for 3 minutes. Samples 
were then centrifuged for 5 minutes at 14,000g ave in a Hettich Micro 
Rapide centrifuge at 4 degrees celsius to sediment precipitated denatured 
protein. Aliquots were subsequently taken for assay of cyclic AMP using a
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competitive binding method.
Determination of amounts of cyclic AMP in the samples assayed for 
adenylate cyclase activity was based on the saturation binding assay of Brown 
et al. (1972) as modified by Tovey et al. (1974) and described by Whetton 
et al. (1983). This assay depends upon the specific binding of cyclic AMP to 
the cyclic AMP binding protein purified from bovine heart as described 
above. Aliquots from experimental samples were incubated with [3 H] cyclic 
AMP and a suitable concentration of binding protein until equilibrium had 
been reached. The labelled and unlabelled [3 H] cyclic AMP compete for a 
finite number of binding sites, thus under suitable conditions increased 
concentrations of unlabelled cyclic AMP will lead to reduced binding of the 
labelled nucleotide. The bound cyclic AMP is then separated from unbound 
cyclic AMP by the addition of a charcoal/BSA slurry, in order to absorb free 
nucleotides. The bound cAMP is then separated by centrifugation, allowing 
estimation of the [3 H] cyclic AMP bound to the protein.
Total cyclic AMP binding to the protein was estimated by incubation of 
[3 H] cyclic AMP in the absence of unlabelled cyclic AMP, whilst non-specific 
binding was estimated by incubating [3 H] cyclic AMP in the absence of both 
unlabelled cyclic AMP and binding protein. By using unlabelled cyclic AMP 
over a certain range of known concentrations, one can sequentially reduce the 
proportion of [3 H] cyclic AMP bound to the protein. This allows a standard 
displacement curve to be constructed for the estimation of cyclic AMP content 
of unknown samples.
The cAMP assays were done by taking aliquots from the sample tubes 
were made up to a volume of 100 pi with binding buffer (50 mM Tris-HCI, 4 
mM EDTA, pH 7.4) before 100 pi [3 H] cyclic AMP (stock solution of 5, 8 3 H 
adenosine 3', 5'-monophosphate in 50% ethanol diluted in binding buffer to 
give 40-50,000 c.p.m. per 100 pi) and 100 pi of a suitable dilution of 
cyclic AMP binding protein in binding buffer were added. Also included in this
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procedure were duplicate tubes containing known amounts of cyclic AMP 
(0.0625, 0.125, 0.25, 0.5, 1, 2, 4, 8 and 16 pmol per tube) with [3 H] 
cyclic AMP and binding protein added to the same concentrations as the sample 
tubes. After incubation for at least 2 hours at 4 degrees celsius, by which 
time binding of cyclic AMP to the binding protein had reached equilibrium, 
bound and free nucleotides were separated by the addition of 250 pJ of a 
continuously stirred, chilled 2% (w/v) Norit GSX charcoal/1 % (w/v) BSA 
slurry in assay buffer. This was vortexed and subsequently centrifugation at 
1 4 ,000g av  at 4 degrees celsius for 4 minutes. 300 pi of the supernatant 
was extracted and added to 4 ml Ecoscint before being subject to scintillation 
counting. The inclusion of tubes with known amounts of cyclic AMP allowed 
for a standard curve of c.p.m. versus pmol cyclic AMP to be derived, from 
which amounts of cyclic AMP formed in the sample tubes could be deduced. 
The counter which I used had a computer attachment which allowed a curve of 
best-fit to be drawn for the standards used in each experiment, and printed 
out pmol cyclic AMP present in each sample.
2.6.2 Determination of cyclic AMP formation by purification 
using sequential column chromatography with dowex and alumina
Reaction conditions employed were identical to those above , except 
that [a-32P] ATP (2x106 c.p.m. per tube) was also present. Reactions were 
terminated by the addition of 100 ^l of a "stopping solution" consisting of 1.4 
mM cyclic AMP, 40 mM ATP and 0.2% (w/v) SDS, pH 7.5. Following the 
addition of 100 \i\ [3 H] cyclic AMP (10x10^ c.p.m. per tube) and 750 pi 
distilled water, [3 2 P] cyclic AMP was partially purified by the double 
column method of Salomon et at. (1974). This procedure involves 
separating cyclic AMP from other nucleotides by sequential column 
chromatography with Dowex and alumina.
D o w e x -H + 50 x 4-400 was mixed with distilled water to form a
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slurry (1:1 ratio, v/v). 2 ml of this was then added to each column and the 
water left to drain out: the columns were then ready for use. After use, the 
Dowex was washed with 2 ml 1 M hydrochloric acid until just before the next 
set of samples were applied, when the columns were washed with 10 ml 
distilled water.
The alumina columns were prepared with 0.6g of neutral alumina per 
column. These were washed with 8 ml 0.1 M imidazole, pH 7.4, before use 
and with 2 ml 0.1 M imidazole, pH 7.4, after each experiment. Before the 
next set of samples were loaded, the columns were washed with another 8 ml 
0.1 M imidazole, pH 7.4.
Reaction tubes with added distilled water and [3 H] cyclic AMP were 
applied gently down the side of the Dowex columns using a Pasteur pipette. 
Once the columns had run dry, 1 ml distilled water was added slowly and the 
columns run dry once more. Another 1 ml distilled water was then added and 
the columns allowed to run dry again before being placed over the alumina 
columns. 3 ml distilled water were added to elute the Dowex columns and the 
system run until the alumina columns had run dry. Then the alumina columns 
were placed over scintillation vials and eluted with 4 ml 0.1 M imidazole, pH 
7.4 .
The final eluate from the alumina columns was collected and added to 
12 ml Ecoscint before scintillation counting. Recovery of cyclic AMP in these 
experiments was routinely between 70 and 90%. The amount of cyclic AMP 
per sample was calculated by a computor program which converted the d.p.m. 
per sample into pmol cyclic AMP by using the specific activity of the [a- 
3 2 P] ATP used and by taking into account the recovery of cyclic AMP from 
the column steps.
Unless otherwise stated, formation of cyclic AMP was linear over the 
incubation periods and initial rates were taken for subsequent analysis.
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2.7 Sodium dodecyl sulphate polyacrylamide electrophoresis 
(SDS-PAGE)
For these studies, a discontinuous SDS-PAGE system was used as 
originally described by Laemmli (1970), and subsequently modified by 
Milligan & Klee (1985). This involved concentrating samples in a 0.3%  
(w/v) acrylamide/0.08% (w/v) N, N'-methylenebisacrylamide stacking gel 
follwed by resolution in a 10% (w/v) acrylamide/0.25% (w/v) N, N'- 
methylenebisacrylamide 12 cm x 14 cm resolving gel using a LKB Bromma 
electrophoresis system.
2.7.1 Stock Solutions (all stored at 4 degrees celsius)
a. Buffer 1:- 1.5 M Tris, 0.4% (w/v) SDS adjusted to pH 8.8 with HCI.
b. Buffer 2 :- 0.5 M Tris, 0.4% (w/v) SDS adjusted to pH 6.8 with HCI.
c. Acrylamide solution:-30% (w/v) acrylamide , 0.8% (w/v) N , N'- 
methylenebisacrylamide.
d. 50% (v/v) glycerol solution.
e. N, N, N', N'-Tetramethylenediamine (TEMED).
2.7.2 Gel Preparation
After assembly of the gel plates, a resolving gel solution was made 
consisting of 8.2 ml distilled water, 6 ml buffer 1, 8 ml acrylamide solution,
1.6 ml glycerol solution, 20 pi TEMED and 90 pi 10% (w/v) ammonium 
persulphate (prepared fresh). Once poured between the plates, 1 ml distilled 
water was added to cover the top of the solution thereby excluding air and 
enhancing polymerization. When set, the water was poured off and any 
unpolymerized acrylamide washed away with distilled water. A stacking gel 
mixture was then poured onto the resolving gel: this consisted of 9.75 ml 
distilled water, 3.75 ml buffer 2, 1.5 ml acrylamide solution, 20 pi TEMED  
and 150 pi 10% (w/v) ammonium persulphate. A gel comb was then inserted 
to facilitate loading of samples. Once set, the remainder of the kit was
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assembled and the samples loaded using a Hamilton Microsyringe. The anode 
and cathode were immersed in running buffer (25 mM Tris , 200 mM 
glycine and 0 .1% (w/v) SDS) and samples run overnight at 12 mA, 60 V.
2.7.3 Sample preparation
The required amount of membrane protein (10-300 pg) was 
sedimented by centrifugation at 14,000gav  for 10 minutes at 4*C. After 
removal of the supernatant the membrane pellet was resuspended in 40 pi 
electrophoresis sample buffer (50mM Tris, 4.5 M urea, 5% (w/v) SDS, 40 
mM DTT and a grain of bromophenol blue dye). After solubilisation of 
samples by vortexing and incubation in a boiling water bath for 3 minutes, 
they were ready for electrophoresis.
2.7.4 electrophoretic separation of a;1 and a;2
Separation of the alpha-subunits of Gj-1 and G,--2 was achieved by 
alkylating membrane samples before resolution of membrane proteins on a 
12% (w/v) acrylam ide/0.06%  (w/v) N, N'-methylenebisacrylamide 
resolving gel, as described by Mitchell et al. (1989).
Before alkylation, the required amount of membrane protein (10- 
300 pg) was sedimented by centrifugation at 14,000g av at 4 degrees 
celsius for 10 minutes. The supernatant was discarded and the pellet 
resuspended in 20 pi 10 mM Tris-HCI, 1 mM EDTA, pH 7.5. After the 
addition of 10 pi 5% (w/v) SDS in 50 mM DTT, the samples were boiled for 
5-10 minutes before cooling on ice for 30 seconds (before the SDS 
precipitated out). 10 pi 100 mM N-ethylmaleimide (NEM) were added and 
the samples left at room temperature for at least 15 minutes to allow the 
alkylation reaction to occur. To stop the reaction, 20 pi electrophoresis 
sample buffer were added and the samples left overnight at 4 degrees celsius.
The method for electrophoretically separating the alkylated samples is 
very similar to the protocol described in section 2 .8.2 using the solutions
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described in section 2 .8.1 apart from the following differences:-
a. A Bio-Rad Protean electrophoresis system was used to allow the use of a 
20 cm x20 cm resolving gel.
b. For the resolving gel, a different stock acrylamide solution was used, 
consisting of 30%  (w/v) acrylam ide, 0 .15%  (w/v) N, N'-
methylenebisacrylamide.
c. The resolving gel mixture consisted of the following:- 11.6 ml distilled 
water, 12 ml buffer 1, 20 ml acrylamide solution (described above), 4
m I
glycerol solution, 160 pi 10% (w/v) ammonium persulphate and 40 pi 
TEMED.
d. The stacking gel mixture consisted of the following:- 14.6 ml distilled 
water, 5.6 ml buffer 2, 2.3 ml "normal" acrylamide solution, 225 pi 
ammonium persulphate and 12 pi TEMED.
e. Once loaded, samples were run at 45 mA, 100 V overnight in the 
running buffer previously described.
2.7.5 Molecular weight markers
These were obtained from Gibco-BRL Research Products, Uxbridge, 
Middlesex, U.K. The biotinylated pre-stained proteins were myosin H-chain 
(200 KDa), phosphorylase b (97.4 KDa, BSA (68 KD), ovalbumin (43 
KD), carbonic anhydrase (29 KD), 6-lactoglobulin (18.4 KD), and lysozyme 
(14.3 KD).
2.7.6 Staining of gels for protein
After electrophoresis, gels were stained for 1 hour in 200 ml of 
0.1% (w/v) Coomassie Brilliant Blue R in 40% (v/v) methanol and 10% 
(v/v) acetic acid. Destaining was carried out overnight in the same solution 
minus the Coomassie Brilliant Blue R.
2.8 Immunoblotting of SDS-PAGE gels.
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2.8.1 Transfer of proteins to nitrocellulose and detection
This was achieved using a modification of the method of Mitchell et al. 
(1989) which is derived from the original method of Towbin et al. (1979).
After separation of proteins by SDS-PAGE the stacking gel was 
removed and the resolving gel allowed to soak in transfer buffer (25 mM 
Tris, 200 mM glycine in 20 (v/v) methanol) for a few minutes. After 
soaking, a blotting sandwich was constructed which allowed the gel to press 
tightly against a piece of nitrocellulose paper (Schleicher & Schull, 0.45 
pm). These were kept firmly in place by pressing a piece of chromatography 
paper (Whatman) and foam rubber either side of this sandwich and keeping 
them together with plastic holders. This sandwich was placed into a LKB 
Transblot tank and completely immersed in transfer buffer. A LKB Transphor 
powerpack was connected such that the gel side of the sandwich was connected 
to the negative electrode and the proteins transferred to the nitrocellulose 
paper for 2 hours at maximum voltage, producing a direct current of 1 mA.
After transfer, the blotting sandwich was removed, dismantled and the 
nitrocellulose paper incubated for 3 hours at 30 °C  in a solution of 5%  
(w/v) gelatin in phosphate-buffered saline (PBS; 136 mM NaCI, 2.7 mM 
KCI, 80.5 mM Na2 H P 0 4 & KH2 P 0 4) to block non-specific sites on the 
nitrocellulose which the subsequently-used antibodies might bind to. 
Following blocking, the nitrocellulose paper was washed free of excess gelatin 
with PBS before the primary antibody was added as a 1 in 200 dilution in 
PBS containing 1% (w/v) gelatin, 0.2% (v/v) non-ionic detergent NP-40 
and 0.05% (w/v) thimerisal. The nitrocellulose paper was incubated 
overnight at 30degrees Celsius in this solution, by which time the binding of 
antibody had reached equilibrium. The antibody solution was then poured off 
and the nitrocellulose washed with PBS. The paper was then washed twice for 
10 minutes with shaking in PBS containing 0.2% (w/v) NP-40 before the 
second antibody (horse radish peroxidase-conjugated goat anti-rabbit Ig G)
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was added as a 1 in 200 dilution in PBS containing 1% (w/v) gelatin, 0 .2% 
(v/v) non-ionic detergent NP-40 and 0.05%  (w/v) thimerasal. After 
incubation for 3 hours at 30 degrees Celsius, the antibody solution was 
poured off and the washing procedures outlined above were repeated. These 
were followed by a final wash for 10 minutes in PBS before this solution was 
removed and replaced by 40 ml 10 mM Tris-HCI, pH 7.5, and 1 ml of a 10% 
(w/v) orthodianisidine dihydrochloride solution dissolved in water. To 
develop the blot, 10 jil 30% (w/v) hydrogen peroxide solution were added 
and the mixture swirled over the nitrocellulose paper. Development was 
arrested by pouring off the developing solution and covering the blot with 50 
ml 1% (w/v) sodium azide.
When stored at 4 degrees Celsius before and after use, both the 
primary and secondary antisera could be stored as 1 in 200 dilutions in 
gelatin/PBS/NP-40 and used for up to five different experiments.
2.8.2 Description of antisera
The polyclonal antisera used for these studies were donated by Dr. 
Graeme Milligan, Institute of Biochemistry, University of Glasgow, and have 
been described in several publications (Mitchell et al., 1989; McKenzie & 
Milligan, 1990; Milligan & Unson, 1989). Briefly, antisera were raised in 
New Zealand White rabbits against glutaraldehyde conjugates of keyhole- 
limpet haemocyanin and synthetic peptides which represent sections of the 
deduced amino acid sequences of various cloned G-protein subunits (Table 
2.1).
Antiserum SG1 was raised against the C-terminal decapeptide 
sequence of Gta -1 . This antiserum recognizes both Gja-1 and Gjtx-2 as well 
as Gta-1 and Gta-2, but as the expression of the latter two species is 
restricted to retinal tissue, SG1 can be used as a specific probe for Gja-1 and 
Gja-2 in other tissues. This antiserum does not recognize Gja-3 (Mitchell
78
et al., 1989). Antiserum I3B was raised against a decapeptide which 
corresponds to the C-terminal sequence of Gjtx-3. It does not cross-react 
with Gja-1 or Gjtx-2 but does exhibit weak cross-reactivity with G0 a  
(Mitchell et al., 1989). However, the expression of G0 a  in both liver 
(Lynch et al., 1989; Huff et al., 1985) and adipocytes (Mitchell et al.,
1989) is below current levels of detection. Antiserum CS1 was generated 
against a decapeptide corresponding to the C-terminal sequence of Gsa which 
is present in all four of the Gsa cDNA sequences (Bray et al., 1987). 
Antiserum BN1 was raised against the N-terminal sequence of the B-|- 
subunit, which differs by one amino acid substitution from 62 but by three 
residues from 63 (Levine et al., 1990). Hence BN1 could be used to probe 
for both R.j and B2 under suitable conditions (Evans et al., 1986), although 
we were unable to resolve these proteins under any of the electrophoretic 
conditions described above section.
2.9 Estimation of protein concentration.
This was carried out according to the method of Peterson (1977) 
which is a modification of the method of Lowry et al. (1951). The stock 
solutions were:
a 2% (w/v) sodium carbonate in 0.1 M sodium hydroxide
b 1% (w/v) copper sulphate
c 2% (w/v) sodium potassium tartrate
Just before use the reagents are mixed in the following v/v ratio: 
a/b/c, 100/1/1. Protein standards were preparwed using bovine serum 
albumin. 1ml of the abc solution was added to each sample, mixed and left to 
stand for 10min. 100pl of Folin-Ciocalteau reagent, diluted 1:4 with water 
was added to each tube. The samples were mixed and left for 30 min. The
absorbance of the samples was determined spectrophotometrically at 750nM
in an LKB Ultrospec II spectrophotometer.
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CHAPTER 3
THE REGULATION OF ADENYLATE CYCLASE IN THE 
ADIPOSE TISSUE FROM STREPTOZOTOCIN 
DIABETIC RATS
Fig 3.1 Dose-effect experiments for GppNHp on forskolin 
stimulated adenylate cyclase activity in adipocyte membranes.
Adenylate cyclase activity was monitored in the presence of forskolin 
(10"4M). Increasing concentrations of GppNHp were added to assays employing 
adipocyte membranes from control (open square) and diabetic (closed S ^ y iffe )  
animals. Errors are S.D for six experiments (diabetic) and five experiments 
(control) using different membrane preparations each time. The reference 
activity of 100% is that activity obtained with forskolin (100pM) alone. In 
membranes from control rats the control activity was 335±40 pmol/min/mg, 
whilst in membranes from diabetic rats it was 139±22 pmol/min/mg.
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Fig 3.2 Dose response experiment for GTP on hormone stimulated 
adenylate cyclase activity in adipocyte membranes from control 
animals.
Adenylate cyclase activity was monitored in the presence of 
isoproterenol (5 x 1 0 '4 M). Errors are standard deviations for four 
experiments using different membrane preparations. The control, 100%, 
activity represents that activity with 500jiM isoproterenol alone which was 
157±9 pmol/min/mg. The Vmax activity, ie that activity in the presence of 
500p.M GTP and 500jiM isoproterenol, was 220±28 pmol/min/mg giving a 
1.40-fold stimulation of activity by GTP.
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Fig 3.3 Dose-effect experiment for GTP on isoproterenol 
stimulated adenylate cyclase activity in adipocyte membranes 
from diabetic animals.
Adenylate cyclase activity was monitored in the presence of 
isoproterenol (5 x 1 0 '4 M). Errors are standard deviations for six 
experiments using different membrane preparations. The reference activity of 
100% refers to that activity in the presence of isoproterenol (500|iM) alone, 
which was 56±8 pmol/min/mg. The V max activity, ie that activity in the 
presence 500|iM GTP and 500p.M isoproterenol, was 250±49 pmol/min/mg 
giving a 4.5-fold activation of activity by GTP.
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Fig 3.4 Dose response curve for inhibition of isoproterenol 
stimulated adenylate cyclase activity by GTP in presence of PIA 
for membranes from diabetic animals.
The experiment was carried out in the presence of 1pM PIA and 500p.M 
isoproterenol, using membranes from diabetic animals. Experiment is typical 
of three similar experiments using different membrane preparations. The 
control activity of 100% represents that activity with 500pM isoproterenol 
and 500jiM GTP which was 245±21 pmol/min/mg. ~^r UL d a t a  stanv«> 
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Fig 3.5 PIA mediated effects on adenylate cyclase activity
Dose response curves for PIA were carried out in the presence of 
isoproterenol (5x10"4 M) and GTP (10‘ 5 M) using adipocyte membranes 
from control (open square) and diabetic (closed diamond) animals. This 
experiment is typical of three similar ones using different membrane 
preparations. The specific activity of adenylate cyclase in presence of 500p.M 
GTP and 500pM isoproterenol only was 238±19 pmol/min/mg for 
membranes from control rats and 255±32 pmol/min/mg for membranes from 
diabetic rats. Th*. an  A  shxncAcurd c taviaK ons for-
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Fig 3.6. Identification of aj1 and a j2  in adipocyte membranes.
Western blotting data are shown which were obtained using the 
antiserum AS7 which in adipocyte membranes specifically recognizes ocjl 
and otj2 which can be resolved by virtue of the differences in molecular 
weight. Lane 1 contains 70|ig of membranes from control animals. Lane 2 
contains 70|ig of membranes from diabetic animals. This result is 
representative of eight separate experiments using different membrane 
preparations from control and diabetic animals.
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Fig 3.7 Detection of ocj3 in m em branes from  contro l and 
diabetic animals.
The G-protein subunit otj3 was identified by immunoblotting with 
antiserum I3B which specifically recognizes aj3. Lane 1 was loaded with 
70|ig of protein from membranes prepared from control animals. Lane 2 
was loaded with 70pg of protein from membranes prepared from diabetic 
animals. This result is representative of eight separate experiments using 
different membrane preparations.
1 2
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Fig 3.8 Detection of a s in membranes from control and diabetic  
anim als.
The G-protein subunit a s was detected in adipocyte membranes by use 
of antiserum CS1 which specifically recognizes a s . Lane 1 was loaded with 
70|ig of protein from membranes prepared from control animals. Lane 2 was 
loaded with 70jig of protein from membranes from diabetic animals. This 
experiment is representative of six different experiments using different 
membrane preparations each time.
1 2
alpha Gs
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Table 3.1 Receptor mediated inhibition of adenylate cyclase.
Assays were performed in the presence of 10'®M GTP and 5x1 O' 4 M. 
The maximal inhibitory effect of PGE2 , nicotinate and PIA is shown together 
with the IC50 values*. Data were obtained from dose effect-curves done at 
eight different ligand concentrations, and errors are standard deviation for 
three separate experiments using different membrane preparations. The 
specific activity of adenylate cyclase in the absence of any inhibitory ligand 
was 220±18 pmol/min/mg for membranes from control animals and 
248±15 pmo/min/mg for membranes from diabetic animals.
Ligand
Normal Diabetic
Inhibition
(%)
,C50
(nM)
Inhibition
(%)
,C50
(nM)
PIA 54±8 37±7 83±9 20±4
PGE-j 54±6 38±6 68±9 45±7
Nicotinate 51 ±11 708±48 67±13 753±46
* The IC50 value is that concentration of the compound which causes half 
maximal inhibition of adenylate cyclase.
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3.1 INTRODUCTION
Previous studies on the regulation of adenylate cyclase in hepatocyte 
membranes from rats made diabetic by injection of streptozotocin have shown 
that there is a defect in the regulation of adenylate cyclase by Gj (ch 1). The 
consequences of this alteration in Gj function are such that tonic inhibition of 
adenylate cyclase is lost and consequently the response to glucagon 
stimulation of adenylate cyclase is enhanced in hepatocyte membranes from 
diabetic animals (ch 1). Previous studies on adipocyte adenylate cyclase 
system of diabetic animals had reported an increased response to 6-AR 
stimulation of adenylate cyclase by B-AR agonists (Zumstein et al 1980). 
However nothing was known about the molecular basis of this effect and thus I 
set out to identify possible underlying molecular mechanisms.
3.2 PHILOSOPHY OF ANALYSES EMPLOYED.
Forskolin is a diterpene which profoundly activates adenylate cyclase 
(Seamon & Daly, 1986). There appear to be two sites of action: firstly a 
direct activation of the catalytic unit (C) of adenylate cyclase, secondly an 
activation of adenylate cyclase involving the presence of functional Gs. The 
activation of adenylate cyclase by Gs and forskolin appears to be synergistic 
in nature. The degree of stimulation by forskolin is commonly used as a 
measure of the activity of the catalytic unit of adenylate cyclase itself, 
independent of any G-protein input, but this is not strictly true for the 
reason mentioned above. However MnC^, will stimulate the activity of the 
catalytic unit directly as mentioned in ch 1 with a K0.s of ~0 .3mM compared 
with ~3.0mM for Mg++ (Somkuti et al, 1981). It is quite possible then to 
imagine that the response of the catalytic unit of adenylate cyclase can be 
altered with respect to stimulation by Gs whilst leaving stimulation by the 
Mg++ binding site unaltered. This must therefore be a consideration in the
interpretation of experiments employing MnC^.
NaF in the range 3-20mM activates adenylate cyclase by virtue of the 
presence of AIF4' ions which are a tetrahedral species thought to mimic the 
phosphate ion P 0 4' \  Thus, since GDP is bound to G-proteins in isolated 
membrane preparations the tetrahedral A1F4- ion has been suggested to 
occupy the site occupied normally by the y-phosphate of GTP such that 
GDP*AIF4‘ mimics the effect of non-hydrolysable GTP and thereby leads to 
activation.
GTP itself elicits a small stimulation of adenylate cyclase (Cooper et 
al, 1979). The dose response of adenylate cyclase to GTP, in the presence of 
an Rs linked agonist is biphasic in adipocyte membranes (Cooper 1982). At 
low concentrations one sees the activation of G s while at higher 
concentrations, in the second phase, activation of Gj ensues with resultant 
inhibition of adenylate cyclase. Thus a GTP dose response curve can be used to 
determine inputs into adenylate cyclase from both Gs and Gj.
The GTP analogue GppNHp, unlike GTP, activates adenylate cyclase 
significantly even in the absence of an added stimulator of adenylate cyclase 
such as an Rs linked agonist or forskolin. If GppNHp alone is used to activate 
adenylate cyclase then the dose response curve to this agent is monophasic so 
that only a stimulatory action of GppNHp upon adenylate cyclase is seen 
(Cooper et al, 1982). However, when forskolin is used to activate the 
system then the GppNHp dose response curve is biphasic. This results from 
low concentrations of GppNHp activating Gj and thus leading to inhibition of 
adenylate cyclase whilst at higher concentrations Gs is activated and 
stimulation is seen (Cooper et al, 1982). This type of assay can be used to 
measure the balance of inputs from Gs and Gj. The reason why there is no 
inhibition of adenylate cyclase by low concentrations of GppNHp in the 
absence of forskolin is uncertain but it is probably due to the fact that
9 5
adenylate cyclase can only be inhibited while in a state of increased activity.
The adenosine A-| receptor selective agonist PIA (N 6- 
(phenylisopropyl)adenosine is has been used in this system to stimulate the 
activity of this receptor which is coupled to Gj, in order to observe inhibition 
of adenylate cyclase. Similarly PGEi (prostaglandin E-|) and nicotinic acid 
are agonists which activate Rj type receptors which couple to Gj in 
adipocytes.
Quantification of relative levels of G-protein subunits was done by 
immunoblotting using specific antipeptide antisera (chapter 2 & appendix).
3.3 RESULTS AND DISCUSSION
The dose response to GppNHp, in the presence of 100pM forskolin, 
was examined in adipocyte membranes membranes from control and 
strepotozotocin diabetic animals (Fig 3.1). Analysis of data in Fig 3.1 shows 
that, for membranes, from control animals the classical biphasic response to 
GppNHp was clearly evident with inhibition of adenylate cyclase activity 
occurring at low concentrations of GppNHp, ie 0.1-100nM, whilst activation 
occurs at concentrations greater than 100nM. Maximal inhibition achieved 
was 42±7% of the stimulated activity elicited in the presence of 100pM 
forskolin. In contrast, analysis of the response of membranes from diabetic 
animals to GppNHp (Fig 3.1) showed that there was no inhibition of adenylate 
cyclase at low concentrations of GppNHp. Thus it appears that the ability of Gj 
to exert a tonic inhibition on adenylate cyclase was lost in membranes from 
diabetic animals. The control activity of adenylate cyclase, obtained in the 
presence of 100jiM forskolin only, was much lower in membranes from 
diabetic animals than in membranes from control animals (Fig 3.1). It is 
possible that, either the catalytic activity of individual adenylate cyclase 
molecules was reduced or the number of molecules was reduced.
The GTP dose response of membranes prepared from control animals
was also determined (Fig 3.2) where a classical biphasic response toJ3TP w as____
gg*Densiometric scanning of immunoblots, using an Abaton-30C
densiometric scanner driven by Apple Macintosh 'C-Scar
Software', was employed for the comparison of G-proteir
subunit levels between membranes from control and diabetic
demonstratable. Thus, high concentrations of GTP inhibit activity which, as 
described in ch 1, is due to the action of Gj. However when the same 
experiment was performed on membranes prepared from diabetic animals the 
classical biphasic response was completely lost (Fig 3.3). Analysis of Fig 3.3 
shows that only a stimulatory phase was seen with GTP. Thus, as deduced from 
studies done with GppNHp, the ability of Gj to exert a tonic inhibitory effect 
on adenylate cyclase was abolished in membranes from isolated from diabetic 
animals. The control adenylate cyclase activity of membranes from diabetic 
animals was significantly lower than the corresponding activity in 
membranes from control animals (Figs 3.2 & 3.3).
A dose response curve to GTP was also conducted in the presence of PIA 
using membranes from diabetic animals (Fig 3.4), C learly under the 
conditions employed in this experiment, a biphasic response to GTP was 
evident. This result was in marked contrast to that seen in Fig 3.3. Thus here 
we see that, using membranes from diabetic animals, as long as PIA is 
present then concentrations of GTP greater than 100nM leads to inhibition of 
adenylate cyclase. The dose response curve of membranes from control and 
diabetic animals to PIA is shown in Fig 3.5 which shows that inhibition by 
PIA was actually somewhat greater in membranes from diabetic animals than 
in membranes from control animals.
The fact that PIA appears to show enhanced inhibition of adenylate 
cyclase in membranes from diabetic animals (Fig 3.5; Table 3.1) is probably 
due to the fact that inhibition of adenylate cyclase, mediated by GTP alone, is 
abolished in the very same membranes and consequently PIA is able to achieve 
further inhibition because the system is more open to inhibition. On a some 
what similar note, it is well documented that pertussis toxin treatment of 
cells, thereby ADP-ribosylating and inactivating Gj, leads to enhanced 
stimulation of adenylate cyclase by glucagon in hepatocyte membranes
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(Heyworth et al, 1984) and enhanced stimulation of adenylate cyclase by 
isoproterenol in adipocyte membranes (Katada et al, 1982).
In order for the inhibitory action of Gj to be seen in membranes from 
diabetic animals it was essential that PIA was present rather than membranes 
briefly subjected to its exposure. Indeed pre-incubation of membranes from 
diabetic animals in adenylate cyclase assay buffer for periods of 5-10min 
with 1pM PIA followed by harvesting of the membranes by centrifugation, 
and washing once with EDTA/Tris buffer, failed to expose any function of Gj 
when membranes were subsequently challenged for GTP dependent inhibition 
in the absence of PIA.
We sought to ascertain whether these changes in G j-m ediated  
responses could be attributed to any alteration in the expression of the three 
forms of Gj that have been shown to be expressed in adipocytes (Mitchell et 
al, 1989). Although the functional role of these various G-proteins has yet 
to be definitely ascertained it has been suggested that Gj2 might be the major 
species responsible for mediating the inhibition of adenylate cyclase 
(Bushfr^d et al, 1990; Codina et al, 1988). We found no evidence for 
differences in the apparent amounts of a-subunits for either of these two G- 
proteins in adipocyte membranes from normal and diabetic animals (Fig 
3.6). In 8 separate experiments using different membrane preparations 
immunoblotted with antiserum AS7 we found that the level of ctjl in 
membranes from diabetic animals differed by only some -5.5±8% compared 
with that in membranes from control animals. The same experiments showed 
that the level of a\2 differed only by some 8±7% in membranes from diabetic 
animals as compared with membranes from control animals. In contrast to 
this, using antiserum I3B to detect aj3 we observed that levels of this 
particular G-protein a-subunit were actually increased by some 88±18%  
(8 separate experiments) in adipocytes from diabetic animals compared with
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those from control animals. These results suggest that the loss of guanine 
nucleotide elicited Gj activity in adipocyte membranes of diabetic animals is 
not due to any selective loss of one form of Gj which might, for example, 
effect receptor independent (tonic) inhibition whereas other retained species 
might mediate receptor dependent inhibition. It is possible that the more 
pronounced inhibitory potency of PIA in membranes from diabetic animals 
could be due to elevated aj3 levels or increased numbers of A-j-adenosine 
receptors. However I believe that it is equally possible that the effect is due 
to a loss of the tonic inhibition of adenylate cyclase by Gj.
The increased response employing membranes from diabetic animals 
was not due to any increase in the amount of the stimulatory G-protein Gs as 
the induction of diabetes did not affect the amount of the two forms of this G- 
protein that I detected here (45kD and 42kD). Fig 3.8 shows that the levels 
of 45 and 42 kD forms of a s differed only by some 6±5% and -7±6%  
respectively from those seen using membranes from control animals.
Thus it appears somewhat paradoxical that Rj receptor mediated 
inhibition of adenylate cyclase was unimpaired in membranes from diabetic 
animals but that tonic inhibition mediated by Gj was abolished. However this 
latter effect is not completely unprecedented since the two functions can be 
divorced in normal adipocyte membranes such that inhibition by GTP or 
GppNHp is completely abolished but that by PIA is increased (Cooper 1982). 
This was shown in studies where the NaCI concentration in the adenylate 
cyclase assay buffer was increased to 150mM or greater. Under such 
conditions inhibition, achieved using low concentrations of GTP was abolished 
while inhibition by PIA was actually increased.
The tonic inhibition of adenylate cyclase could employ two potential 
mechanisms. Firstly the inhibition could be achieved by residual turnover of 
Gj without any requirement for input from agonist occupied Rj receptors. 
Alternatively it could be achieved by some input from unoccupied Rj
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receptors activating Gj, as has been suggested for 3-opiate (ch 1). The 
question of how 'tonic' inhibition, but not Rj mediated inhibition, is abolished 
in membranes from diabetic animals is made complex by the fact that the 
mechanism by which Gj inhibits adenylate cyclase is ill-understood. The 
inhibitory action of Gj has been suggested to be mediated by the release of py 
subunits upon receptor activation of Gj (Katada et al, 1984). However 
various studies have implied that a; also contributes to the inhibition of 
adenylate cyclase stimulated by activated Rs, but inhibition of basal adenylate 
cyclase activity is mediated by py subunits (Hildebrandt & Kohnken, 1990). 
It has been demonstrated recently that a\ can be phosphorylated by 
challenging hepatocytes with TPA or PKC activating agents. This leads to the 
loss of the ability of GppNHp to inhibit forskolin stimulated adenylate cyclase 
activity. Indeed, the a-subunit of Gj is now known to be a substrate not only 
for PKC (Pyne et al, 1989; Katada et al ,1985) but also PKA (Wanatabe 
et al, 1988) and the insulin receptor kinase (O'Brien et al, 1987; 
Krupinski et al, 1988). It is therefore possible that the lesion which leads 
to a change in functioning of Gj is its phosphorylation state. In adipocyte 
membranes from diabetic animals only a stimulatory action of GTP was 
apparent (Fig 3.3). However, the net effect of any relative enhancement of 
catecholamine stimulated intracellular adenylate cyclase activity in the 
diabetic state will be attenuated by the fact that basal adenylate cyclase 
activity was itself reduced in diabetic adipocytes (Table 3.1). Thus, even 
though the response of adenylate cyclase to stimulation by isoproterenol in 
diabetic rats is increased, there is unlikely to be a large increase in the 
intracellular concentration of cAMP in response to stimulation by 
catecholamines in the intact adipocytes of these animals. Concerning the 
reduction in activity of the catalytic unit of adenylate cyclase itself, remains 
to be seen whether this is due to a reduction in the amount or activity of the
catalytic unit itself.
The situation found in streptozotocin diabetic rat adipocyte bears 
comparison with hepatocytes membranes of obese Zucker rats. In this case 
hepatocyte membranes from obese animals exhibit little functional Gj, as 
assessed by either GTP or GppNHp dependent inhibition, whereas an activity 
comparable with that seen in Sprague-Dawley rats was seen with the lean 
animals (Houslay et al, 1989). This occurred despite there being similar 
amounts of Gj in membranes from both types of animals.
The loss of the ability of Gj to to cause the inhibition of adenylate
cyclase activity in adipocyte membranes from genetically obese and insulin 
resistant obese (ob/ob) mice has similarly been noted (Begin-Heick, 1985; 
Begin-Heick, 1988). Such experiments bear similarity to those described in 
this study and previous investigations (Houslay et al, 1989; Gawler et al, 
1987) in highlighting a lesion in the inhibitory function of Gj, rather than 
any loss its of expression, in insulin-resistant states. However in the ob/ob 
mouse system, adipocyte membrane adenylate cyclase can still be inhibited by 
PIA (Greenberg et al, 1987). Thus again it appears that tonic inhibition of 
adenylate cyclase can be lost in a pathological state while adenylate cyclase is 
still fully responsive to inhibition by Rj receptor mediated mechanisms. 
Indeed, as reported here for adipocyte membranes from streptozotocin 
diabetic animals, Greenberg et al, (1987) also observed an enhanced ability 
of PIA to elicit inhibition in membrane preparations from obese animals
which lack the tonic inhibitory capacity of Gj.
It has been demonstrated recently that a\ can be phosphorylated by 
challenging hepatocytes with TPA or PKC activating agents. This leads to the 
loss of the ability of GppNHp to inhibit forskolin stimulated adenylate cyclase 
activity. Indeed, the a-subunit of Gj is now known to be a substrate not only 
for PKC (Pyne et al, 1989; Katada et al, 1985) but also PKA (Wanatabe
10 1
et al, 1988) and the insulin receptor kinase (O'Brien et al, 1987; 
Krupinski et al, 1988). It is therefore possible that the lesion which leads 
to a change in functioning of Gj is its phosphorylation state.
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CHAPTER 4 
REGULATION OF ADENYLATE CYCLASE IN THE 
ADIPOSE TISSUE OF OBESE (fa/fa) ZUCKER RATS
Fig 4.1. Dose-response curves for stimulation of adenylate cyclase 
by isoproterenol in adipocyte membranes from lean and obese 
Zucker rats
The 100pM GTP stimulated activity was 16±1.6 pmol/min/mg and 
17±1.7 pmol/min/mg for membranes from lean and obese animals respectively. 
The maximal specific activities attained when saturating doses of isoproterenol 
were used together with GTP were 262±26 pmol/min/mg and 100±9 
pmol/min/mg for membranes from lean and obese animals respectively. The 
fold-stimulations by isoproterenol over GTP-stimulated activity were thus 
calculated to be 16 and 6 for membranes from lean and obese animals 
respectively. The K0.s values for isoproterenol-stimulation were deduced to be 
6.3±0.8p.M and 8.9±1.1|iM  for membranes from lean and obese animals 
respectively. Result shows mean and standard deviations for a typical experiment 
repeated six times with six different sets of lean (open square) and obese (filled 
diamond) Zucker rat membranes.
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Fig 4.2 Dose response to isoproterenol stimulation of adenylate 
cyclase in the presence of GTPyS
The dose response to isoproterenol done in the presence of 100pM 
GTPyS was assessed for membranes from lean (closed ) and obese
(open square) animals. The data shows mean and standard deviation for a 
typical result repeated three times in separate sets of membranes from lean 
and obese animals. The activities of adenylate cyclase with 100uM GTPyS alone 
were 83±7.5 and 70±9.1 pmol/min/mg for membranes from lean and obese 
animals respectively. V m a x  activities were 134±12.5 and 119±12 
pmol/min/mg for lean and obese membranes respectively.
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Fig 4.3 Dose response to GTPyS stimulation of adenylate 
cyclase in presence of 50p.M isoproterenol
Data points show mean and standard deviations of a typical experiment 
repeated three times with different sets of lean (closed diamond) and obese 
(open square) membranes. Adenylate cyclase was stimulated with 50nM 
isoproterenol and the effect of increasing concentrations of GTPyS were 
determined. In membranes from lean animals the control activity was 46±5 
pmol/min/mg, the V max activity was 120±9 pmol/min/mg, the fold 
stimulation by GTPyS was calculated to be 2 .6-fold and the Kg.5 for GTPyS 
was 0.45±0.1nM. In membranes from obese animals the control activity was 
15.6 pmol/min/mg, the Vmax activity was 125±11 pmol/min/mg, the fold 
stimulation by GTPyS was calculated to be 8.0 fold and the Kq.5 for GTPyS was 
4.0±1nM.
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Fig 4.4. Dose-response curves for stimulation of adenylate cyclase 
by glucagon in membranes from lean and obese Zucker rats.
In membranes from lean animals glucagon stimulated adenylate cyclase 
activity in the presence of 100|iM GTP some 4.6-fold to a Vmax of 55.4±4.3 
pmol/min/mg with a Kq.5 of 501±100nM. In membranes from obese animals 
glucagon stimulated adenylate cyclase activity in the presence of 100p.M GTP 
some 2 .1-fold to a V m a x  of 25.7±3.0 pmol/min/mg with a Kg.5 of 
1333±500nM. The data shows mean and standard deviations of a typical 
experiment repeated three times with different lean (open square) and obese 
(filled diamond) Zucker rat membranes.
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Fig 4.5. Dose-response curves for stimulation of adenylate cyclase 
by secretin in from membranes lean and obese Zucker rats.
In membranes from lean (open square) animals, secretin stimulated 
adenylate cyclase activity, in the presence of 100pM GTP, some 4.15-fold, to a 
Vmax ° f  27±1.5 pmol/min/mg with a Kg 5 of 141±20nM. In membranes from 
obese animals (filled diamond) stimulation of adenylate cyclase (+ 100pM GTP) 
by secretin was negligible. The data shows mean and standard deviations for a 
typical experiment repeated three times with different lean and obese Zucker rat 
membrane preparations.
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Fig 4.6 Dose-response curves for stimulation of adenylate cyclase 
by TSH in adipocyte membranes from lean and obese Zucker rats.
Basal activity is that with 100 pM GTP only. In membranes from lean 
animals (open square) TSH stimulated adenylate cyclase by some 3.75-fold 
reaching a Vmax of some 30.4±3.5 pmol/min/mg with a K0 5 of 266±50nM. In 
membranes from obese animals (filled diamond) TSH stimulation of adenylate 
cyclase was negligible. The data shows mean and standard deviation for a typical 
experiment repeated three times with different lean and obese Zucker rat 
membrane preparations.
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Fig 4.7 Dose response curves of adenylate cyclase stimulation to 
GTPyS in the absence of any hormones.
Adenylate cyclase activity was assayed with increasing concentrations of 
GTPyS with adipocyte membranes from lean (open square) and obese (closed 
diamond) Zucker rats. Results are mean±standard deviation for 3 different 
experiments using different membrane preparations each time. In membranes 
from lean animals the Vmax activity was 77±3 pmol/min/mg and the K0 5 was 
8.5±1.2nM. In membranes from obese animals the Vmax activity was 70±5 
pmol/min/mg and the K0>5 was 28±3nM.
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Fig 4.8. Detection of a s -subunits in adipocyte m em branes from  
lean and obese animals.
Detection of the 42KD and 45kD forms of Gs using the antiserum CS1 
with membranes from lean (tracks 1,2,3) and obese (tracks 4,5,6)animals 
at 20|ig (track 1,4), 40p.g (track 2,5) and 60|ig(track 5,6) of membranes. 
Plasma membranes were subjected to SDS-PAGE and immunoblotted with 
antipeptide antisera as described in Materials and Methods. Data shown are 
typical experiments of those done three times using membranes from 
different lean and obese animals.
1 2  3 4 5 6
alpha Gs 45KD 
"a lp h a  G$ 42KD
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Fig 4 .9  D e tectio n  of G -p ro te in  3 -s u b u n it in ad ip o cyte  
membranes from lean and obese animals.
Detection of 3-subunit by immunoblotting with antiserum BN1 
with membranes of lean (tracks 4,5,6) and obese (tracks 1,2,3) animals 
at 40pg (tracks 3,6), 80pg (tracks 2,5) and 120pg (tracks 1,4) of 
membranes. Plasma membranes were subjected to SDS-PAGE and 
immunoblotted with antipeptide antisera as described in Materials and 
Methods. Data shown are typical experiments of those done three times 
using membranes from different lean and obese animals.
1 2 3 4 5 6
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Fig 4.10. Detection of ocj1 and ocj2 in adipocyte membranes from  
lean and obese animals.
Detection of the a  subunits of G j-1  and G j - 2  using the antiserum AS7; 
track 1 80|ig lean, track 2 obese 80jig and track 3 obese 160pg. Plasma 
membranes samples were subjected to SDS-PAGE and immunoblotted with 
antipeptide antisera as described in Materials and Methods. Data shown are 
typical experiments of those done three times using membranes from 
different lean and obese animals.
Fig 4.11. Detection of cxj3 in adipocyte membranes from  lean and 
obese animals.
Detection of a j3 using antiserum 13B for membranes of lean (tracks
1,2,3) and obese (tracks 4,5,6) animals using 50pg (tracks 1,4),100|ig 
(tracks 2,5) and 150jig (tracks 3,6) of membranes. Plasma membranes 
were subject to SDS-PAGE and immunoblotted with antipeptide antisera as 
described in Materials and Methods. Data shown are typical experiments of 
those done three times using membranes from different lean and obese 
animals.
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Fig 4.12 Dose response of forskolin  stim ulated adenylate cyclase  
curve to GppNHp in adipocyte m em branes from lean and obese  
Zucker rats.
Adenylate cyclase activity was determined with 100jiM forskolin and 
inhibition assessed by increasing concentrations of GppNHp. Membranes from 
lean (open square) and obese (filled diamond) were used. Results are means and 
standard deviations of three experim ents using membranes from different 
animals. The value at 100% activity was taken to be that activity at 100pM 
forskolin alone this being 180±12 and 185±15 pmol/min/mg for membranes 
from lean and obese animals respectively.
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Fig 4.13 Scatchard representation of 125l-cyanopinidol binding 
to lean and obese Zucker rat adipocyte membranes.
Binding of 125I-CYP to membranes was determined as described in 
Material and Methods. The parameters Bmax and are given in Table 4.2. 
Graphs A & B show the plots for membranes from lean and obese animals 
respectively.
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TABLE 4.1 The effect of guanine nucleotide upon the dose 
response curve to isoproterenol in membranes from lean and 
obese Zucker rats.
Data are obtained from Figs 4.1 and 4.2 respectively. AK0 5 is the ratio of 
K0 5 for isoproterenol while utilizing GTP/K0 5 for isoproterenol while 
utilizing GTPyS.
L E M  OBESE
GTP
control* (pmol/min/mg) 17.7±1.7 16±1.6
Vmax (pmol/min/mg) 262±26 100±9
fold activation 16.0 6.25
Kq 5 OlM) 6.3 8.9
GTPyS
control** (pmol/min/mg) 83±7.5 70±9.1
Vmax (pmol/min/mg) 134±12.5 119±12
fold activation 1.61 1.70
K0 5 biM) 0.6 2.5
a K0.5 10.5 3.56
* (100pM GTP only)
**(100pM GTPyS only)
1 2 3
Table 4.2 Receptor-independent stimulation of adenylate 
cyclase and B-adrenergic receptor number in membranes from 
lean and obese Zucker rats.
Data relating to adenylate cyclase stimulation shows means and 
standard deviations of a typical experiment repeated five times with different 
lean and obese Zucker adipocyte membrane preparations. Data relating to 
125I-CYP binding shows typical result for binding to lean and obese 
membranes repeated six times with separate lean and obese membrane 
preparations each time. The parameters Bmax and were derived from 
Scatchard plot (Fig 4.13) of the data which gave a straight line.
ADENYLATE CYCLASE 125i-c y p  BINDING
ACTIVATOR
Forskolin NaF MnCI2 ®max Kd
100pM 20mM 5mM
(pmol/min/mg) (fmol/mg) (pM)
Lean 170±15 47±3 220±12 85±7 35
Obese 160±12 45±5 210±13 42±5 35
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Table 4.3. Inhibition of isoproterenol-stimulated adenylate 
cyclase activity.
Assays were performed in the presence of 100 pM isoproterenol and 
100 pM GTP. The maximal inhibitory effect of saturating doses of PIA, PGE1f 
nicotinate and DDA are shown as percentage inhibitions of isoproterenol- 
stimulated adenylate cyclase which exhibited specific activities of 280±18 
and 102±12 pmol/min/mg in membranes from lean and obese animals 
respectively. The data shows the mean and standard deviation of a typical 
experiment repeated four times with different lean and obese Zucker rat 
adipocyte membrane preparations.
Percentage inhibition of adenylate cyclase activity
Lean Obese
Inhibitory ligand
PIA (1pM) 65±8 63±8
nicotinate (10pM) 54±7 58±5
DDA (100pM) 85±9 85±6
PGE-j (1pM) 55±12 58±9
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Tab le  4 .4 . In h ib itio n  of fo rs k o lin -s tim u la te d  adeny la te  
cyclase activ ity .
Assays were performed in the presence of 100 pM GTP and 100 p.M 
forskolin. The maximal inhibitory effects of saturating doses of PIA, PGE-j, 
nicotinate and DDA are shown as percentage inhibitions of forskolin- 
stimulated adenylate cyclase activity. The data shows the mean and standard 
deviation of a typical experiment repeated four times with separate lean and 
obese Zucker rat adipocyte membrane preparations. The specific activities of 
forskolin-stimulated adenylate cyclase in lean and obese membranes were 
180±12 and 185±15 pmol/min/mg respectively.
Percentage inhibition of stimulated activity
Lean Obese
Inhibitory ligand
48±4 49±3
nicotinate (10pM) 45±3 41 ±4
DDA (100jiM) 83±5 87±7
PG E1 (1jxM) 47±5 46±4
1 2  6
TABLE 4.5 Changes in G-protein levels in adipocyte
membranes from lean and obese Zucker rats.
Changes in levels of G-proteins were quantified by densiometric
scanning using an Abaton-300 densiometric scanner. The notation N.S in 
brackets means not statistically significant by student t-test. The relative 
amount of each G-protein subunit (under the column OBESE(fa/fa)) is 
expressed as a percentage of that in lean membranes (100%).
G-PROTEIN SUBUNIT OBESE (fa/fa) ANTISERUM
ocs42 65±10% CS1
as45 58±10% CS1
035+36 105±8% BN1
aj1 35±6% AS7
q 2 84±9%(NS) AS7
otj3 38±7% I3B
*  driven by Apple Macintosh 'C-Scan Software’
1 2 7
4.1 RESULTS AND DISCUSSION
The regulation of adenylate cyclase by lipolytic hormones in lean 
(Fa/?) and obese (fa/fa) Zucker rat white adipocyte membranes was 
investigated in order to document any alteration in the hormonal 
responsiveness of adenylate cyclase in the obese state.
The dose-response to isoproterenol is shown in Fig 4.1 for 
membranes from lean and obese animals. Control activity was equivalent in 
membranes derived from both lean and obese animals. The maximal specific 
activity (Vmax) stimulated by saturation concentrations of isoproterenol was 
markedly lower in membranes from obese animals than the corresponding 
activity in membranes from lean animals, yielding fold-stimulations of 16- 
fold and 6-fold for membranes derived from lean and obese animals 
respectively (Table 4.1 & Fig 4.1). In contrast there was little change in K0 5 
values for isoproterenol stimulation, being between 6.3±0.8 pM and 8.9±1.1 
pM respectively for membranes from lean and obese animals (Table 4.1 & 
Fig 4.1).
Thus the regulation of adenylate cyclase in adipocytes from the fa/fa 
rat shows similarities with other genetically obese rodents, which also 
exhibit impaired catecholamine stimulation of adenylate cyclase (ch 1). 
Indeed, one might predict that the obese Zucker rat is likely to show impaired 
catecholamine stimulation of adipocyte membrane adenylate cyclase as these 
animals are hypothyroid (ch 1), an alteration known to lead to impaired 
catecholamine stimulation of adipocyte adenylate cyclase activity (ch 1).
In order to explore the kinetics of the alterations further, the dose 
response to isoproterenol was performed in the presence of 100|iM of the 
non-hydrolysable analog GTPyS (Fig 4.2 & Table 4.1). The activities seen 
with GTPyS alone were similar for membranes from both lean and obese
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animals, as were the Vmax activities observed in the presence of saturating 
concentrations of isoproterenol (Table 4.1). The fact that V max activities 
were similar in Fig 4.2 is at first sight quiteSyrprising given the large 
difference in Vmax values seen in Fig 4.1 for isoproterenol stimulation of 
adenylate cyclase. However it can be seen in Table 4.1 that the Vmax activity 
achieved with membranes from lean animals is much less when GTPyS was 
utilized rather than GTP. The reason for the lower efficacy of GTPyS 
+isoproterenol, rather than GTP+isoproterenol, is unknown. As a further 
point of interest, the concentration of isoproterenol which caused half 
maximal (Kq 5) activation of adenylate cyclase, done in the presence of 
GTPyS, was significantly lower than when GTP is used (Table 4.1). Indeed, 
such a decrease in the K0 5 for isoproterenol activation of adenylate cyclase 
was much smaller when membranes from obese animals were used rather 
than those from lean: being only 3.6-fold compared with 10.5-fold in 
membranes from lean animals. Thus the ability of GTPyS to decrease the Kq.s 
for isoproterenol stimulation of adenylate cyclase is severely impaired in 
membranes from obese animals. Seemingly then, the kinetic changes seen in 
membranes from obese animals do depend upon which guanyl nucleotide 
analogue was employed.
The effect of isoproterenol upon the dose response curve to GTPyS was 
also investigated (Fig 4.3), showing that the Vmax values for adenylate 
cyclase in membranes from lean and obese were essentially equivalent as one 
would predict from Fig 4.2 However, in contrast, the K0 5 for GTPyS was 
markedly lower in membranes from lean animals as opposed to those from 
obese animals (Fig 4.3). Thus it appears that isoproterenol is less able to 
bring about an increase in the 'affinity' of Gs for GTPyS in membranes from 
obese animals. Alternatively isoproterenol may simply be less able to 
decrease the amount of Gs which has to be activated in order to achieve half
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maximal activation of adenylate cyclase in membranes from obese animals. 
The activity of adenylate cyclase determined with 50pM isoproterenol only is 
markedly lower in membranes from obese animals than in membranes from 
lean animals (Fig 4.3). Consequently, the fold stimulation of adenylate 
cyclase activity by GTPyS is significantly greater in membranes from obese 
animals than in membranes from lean animals (Fig 4.3).
The response to glucagon in lean and obese membranes, measured 
against the activity recorded with 100 pM GTP is given in Fig 4.4. Here it can 
be seen that glucagon achieves a much higher stimulation of adenylate cyclase 
activity in membranes from lean animals as opposed to membranes from 
obese animals. In addition, the sensitivity to glucagon stimulation of adenylate 
cyclase was reduced in membranes from obese animals.
Fig 4.5 details the response of membranes from both lean and obese 
animals to secretin stimulation of adenylate cyclase assayed in the presence of 
100 pM GTP. In membranes from lean animals, secretin stimulated this 
activity some 4.2-fold however, in contrast, secretin failed to stimulate 
adenylate cyclase activity significantly in membranes from obese animals.
The response of adenylate cyclase in membranes from lean and obese 
animals to TSH-mediated stimulation of adenylate cyclase activity done in the 
presence of 100 jiM GTP is detailed in Fig 4.6. Here we see membranes from 
lean animals the TSH stimulated activity some 3.8-fold, however in 
membranes from obese animals stimulation of activity by TSH was negligible.
It is thus apparent that the response of adenylate cyclase to all Gs- 
linked hormones is greatly reduced in membranes from obese animals. In 
particular, both secretin and TSH show negligible stimulation in membranes 
from obese animals. It is possible that a common defect at the G-protein level 
could contribute to all of this. However, the more marked effect seen with 
TSH and secretin could be due to a receptor specific action at the level of 
expression or post-translational modification. The number and affinity of p-
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AR in membranes from lean and obese animals was determined using the high 
affinity p-AR antagonist 125l-cyanopinidolol (Table 4.2). This revealed 
(Table 4.2) that there was a roughly half the number of p-AR in membranes 
from obese animals compared with that found using membranes from lean 
animals. There was no apparent change in the affinity for 125I-CYP, the K<j 
being similar in both instances. The reduced response of adenylate cyclase to 
isoproterenol stimulation in membranes from obese animals could simply be 
due to the reduced number of p-AR. However reduced p-adrenergic receptor 
number does not necessarily lead to a reduction in catecholamine stimulated 
adenylate cyclase activity, as spare B-AR are believed to occur in adipocytes. 
Thus, a quite substantial reduction in the number of 6-AR is believed to be 
needed to occur before any reduction in isoproterenol stimulated adenylate 
cyclase activity can ensue. It is also relevant that an inherent feature of the 
Collision Coupling Model, thought to represent the mode of RSG S activation of 
adenylate cyclase in a number of cells, buffers the adenylate cyclase system 
against any receptor loss (Houslay et al, 1980; Braun & Levitzki, 1979). 
Thus, unless the degree of receptor loss is very large, the Vmax of adenylate 
cyclase activity achieved through activation of the Rs in question will be 
unaffected although K0 5 is likely to be increased. Furthermore since B i, B2 
and B3-AR are present in adipocytes (Bojanic & Nahorski, 1984; Emorine 
et al, 1989) a detailed analysis of changes of subtypes needs to be done in 
order to explore this further.
The fact that the response to other Rs hormones was also reduced 
implies to me that a defect, at a level common to all Rs linked hormones, may 
exist. Whilst this may be a general reduction in expression or inactivation of 
receptors by phosphorylation, it could also be at the level of Gs , or at the 
catalytic unit of adenylate cyclase itself. In this regard, we assessed the 
functional status of the catalytic unit of adenylate cyclase by using direct, G-
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protein-independent activators. Table 4.2 records the stimulation of 
adenylate cyclase activity by the diterpene forskolin, NaF and MnCI2. These 
showed little difference between adenylate cyclase in membranes from both 
lean and obese. Thus the functioning of the catalytic unit and its stimulation 
by Gs is, as far as we can detect, identical in membranes from lean and obese 
animals. Therefore it would appear that the defective hormonal stimulation of 
adenylate cyclase in membranes from obese animals is not due to a defect in 
the catalytic unit of adenylate cyclase or in the ability of Gs to stimulate it. 
This suggests that the defect is at the level of Rs or at the receptor coupling 
interface of Gs.
The receptor-independent G-protein stimulation of adenylate cyclase 
was also assessed by monitoring the stimulation of adenylate cyclase by 
GTPyS in the absence of any Rs linked agonist Fig 4.7. Fig 4.7 shows that the 
degree of activation was identical for membranes from both lean and obese 
animals. However, the K0-5 GTPyS was higher in membranes from obese 
animals than those from lean animals (Fig 4.7). Thus the membranes from 
obese animals appear to show a defect at the level of Gs functioning. Possible 
explanations for this are (i) adipocyte Gs molecules in membranes from lean 
and obese animals may be different and could actually exhibit different K^s 
values for GTPyS, such that the affinity for GTPyS was decreased in the obese 
state; (ii) whilst, the actual affinity of Gs molecules for GTPyS in both 
instances might be identical, the amount of Gs which has to be activated to 
yield a particular degree of activation of adenylate cyclase might be different 
and (iii) the levels of free 8-subunits may be different thus altering the 
ratio of Gs in the holomeric state/Gs in dissociated state and hence altering 
the K0 5 for Gs activation of adenylate cyclase.
The levels of a subunits and p subunit of Gs in membranes from lean 
and obese animals were compared by immunoblotting with specific anti­
1 32
peptide antisera. The result of such studies, using the antiserum CS1 to detect 
a s specifically, is shown in Fig 4.8 and the quantification of relative changes 
in levels is given in Table 4.5. It can be seen there is a reduction of the 42kD 
form of Gs species in membranes from obese animals, such that levels fall to
j
some 50±6% of those in membranes from lean animals. Levels of the 45kD 
form of a s wereol$om^ucd,Thus the reduction in the levels of Gs and changes 
in ratio of the forms may explain the increase in the K0 5GTPyS seen in 
membranes from obese animals in Fig 4.7.
Immunoblotting with antiserum BN1, which specifically recognizes 
G-protein p subunits showed no significant change in the levels of this species 
between membranes from lean and obese animals (Fig 4.9 and Table 4.5). 
However at least two p subunits, 36 KD pi and 35 KD p2 are known to exist in 
adipocyte membranes and others have been recently identified from cloning 
studies (ch 1). The antiserum BN1 identifies both 61 and 82 forms of 
subunit. Therefore, because we do not have the reagents to distinguish 
between various forms in adipocyte membranes, we cannot eliminate the 
possibility that there has been an alteration in the relative proportions of 
different 8-subunits. Neither can we rule out the possibility of an alteration 
in the y-subunits associated with the p subunits of which their are believed 
to be multiple types (ch 1).
Increased activity of Gj could also impede hormonal stimulation of 
adenylate cyclase via increased tonic inhibition of adenylate cyclase (ch 1). 
To this end we determined the levels of aj-1,2 and 3 in membranes from lean 
and obese animals. Fig 4.10 shows the result of an immunoblot with 
antiserum AS7, specific for the 41 KD aj-1 and 40 KD aj-2 proteins. We 
observed (Fig 4.10; Table 4.5) that there was a large reduction in the level 
of a jl in membranes from obese animals, such that its level is only some 
35±6% of that found in membranes from lean animals. There was no obvious 
alteration in the level of oij2 in membranes from obese animals Fig 4.10 and
13 3
Table 4.5.
We examined the ability of the Rj-linked receptor agonists PIA, PGE-| 
and nicotinic acid to inhibit isoproterenol stimulated adenylate cyclase (Table
4.3). We noted that the maximum inhibition achieved, using membranes from 
lean and obese animals, was similar. We also tested the ability of the R; 
linked agonists to inhibit forskolin stimulated adenylate cyclase (Table 4.4). 
The results showed that the maximum inhibition of forskolin stimulated 
adenylate cyclase achieved was similar for these ligands irrespective of the 
membranes used.
The ability of P-site agonists to inhibit adenylate cyclase activity was 
determined. This was done using a saturating concentration of 2',5'- 
dideoxyadenosine to inhibit isoproterenol (500 pM) and forskolin (100 pM) 
stimulated adenylate cyclase. The degree of inhibition was identical using 
membranes from both lean and obese animals. Thus the functional capacity of 
the P-site appears to be unaltered in the obese state.
The ability of Gj to exert 'tonic' inhibition on adenylate cyclase was 
determined by the ability of GppNHp to inhibit forskolin stimulated adenylate 
cyclase (Fig 4.12). This showed that GppNHp inhibited adenylate cyclase 
activity only in membranes from lean animals.
Obese Zucker rats are hypothyroid and in normal rats made 
hypothyroid a number of defects have been identified (ch 1) which are 
consistent with a reduced efficacy of Rs receptor linked agonists. These 
include a reduced I3-AR action without any reduction in B-AR number. 
However as we see here for membranes from obese animals, they exhibit no 
change in levels of a s and no apparent change in the functioning of the 
catalytic unit of adenylate cyclase (ch 1). A point of difference concerns Gj 
expression where in membranes from hypothyroid animals there is an 
increase in aj-1, no alteration in aj-2 but an increase in p-subuni: levels.
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Consistent with the changes I have observed in adipocyte membranes, 
membranes prepared from obese Zucker rat hearts also show reduced 
stimulation of adenylate cyclase by isoproterenol, secretin and other Rs-type 
agonists (chatelain et al, 1981). However, such changes are not uniform 
throughout the various tissues of the obese animals since membranes from 
both hepatocytes and anterior hypophysis (Robberecht et al, 1983) do not 
show the same decrease in the efficacy of Rs-linked hormones.
The brown adipose tissue of obese Zucker rats shows a 40% decrease 
in isoproterenol stimulated activity associated with a 38% decrease in NaF- 
stimulated adenylate cyclase activity (Muzzin et al, 1989). Therefore the 
changes in the B-AR adenylate cyclase system of obese Zucker rat brown 
adipose tissue are distinct to those of white adipocytes reported here. Other 
obesity model systems such as the obese (ob/ob) mouse, the diabetic mouse 
(db/db), the high-fat diet-fed rat, the Toronto-KK mouse and the New 
Zealand obese mouse (ch 1) show the same decreased efficacy to 
catecholamines in adipocytes as we report here for obese Zucker rats. The 
pathological significance of this latter trend could relate to the developement 
of obesity itself. The ob/ob mouse, the db/db mouse, the Toronto-KK, and 
the New Zealand obese mouse (ch 1) all exhibit reduced catecholamine- 
stimulated lipolysis. Increased adipocyte volume, due to increased 
triglyceride globule mass, is a major feature of hyperadiposity of obesity. 
Since cAMP concentrations appear to be the major determinant of adipocyte 
lipolytic rates then the defect in adenylate cyclase in the obesity models 
mentioned above would certainly contribute to, and could in principle be the 
cause of (or significantly contribute to), the altered adipocyte morphology 
characteristic of obesity.
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CHAPTER 5
REGULATION OF ADENYLATE CYCLASE ACTTIVITY 
IN THE ADIPOSE TISSUE FROM DIABETIC {db/db) 
MICE
Fig 5.1 Dose response curve for isoproterenol stimulation of 
adenylate cyclase in adipocyte membranes from +/+ and d b /d b  
mice.
Adenylate cyclase activity was assayed with increasing concentrations of 
isoproterenol in the presence of 100p.M GTP. In membranes from +/+ mice the 
maximal specific activity, Vm ax, was 300 pmol/min/mg and the activity with 
GTP alone was 4.1±1.2 pmol/min/mg. In membranes from db/db mice the Vmax 
activity was 160±12 pmol/min/mg and the activty in the presence of GTP alone 
was 4.2±0.5 pmol/min/mg. The data shows mean and standard deviations of a 
typical experiment repeated 3 times with different membrane preparations.
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Fig 5.2 Dose response curve for glucagon stimulation of adipocyte 
membrane adenylate cyclase from +/+ and db/db mice.
Adenylate cyclase was assayed with increasing concentrations of glucagon 
in the presence of 100pM GTP. In membranes from +/+ mice (closed diamond) 
the Vmax activity was 33 pmol/min/mg, the activity in the presence of GTP 
alone was 5.9±0.3 pmol/min/mg and the fold-stimulation by glucagon was 5.5- 
fold. In membranes from db/db mice (open square) the Vmax activity was 16.1 
pmol/min/mg, the activty in the presence of GTP alone was 6.3±1.3  
pmol/min/mg and the fold stimulation by glucagon was 2.7-fold. The result 
shows mean and standard deviation values for a typical experiment repeated three 
times with different membrane preparations each time.
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Fig 5.3 Dose response curve for TSH stimulation of adenylate 
cyclase activity in membranes from +/+ and db/db mice
The effect of increasing concentrations of TSH in the presence of 100jxM 
GTP were determined. In membranes from +/+ mice (open square) the Vmax 
activity was 18.2±1.8 pmol/min/mg, the activty in the presence of GTP alone 
was 8.3±0.8 pmol/min/mg and the fold stimulation by TSH was 2.7-fold. In 
membranes from db/db mice (closed diamond) the Vmax activity was 18.0±1.9 
pmol/min/mg, the activity in the presence of GTP alone was 8.1 ±0.7 
pmol/min/mg and the fold stimulation by TSH was 2.7-fold. The data shows a 
typical result repeated three times with separate membrane preparations of +/+ 
and db/db mice with data points showing means and standard deviations.
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Fig 5.4 Dose response curve for secretin stimulation of adenylate 
cyclase activty in adipocyte membranes from +/+ and db/db mice.
Adenylate cyclase activity was assayed in the presence of increasing 
concentrations of secretin in the presence of 100p.M GTP. In membranes from 
+/+ mice (open square) Vmax activity was 24±1 pmol/min/mg, activity in the 
presence of GTP alone was 7.2±0.5 pmol/min/mg and fold stimulation by 
secretin was 3.4-fold. In membranes from db/db mice (closed diamond) the 
V max act'vty was 13.5±1.7 pmol/min/mg, the alone activty in the presence of 
GTP alone was 6.0±0.6 pmol/min/mg. and the fold stimulation was 2.3-fold. 
The data shows means and standard deviations for a typical experiment repeated 
three times with different membrane preparations.
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Fig 5.5 Immunoblot detection of a s in adipocyte membranes from  
+/+ and d b /d b  mice.
The antiserum CS1 was used to detect the a-subunit of Gs in adipocyte 
membranes. Data was determined from four different +/+ and four different 
db/db  membrane preparations with comparisons being made of loadings of 
40pg of membrane protein, over which linear increases in absorbance were 
obtained in quantitation studies as described in Materials and Methods Section. 
Quantification data is given in Table 5.2.
Comparison of levels of Gsa m  
control and db/db mouse adipocyte membranes
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Fig 5.6  Im m unodetection of G -protein 6 -subunit in adipocyte  
membranes from +/+ and d b /d b  mice.
The antiserum BN1 was used to detect the 6-subunit in adipocyte 
membranes. Data were obtained from four different +/+ and db/db  mice 
with comparisons being made between 70pg of protein, over which linear 
increases in absorbance were obtained in quantitation studies as described in 
chapter 2. Quantification of this data is given in Table 5.2.
Comparison of levels of /3-subunit 
in control and db/db mouse adipocyte membranes
0
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Fig 5.7 Im munodetection of aj1 and otj2 in adipocyte membranes 
from +/+ and db/db mice
The antiserum AS7 was used to detect the expand 2 subunits of G j.  Data 
was obtained from four different +/+ and db/db  membrane preparations 
with comparisons being made between 30pg of membrane protein, over 
which linear increases in absorbance were obtained in quantitation studies as 
described in chapter 2. Quantification of this data is given in Table 5.2.
Comparison o f levels of G.ai and 2 
In lean and db/db adipocyte membranes
4 0  KDa
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Fig 5.8 Im m unodetection of a j3  in adipocyte m em branes from  
+/+ and d b /d b  mice.
The antiserum I3B was used to detect aj3 in adipocyte membranes. 
Data were obtained from four different membrane preparations from +/+ 
and db/db mice and comparisons of 100jig of membrane protein are shown, 
over which linear increases in absorbance were obtained in quantitation 
studies as described in chapter 2. Quantification data is given in Table 5.2.
Comparison of levels of GjOd3 in 
control and db/db mouse adipocyte membranes
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Fig 5.9 Dose response curve to PIA mediated inhibition of 
isoproterenol stimulated adenylate cyclase of adipocyte membranes 
from +/+ and db/db  mice.
The effects of increasing concentrations of PIA upon the activity of 
isoproterenol (500jxM) stimulated adenylate cyclase done in the presence of 
100p.M GTP were determined. The data shows means and standard deviations of a 
typical experiment repeated three times with different membrane preparations. 
In membranes from both db/db  and +/+ mice the IC50 for PIA was 25±8nM. 
However in membranes from +/+ mice the maximal percentage inhibition was 
60±5%, while in membranes from db/db mice it was 80±10%.
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Fig 5.10 Dose response curve to PGE1 mediated inhibition of 
isoproterenol stimulated adenylate cyclase of adipocyte 
membranes from +/+ and db/db mice.
The effect of increasing concentrations of PGE-j upon isoproterenol 
(500|iM) stimulated adenylate cyclase were determined in the presence of 
10OpM GTP. The results means and standard deviations of a typical result 
repeated three times in separate membrane preparations. The IC50 for PGE-| in 
membranes from both +/+ and db/db mice were 15nM.
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Fig 5.11 Dose response curve to nicotinic acid mediated 
inhibition of isoproterenol stimulated adenylate cyclase in 
adipocyte membranes from +/+ and db/db mice.
The effect of increasing concentrations of nicotinic acid upon adenylate 
cyclase in the presence of 100p.M GTP and 500p.M isoproterenol were 
determined. The data shows means and standard deviations for a typical 
experiment representative of three performed with different membrane 
preparations. In membranes from +/+ and db/db mice the IC50s for nicotinic 
acid were 315nM and 562nM respectively. The maximal degree of inhibition 
by nicotinic acid was equivalent in membranes from both +/+ and db/db mice 
at 70±6%.
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Fig 5.12 Dose response of forskolin stimulated adenylate cylcase to 
GppNHp.
The effect of increasing concentrations of GppNHp upon forskolin 
(100pM) stimulated adenylate cyclase was determined. The data shows means and 
standard deviations of a typical experiment representative of three performed 
with different membrane preparations. In membranes from +/+ mice (open 
square) the control activity, represented as 100% stimulation, with 100pM 
forskolin alone was 178±13 pmol/min/mg. In membranes from db/db  mice 
(closed diamond) the control activity, represented as 100% stimulation, with 
100pM forskolin alone was 183±15 pmol/min/mg.
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Fig 5.13 Scatchard representation of 125l-cyanopinidol binding 
to +/+ and db/db mouse adipocyte membranes.
Binding of 125I-CYP to membranes was determined as described in 
Material and Methods. The parameters Bmax and are given in Table 5.1. 
Graphs 1 & 2 show the plots for membranes from 4 /+  and db/9b animals 
respectively.
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Table 5.1 Receptor-independent stimulation of adenylate cyclase 
and determination of B-adrenergic receptor number in 
membranes from +/+ and db/db mice.
Adenylate cyclase was assayed in the presence of fixed concentrations 
of either forskolin or NaF. Binding of 125 I-CYP to membranes was 
determined as described in Materials and Methods. Binding parameters Bmax 
(Total specific binding) and (equilibrium dissociation constant) were 
determined by Scatchard analysis of the data which fitted a straight line on 
the Scatchard representation (Fig 5.13). The results for the adenylate 
cyclase determinations show means and standard deviations of an experiment 
typical of four, performed on different membrane preparations from +/+ 
and db/db mice.
ADENYLATE CYCLASE 125I-CYP BINDING 
ACTIVATOR
10OpM forskolin 20mM NaF ^max ^d
(pmol/min/mg) (pmol/min/mg) (fmol/mg) (pM)
Control (+/+) 180±14 52±3 90±5 30
Diabetic (db/db) 175±12 51 ±5 26±6 32
15 9
Table 5.2 Quantification of relative changes in G-protein levels 
between membranes from +/+ and db/db mice.
lmmunoblotting was performed as outlined in chpt 2. lmmunoblots 
were quantified by densometric scanning of blots employing non-saturating 
amounts of membrane protein (appendix).
DIABETIC {db/db) ANTISERUM
ocs45 108±7% CS1
ocs42 111 ±7% CS1
P35+36 105±2% BN1
(Xj1 192±8% AS7
ttj2 115±12% AS7
ttj3 115±10% I3B
data shown as % (percentage) of that found using membranes from lean 
animals (100%).
An Abaton-300 densiometric scanner driven by Apple Macintosh 'C- 
Scan Software was employed for the purpose of densiometric scanning.
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5.1 INTRODUCTION
Previous studies have shown stimulation of adenylate cyclase activity 
and lipolysis by catecholamines was significantly reduced in adipocytes from 
db/db mice in comparison with adipocytes from control animals (ch 1). The 
appropriate control animals are the C57BL/KsJ mice and are here after 
referred to as +/+ mice. As mentioned before (ch 1), db/db mice are obese 
with excessive deposition of adipose tissue. A number of other rodent obesity 
model systems, specifically the Toronto-KK mouse, the Zucker fatty rat and 
the New Zealand obese mouse, all exhibit reduced stimulation of adenylate 
cyclase by catecholamines (ch 1). Since this defect is potentially of great 
pathological significance in etiology of obesity, it was decided to investigate 
the defect in the d b /d b  mouse system more fully. Thus a full 
characterization of the regulation of adenylate cyclase by all hormones and 
autocrine factors controlling lipolysis was conducted.
5.2 RESULTS AND DISCUSSION
In adipocyte membranes from +/+ mice, isoproterenol stimulated 
adenylate cyclase activity to a much greater degree (higher Vmax) and with 
higher sensitivity (lower K0.5 for isoproterenol)in membranes from +/+ 
mice than in membranes from db/db mice (fig 5.1). This result confirms 
previous studies (ch 1) that detail a large reduction in the efficacy of 
catecholamines to stimulate adenylate cyclase in membranes from db/db 
mice compared with their controls. I also confirmed that there is no 
alteration in the activity of adenylate cyclase in the presence of 100p.M GTP 
alone, between membranes from +/+ or db/db mice.
The dose response curve for the stimulation of adenylate cyclase by 
glucagon (Fig 5.2) shows that in membranes from +/+ mice, glucagon 
stimulated adenylate cyclase to a much greater degree than in membranes
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from db/db mice.
The dose response curve (Fig 5.3) for the stimulation of adenylate 
cyclase by TSH was found to be similar both in terms of K0 5 and Vmax in 
membranes from +/+ and db/db mice.
Analysis of dose response curve for the stimulation of adenylate 
cyclase by secretin (Fig 5.4) shows that in membranes from +/+ mice, 
secretin stimulated adenylate cyclase activity to a much greater extent than 
in membranes from db/db mice.
Thus it appears that the defect in catecholamine stimulation of 
adenylate cyclase in membranes from db/db mice extends to glucagon and 
secretin but not to TSH. Therefore, I submit that receptor specific defects 
may occur.
Nevertheless, to assay Gs functioning, I determined the ability of NaF 
to stimulated adenylate cyclase activity (Table 5.1) which was similar in 
membranes from both +/+ and db/db  mice. Also, direct stimulation of 
adenylate cyclase activity activity by forskolin was similar in membranes 
from both +/+ and db/db mice (Table 5.1).
The number and affinity of B-AR for ligand was determined using the 
high affinity antagonist 125l-cyanopindolol in membrane from +/+ and 
db/db mice (Table 5.1). This showed that there was a very marked reduction 
in the maximal specific binding (Bm ax) in membranes from db/db  but 
essentially no change in was observed. This large reduction in Bmax of 
membranes from db/db  mice could, in principle, explain the reduced 
response to isoproterenol. The uncertainty arises because there may well be 
spare B-ARs such that a very substantial decrease in receptor number may 
have to occur before an alteration in the Vm ax of adenylate cyclase 
stimulation by isoproterenol is reduced (ch 4).
I also conducted immunoblot analysis to determine the levels of G- 
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proteins in membranes from +/+ and db/db  mice using anti-peptide 
antisera recognizing specific G-protein subunits. Using the antiserum CS1, 
which specifically recognizes a s subunit of Gs (Fig 5.5) I found no difference 
in the levels of either 42kD or 45kD a s subunits in adipocyte membranes 
from both types of animal (Table 5.2). Thus the reduced efficacy of 
isoproterenol, glucagon and secretin in adipocytes db/db mice cannot be due 
to a selective reduction in one form of a s.
Immunobloting membranes from +/+ and d b /d b  mice with 
antiserum BN1, which recognizes the G-protein 6-subunit, shows that there 
is no detectable difference between membranes from +/+ and db/db mice Fig 
5.6 (Table 5.2 for quantification). Therefore the reduced efficacy of 
isoproterenol, secretin and glucagon in membranes from db/db mice cannot 
be due to an increase in the levels of 6-subunits which might reduce 
hormonal activation of adenylate cyclase by inhibiting a s dissociation.
Reduced efficacy of Gs linked hormones could also be due to increased 
levels of aj in membranes from db/db  mice, a situation which occurs in 
hypothyroid rat adipocyte membranes (ch 1). In order to address this 
question membranes from +/+ and db/db animals were immunobloted with 
antiserum AS7 which specifically recognizes ap and a\2 (Fig 5.7 and 5.2). 
This showed that membranes from db/db  mice had nearly 2-fold greater 
levels of aj1 compared with membranes from +/+ mice (Table 5.2). 
Immunobloting of membranes from +/+ and db/db  mice with antiserum 
I3B, which specifically recognizes aj3 (Fig 5.8), showed no alteration in the 
levels of aj3 between membranes from both animals. Since the levels of ap 
do increase substantially, it remains possible that the decreased response of 
membranes from db/db mice to stimulation via certain Rs type receptors 
could be due to increased tonic inhibition of adenylate cyclase. However it is 
difficult to Imagine how this could be selective and thus not affect stimulation 
via the TSH receptor. Nevertheless, tonic Gj inhibition of adenylate cyclase
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was determined (Fig 5.12) and from this data it was seen that GppNHp- 
activated Gj can inhibit forskolin stimulated adenylate cyclase equally 
effectively in membranes from both animals. Thus the reason for the 
decreased response of membranes from db/db  mice to isoproterenol, 
glucagon and secretin is unlikely to be due to increased tonic inhibition of 
adenylate cyclase in these membranes.
I also examined the response of adenylate cyclase to inhibitory, Rj-Gj 
linked agonists to see if these responses were altered in membranes from 
db/db  mice, since this is a possible point of modulating the ability of 
adenylate cyclase to be regulated by lipolytic hormones. The dose response 
curve to PIA in membranes from +/+ and db/db  mice (Fig 5.9) showed 
similar IC50 values but the maximal degree of inhibition achieved was 
greater in membranes from db/db mice than in membranes from +/+ mice. 
This difference might serve to magnify the effect of reduced stimulation of 
adenylate cyclase by catecholamines helping to reduce hormone-stimulated 
lipolysis in vivo. The mechanism behind increased the inhibition seen with 
PIA in membranes from db/db mice may relate to the large increase seen in 
the levels of aj1. It could also be due to a change in the activity of A-j- 
adenosine receptors. Using PGE1f the maximal degree of inhibition was 
similar for membranes from both animals (Fig 5.10) as was the case for 
nicotinic acid (Fig 5.11).
The mechanism(s) responsible for the decreased response of adenylate 
cyclase to Rs linked hormones, except that for TSH, remains unclear but 
several possibilities exist. It is possible that a selective reduction in 
receptor number in db/db  adipocyte membranes may occur, although 
nothing is known about the degree of spare G-ARs. Since the response to TSH 
is equivalent in adipocyte membranes from +/+ and db/db  animals one 
might conclude that the defect probably occurs at a level prior to the
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activation of Gs ie a selective ioss or modification of these receptors. However 
this is not necessarily the case since there are two forms of Gs present in 
these membranes and very little is understood about their relative roles in 
the regulation of adenylate cyclase. In addition, two different B-subunits 
occur in adipocytes, with an uncertain number of y-subunits (ch 1), there 
could be anything up to eight or so species of Gs in normal adipocyte 
membranes. It is possible to envisage that these hypothetical multiple forms 
of Gs could recognize different Rs type receptors within the adipocyte plasma 
membrane. Indeed it is possible to conceive of a scenario in which a G-protein 
defect at the level of Gs has occurred in the adipocytes of db/db mice which 
could be selective for particular groups of receptors. Another possibility is 
selective uncoupling of Rs type receptors from the stimulation of Gs. This 
might be achieved by covalent modification of receptors by phosphorylation 
as occur in B-AR desensitization. A change in receptor subtype might occur in 
the case of the B-AR, such that the normal complement of receptors is 
replaced with a subtype which is less effectively coupled to activation of Gs.
The db/db mouse shows the same trend seen with other known obese 
rodents, specifically the Toronto-KK mouse; the Zucker fatty rat and the New 
Zealand obese mouse, in exhibiting decreased stimulation of adenylate cyclase 
by catecholamines. As pointed out before this defect may play a pivitol role in 
determining obesity through controlling adipocyte triacylglcerol levels.
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APPENDIX
Appendix 1 Effects of increasing protein concentrations on the 
detection of a s and in adipocyte membranes from +/+ mice and 
Sprague-Dawley rats.
Increasing amounts of adipocyte membrane protein prepared from 
+/+ animals were subjected to SDS-PAGE before transfer to nitrocellulose 
and immunoblotting with the appropriate antiserum. For the detection of a s 
the amounts loaded were, from left to right, 80pg, 40jxg and 20jig and the 
antiserum used was CS1. The result is representative of three performed 
with different membrane preparations. Identical results were obtained using 
membranes prepared from Sprague-Dawley rats used as controls in the 
studies described in chapter 3.
alpha Gs 
alpha Gs <
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Appendix 2 Effects of increasing protein concentrations on the 
detection of ocji and a \2  in adipocyte membranes from +/+ mice 
and Sprague-Dawley rats.
Increasing amounts of adipocyte membrane protein prepared from 
+/+ animals were subjected to SDS-PAGE before transfer to nitrocellulose 
and immunoblotting with the appropriate antiserum. For the detection of aj1 
and a\2  the amounts loaded were, from left to right, 15, 30, 60 and 120|xg 
and the antiserum used was AS7. The result is representative of three 
performed with different membrane preparations. Identical results were 
obtained using membranes prepared from Sprague-Dawley rats used as 
controls in the studies described in chapter 3.
alpha Gj-1 
alpha Gj-2
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Appendix 3 Effects of increasing protein concentrations on the 
detection of a j3  in adipocyte membranes from +/+ mice and 
Sprague-Dawley rats.
Increasing amounts of adipocyte membrane protein prepared from 
+/+ animals were subjected to SDS-PAGE before transfer to nitrocellulose 
and immunoblotting with the appropriate antiserum. For the detection of ocj3 
the amounts loaded were, from left to right 50, 100 and 150 pg and the 
antiserum used was I3B. The result is representative of three performed 
with different membrane preparations. Identical results were obtained using 
membranes prepared from Sprague-Dawley rats used as controls in the 
studies described in chapter 3.
alpha Gj3
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Appendix 4 Effects of increasing protein concentrations on the 
detection of p -s u b u n i t  in adipocyte membranes from +/+ mice.
Increasing amounts of adipocyte membrane protein prepared from 
+/+ animals were subjected to SDS-PAGE before transfer to nitrocellulose 
and immunoblotting with the appropriate antiserum. For the detection of G- 
protein 3-subunit the amounts loaded were, from left to right, 20, 40, 80, 
120, 160 and 200pg the antiserum  used was BN1. The result is 
representative of three performed with different membrane preparations.
/3 -subunit
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